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ABSTRACT 
The measurement of acute phase proteins is used by human clinicians to give valuable 
infonnation about a patient's inflammatory response, both when monitoring clinical 
disease and when assessing the effect of therapy. Levels of soluble receptors for the 
cytokine, tumour necrosis factor, also increase as a result of inflammatory stimuli and 
are useful prognostic markers over the asymptomatic phase of human 
immunodeficiency virus infection. The aim of the work presented in this thesis was to 
detennine whether these markers are of value when investigating feline disease. 
Reference ranges for two acute phase proteins, aI-acid glycoprotein (AGP) and 
haptoglobin were detennined by measuring their concentrations in serum samples from 
healthy cats. Analysis of samples from cats with feline infectious peritonitis (FIP) and 
from cats suffering from conditions with a similar clinical presentation revealed that 
measurement of AGP can be a useful adjunct to other laboratory tests when reaching a 
diagnosis. In contrast, measurement of haptoglobin was not found to be of value. 
Despite increases in the levels of pro-inflammatory cytokines in samples taken from 
cats during the asymptomatic phase of feline immunodeficiency virus (FIV) infection, 
no changes were detected in the levels of AGP and haptoglobin. It was concluded that 
these acute phase proteins are of no benefit as prognostic markers in FlY. 
The L929 bioassay was used to investigate anti-TNF-a activity in cell culture 
fluids from feline splenic cells. Cytotoxic activity was demonstrated in very few of the 
samples whilst anti-cytotoxic activity was detected in the majority of samples. This 
anti-cytotoxic activity was attributed to the presence of feline soluble TNF receptor 
type 1 (sTNFR-I) binding to and inhibiting the effects of TNF-a. This was not 
confinned because of the lack of specific neutralising antibody. Subsequent work was 
therefore directed towards the development of immune-based species-specific assays 
for feline soluble TNF receptors (sTNFRs). 
The polymerase chain reaction was used to amplify the sequences coding for 
feline sTNFRs. Most of the extracellular domain of feline TNFR-l and part of the 
intracellular domain of feline TNFR-2 were cloned and sequenced using this 
technique. The amplified regions demonstrated 85% and 77% homology at the nucleic 
acid level and 83% and 67% homology at the amino acid level to the corresponding 
regions of the human sequences for TNFR-l and 2 respectively. Feline sTNFR-l was 
expressed as a glutathione-S-transferase fusion protein. After purification, 
concentration and electrophoresis, the appropriate protein band was excised and used 
to inoculate a sheep. Antiserum taken from the sheep post-inoculation recognised the 
expressed protein by western blotting, but results were inconsistent and analysis of the 
antiserum was hampered by the very small amounts of expressed protein available. 
Two peptides were synthesised based on regions of antigenicity in feline 
sTNFR-l and were used to inoculate sheep. Antiserum to peptide A showed a strong 
reaction against peptide A in an ELISA and gave a positive result when used as the 
primary antibody to stain healthy feline liver tissue. 
In conclusion, both antiserum to expressed feline sTNFR-l and anti-peptide 
antibody based on a region of feline sTNFR-l have been raised in sheep and are 
available for the development of an assay for this protein. Further expression of feline 
TNFR-l will be required befOre these antisera can be analysed fully. 
)'" " \.' 
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Chapter 1: 
General Introduction 
1.1. Summary of Chapter 
This thesis presents work investigating serological markers of inflammation in the cat 
including acute phase proteins and soluble receptors for the cytokine, tumour 
necrosis factor. The introductory chapter gives a review of the inflammatory 
response, the markers studied in this work and two feline diseases, feline infectious 
peritonitis (FIP) and feline immunodeficiency virus (FlV) infection, that were used as 
models for studying these markers. An outline of the objectives which prompted the 
work is also given. 
1.2. The Acute Phase Response 
1.2.1. Definition 
The acute phase response is a mechanism which attempts to restore normal bodily 
function after homeostasis has been interrupted by noxious stimuli and to remove the 
initiating stimulus (Koj and Gordon, 1985b). It consists of both local and systemic 
effects and mechanisms exist to limit the response since, if excessive or prolonged, it 
can prove detrimental to the host. 
1.2.2. Induction of the Acute Phase Response 
Cells of the mononuclear phagocytic system such as monocytes and macrophages are 
the principal cells involved in the initiation of the acute phase response (Baumann and 
Gauldie, 1994). Cytokines, particularly y-interferon (IFN-y) (Svedersky et al. 1984; 
Woessner, 1992), induced by inflammatory stimulants such as lipopolysaccharide 
(LPS), a major component of the cell wall of Gram-negative bacteria, play a 
definitive role in activating macrophages. These activated cells are then responsible 
for a number of pathways (figure 1.1.) which assist the elimination of pathogens and 
the restoration of homeostasis. They display increased expression of Fc receptor 
proteins and major histocompatibility complex (MHC) class II molecules, enhancing 
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antigen uptake and presentation (De Maeyer and De Maeyer-Guignard, 1994), and of 
costimulatory or cell surface molecules (Doherty, 1995), which play a part in 
macrophage interaction with T -cells. IFN-y also stimulates the secretion of reactive 
oxygen intermediates and hydrogen peroxide from macrophages, augmenting the 
killing of intracellular parasites (Nathan et al. 1983). 
Activated macrophages produce metalloproteinases which assist the digestion 
of endothelial basement membrane and allow migration of these cells from blood to 
tissues (Wahl et al. 1974). There, they are responsible for the release of further 
mediators, in particular the cytokines interleukin-1 (IL-1) and tumour necrosis factor-
a (TNF-o.) which initiate the cascade of events constituting the acute phase response. 
The action of IL-1 and TNF -a results in a secondary wave of cytokines, of which IL-
6 is of particular importance in the acute phase response, and chemokines from 
neighbouring cells which include chemotactic agents to attract cells into the damaged 
area to assist repair. Interleukin-12 production by macrophages directs the 
development of a T helper cell type 1 (Thl)-like or cell-mediated immune response 
(Hsieh et al. 1993). 
Several cytokines including interleukins 4, 10 and 13 and transforming growth 
factor-B have been implicated in causing the deactivation of macrophages (Bogdan 
and Nathan, 1993) although it is now recognised that macrophages can respond to 
cytokine stimulation in different ways depending on the local environment (Doherty, 
1995). 
1.2.3. Mechanisms of the Acute Phase Response 
The local and systemic processes of the acute phase response are summarised in 
figure 1.2. On activation, leukocytes invading infected or inflamed tissue, release 
substances which leak into the extracellular space (Evans and Whicher, 1992). These 
low molecular weight mediators such as the arachidonic acid metabolites act locally 
to alter vascular tone and increase leakage from blood vessels causing tissue oedema 
and redness (Cotran et al. 1994), and, along with molecules liberated during the 
clotting cascade, result in the production of pain. One of these mediators, nitrous 
oxide (NO), is a soluble free radical gas which has been established as a crucial 
mediator of macrophage function. Treatments blocking the production of NO 
CHAPTER 1 14 
Figure 1. 1. Activities of the activated macrophage 
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prevent the tumoricidal and bactericidal functions of macrophages (Lowenstein and 
Snyder, 1992). NO is also produced by endothelial cells, resulting in relaxation of 
adjacent vascular smooth muscle cells. In a similar manner to other mediators of 
inflammation, NO can have both helpful and detrimental effects and it is implicated as 
being a cause of hypotension (Evans and Cohen, 1996) during uncontrolled 
inflammatory diseases, consequently therapeutic roles for inhibitors of NO and the 
enzyme NO synthase have been hypothesised (Groeneveld et al. 1997; Nathan, 
1992). 
Systemically, release of acute phase cytokines can be associated with a 
multitude of reactions including fever, anorexia, leukocytosis, activation of 
complement, a rise in serum glucocorticoids, altered lipid metabolism, a reduction in 
serum iron and zinc levels, an enhanced uptake of amino acids with muscle 
catabolism and the production of acute phase proteins by the liver (Moshage, 1997; 
Whicher and Westacott, 1992). The febrile response arises through the central action 
of the inflammatory cytokines on the hypothalamus (Dinarello, 1994) and induction 
of prostaglandin E2 (Dinarello et al. 1991) which alters the balance between 
peripheral vasoconstriction and sweating and increases muscle metabolism, becoming 
apparent as shivering (Atkins and Bodel, 1972). An elevated incubation temperature 
has been shown to enhance lymphocyte function in vitro (Roberts and Steigbigel, 
1977); fever is considered to be fundamental to the inflammatory response and 
ultimately host survival (Carmichael et al. 1969). Optimisation of the mechanisms of 
the inflammatory response in the pyretic state reduce their potential toxic effect on 
the body during homeostasis. The central action of the pro-inflammatory cytokines 
on the hypothalamus is also responsible for anorexia (Johnson, 1997). 
Corticosteroid synthesis is increased during inflammation as a result of both 
hypothalamic and adrenal stimulation by the inflammatory cytokines. These 
glucocorticoids are responsible for alterations in carbohydrate metabolism (Gordon, 
1985). Conditions inducing an acute phase response such as severe infection and 
major surgery can result in lower circulating levels of thyroxine. It is suggested that 
this alteration in thyroid function is mediated by the direct and indirect effects of 
TNF -a and other cytokines on pituitary and thyroid cells (Wong and Hershman, 
1992). 
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Figure 1.2. Local and systemic effects of the acute phase response 
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IL-1 and IL-6 induce the release of cells from the bone marrow and the 
production of granulocyte and macrophage replication factors. Levels of iron are 
reduced initially (Myers et al. 1984) due to an increase in vascular permeability and 
subsequently through sequestration at the site of injury probably by binding to 
lactoferrin which is released from neutrophils. Zinc is lost from plasma initially 
(within 2 hours) through extravasation of its carrier protein, albumin, and 
subsequently by hepatic uptake when the ratio of zinc to albumin becomes reduced. 
IL-1 and IL-6 also stimulate release of corticotrophin-releasing hormone (Busbridge 
and Grossman, 1991), and lead to increased cortisol production, which inhibits 
cytokine expression by a negative feedback loop. In addition, these cytokines have 
been shown to cause corticosteroid release directly from adrenal gland cells in vivo. 
An increase in urinary nitrogen excretion during inflammation reflects muscle 
proteolysis although the precise mechanisms involved are unclear (Webel et al. 
1997). Studies in vitro have shown that IL-1 (leukocytic pyrogen) induces PGE2 in 
isolated muscles which increases protein breakdown, a response that is enhanced at 
39°C when compared to 37°C (Baracos et al. 1983). The released amino acids are 
used for lymphoid proliferation, antibody production and the production of acute 
phase proteins by the liver. TNF-a. stimulates enhanced lipolysis releasing additional 
substrates for utilisation in the liver. Both of these catabolic processes lead to weight 
loss. The inflammatory mediators cause alterations in the normal metabolic pathways 
of the liver and induce the production of acute phase proteins by hepatocytes. 
1.2.4. TNF-a and the Acute Phase Response 
At the turn of the century, it was observed that haemorrhagic necrosis of tumours 
occurred in human patients during the course of a concurrent bacterial infection 
(Coley, 1919) and the same observation was made in cancer patients inoculated with 
killed bacteria. Further studies of this phenomenon led to the hypothesis that a 
substance, tumour necrosis factor (TNF), mediated endotoxin-induced tumour 
necrosis, and that it may be responsible for the suppression of transformed cells that 
is seen in the presence of activated macrophages (Carswell et al. 1975). Indeed, TNF 
was later purified and characterised by Aggarwal and others (Aggarwal et al. 1985). 
The same protein was also purified by a group investigating a toxic mediator 
responsible for the chronic wasting seen in inflammation and named cachectin 
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(Beutler et al. 1985b). It became clear that both tumour necrosis and cachexia were 
due to the same 17kDa protein, now known as TNF-a (Beutler et al. 1985a). 
However, it was also apparent that any clinical value the protein may have in cancer 
therapy might be limited by the severe systemic toxicity that it could also initiate 
(Beutler and Cerami, 1989). 
Macrophages and monocytes are believed to be the major source of TNF-a 
(Mannel et al. 1980) although a variety of other cells have also been identified that 
are capable of producing the cytokine (Xing et al. 1993). One of the most potent 
stimuli of TNF-a synthesis is bacterial LPS (endotoxin) (Tracey et al. 1988), which 
interacts with the CD14 membrane protein on monocytes and macrophages. TNF-a 
production is also stimulated by other microbial products such as enterotoxins and 
some antigenic determinants. Non-covalent oligomerisation of three monomers of 
TNF-a after secretion results in a trimeric structure (Sprang and Eck, 1992) which is 
essential for biological activity; disruption of the trimer results in loss of activity (Lin, 
1992). TNF -a bound to the plasma membrane can also have bioactivity (Perez et al. 
1990). It is not known whether all secreted TNF-a arises through cleavage of the 
membrane bound form or whether it can be released without formation of the 
intermediate. 
As discussed briefly in section 1.2.l., TNF-a in combination with IL-l is 
released from activated macrophages at the site of tissue damage. It interacts with 
endothelial cells to induce the release of further IL-1 (Nawroth et al. 1986). These 
cytokines then act on neighbouring stromal cells, causing a secondary release of 
cytokines such as IL-6 and initiating the cascade events of the acute phase response. 
TNF-a is chemotactic for phagocytic cells and enhances their phagocytic activity and 
is thus involved in the initial non-specific cellular response to invasion. TNF-a also 
plays a role in the up-regulation of expression of endothelial surface molecules such 
as the major histocompatibility complex antigens HLA-A and HLA-B (Collins et al. 
1986). The TNF -a-induced increased expression of these molecules on tumour cells 
might make them more susceptible to cytotoxic cell attack (Vanky et al. 1998). The 
intercellular adhesion molecule, ICAM-l, is also up regulated by TNF-a, slowing 
leukocyte flow, and enhancing migration from the circulation into tissue. 
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1NF-a is involved in the febrile response to inflammation through the 
induction of prostaglandin E2 (Dinarello et al. 1991). The hypothalamic centres that 
regulate body temperature and appetite do not have a blood-brain barrier and 
systemically administered 1NF-a crosses into this area leading to fever and anorexia. 
Levels of 1NF-a in serum become rapidly elevated in response to an inflammatory 
stimulus (Beutler et al. 1985c) but also decline rapidly, disappearing from serum in 
less than 6 hours in the case of experimental bacteraemia or endotoxaemia (Redl et 
al. 1995). 
The related but distinct cytokine, 1NF-/3 or lymphotoxin-a, is a member of 
the same gene family, and shares 35% amino acid homology and many activities 
with TNF-a including the ability to kill L929 cells. However, TNF-/3 is produced by 
activated lymphocytes and has a role in the development of T -cells and in the 
mediation of graft rejection (Ruddle, 1994). 
1.3. Serum Markers of the Acute Phase Response 
1.3.1. Acute Phase Proteins 
Acute phase proteins alter in concentration during an inflammatory reaction and, in 
general, are produced to assist the defence of the host organism against tissue 
damage and infection. They act in a variety of ways such as contributing towards 
haemostasis (fibrinogen) and opsonisation (C-reactive protein (CRP)), inhibiting 
proteinases (a1-antichymotrypsin) and acting as immunomodulators (a-1 acid 
glycoprotein (AGP)). They also aid wound healing (serum amyloid A (SAA)) and 
act as carriers for certain ions and other proteins (haptoglobin) (Whicher and 
Westacott, 1992). Most acute phase proteins are produced by the liver although a 
small fraction are synthesised in extra-hepatic sites (Ramadori et al. 1985). 
The rapid rise in the concentration of positive acute phase proteins in serum 
as a result of tissue damage has led to their measurement being used in man as a 
marker of inflammation in clinical diagnosis and prognosis (Thompson et al. 1992) 
and to monitor response to treatment (Casl et al. 1993). For many years, the 
erythrocyte sedimentation rate (ESR) has been used to quantify the overall acute 
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phase protein response. The ESR is a measure of the rate at which red blood cells 
settle in a vertical column of anti-coagulated blood. It gives an indirect measurement 
of plasma acute phase protein content since the large, highly glycosylated proteins 
produced during the response influence this rate (Bull, 1981). However, the ESR is 
greatly affected by fluctuations in the haematocrit, is subject to significant diurnal 
variation related to ingestion of food (Mallya et al. 1982), and mainly reflects the 
concentration of the large protein fibrinogen which is a slow acute phase reactant. 
For these reasons, particularly in acute disease, analysis of individual proteins has 
been recommended (International Committee for Standardization in Haematology 
Expert Panel on Blood Rheology, 1988; Sliwinski et al. 1983; Yocum and Doerner, 
1957). 
The plasma concentration of acute phase proteins may either increase or 
decrease as a result of inflammation. Those proteins which are reduced III 
concentration, for example albumin, have been called negative acute phase reactants 
or concentration depressed acute phase plasma proteins (Koj, 1985a). The positive 
acute phase proteins rise in concentration following inflammation and have been 
classified into three groups according to their magnitude of increase (Kushner and 
Mackiewicz, 1987). Group 1 or minor acute phase proteins increase by around 50%, 
group 2 or moderate acute phase proteins increase up to two to five-fold and group 3 
or major acute phase proteins rise up to a thousand fold from a low or negligible 
normal value. A table listing some acute phase proteins and the mode in which they 
respond in man is given (figure 1.3.). 
Acute phase proteins can also be classified by the cytokines which are 
responsible for their induction. In this classification system, type I acute phase 
proteins are those induced by the IL-l-like cytokines which are IL-l a, IL-l P, TNF-a 
and lymphotoxin-a (also known as TNF-(3). The proteins induced by this group 
include AGP, SAA, CRP, complement component C3 and haptoglobin (rat). Type II 
proteins, including fibrinogen, aI-antitrypsin and haptoglobin (human) are induced by 
the IL-6-like cytokines, which are IL-6, leukaemia inhibitory factor, IL-ll, oncostatin 
M, ciliary neurotrophin factor and cardiotrophin-l (Moshage, 1997). Stimulation of 
type-l acute phase protein genes is enhanced by IL-6-type cytokines whereas the IL-
l-type cytokines may inhibit type-2 acute phase protein gene expression (Baumann 
and Gauldie, 1994). 
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Figure 1.3, Classification of some acute phase proteins based on changes in their 
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Major acute phase proteins have received most attention as aids to diagnosis 
in clinical situations. The protein most frequently monitored in man is CRP which 
was originally identified and named because of its ability to bind to pneumococcal C-
polysaccharide (Tillett and Francis, 1930). CRP is a very sensitive marker for the 
acute phase response in man, rising to peak levels of up to 20 times preoperative 
concentrations around 48 hours after minor, uncomplicated surgery and falling 
steadily afterwards (Colley et al. 1983). This protein has been used as the primary 
biochemical marker of inflammation in man for several years. 
There is considerable variation in the acute phase protein response between 
species (Gruys et al. 1994), a prime example being CRP which is present in 
significant amounts in serum from the healthy bovine and does not appear to rise in 
response to inflammation in this species (Maudsley et al. 1987). It is therefore 
important to determine for each species the proteins which behave as major acute 
phase reactants, and thus may be of value in the clinical situation (Kent, 1992). A 
more complete review of the acute phase protein response in the species of veterinary 
interest is given in Chapter 2. 
1.3.2. Acute phase proteins and viral infections 
A study of human patients with a variety of infections, monitoring blood levels of two 
acute phase proteins that act as major responders in man, CRP and serum amyloid A 
(SAA), found that concentrations were higher in bacterial infections than in viral 
infections (Nakayama et al. 1993). Although, in the vast majority of patients, both 
proteins were higher in samples obtained during the acute than the convalescent 
stages, determination of SAA concentration was found to be more sensitive than 
CRP for monitoring viral infections. Indeed, in some situations the lower sensitivity 
of CRP to detect viral infections is considered useful in differentiating symptoms that 
may be of bacterial or viral origins such as meningitis (Clarke and Cost, 1983). 
Patients with acquired immunodeficiency syndrome (AIDS) as a result of 
human immunodeficiency virus (HIV) infection exhibit higher acute phase protein 
levels than healthy controls reflecting the additional inflammatory stimulus of 
secondary infections (Husebekk et al. 1995), although it has also been found that the 
CRP response in patients with pneumococcal pneumonia is impaired if the patient 
also has AIDS (Klenerman et al. 1993). 
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1.3.3. TNF-a. Receptors 
It is known that in man and the mouse, TNF can exert its effect through two separate 
receptors which bind TNF-a. and TNF-~ with equal affinity and are widely distributed 
on virtually all cells except red blood cells (Aggarwal and Reddy, 1994; Beutler et al. 
1985). However, the genes encoding the two receptors are differentially expressed in 
different cell types (Vandenabeele et al. 1995). The smaller, 55-60kDa receptor, 
known as Type 1 (TNFR-l), is expressed mainly on epithelial cells; the larger, 75-
80kDa receptor, known as Type 2 (TNFR-2), is expressed mainly on myeloid cells 
(Hohmann et al. 1989). 
The receptors are members of the nerve growth factor receptor super-family 
which are characterised by cysteine rich repeat domains in the extracellular region. 
The extracellular regions of the receptors show 25% homology in amino acid 
sequence both to each other and to other members of the same family (see figure 
1.4.). However the cytoplasmic domains are not homologous. Crystallographic 
studies indicate that three TNFR-l molecules bind to one TNF-a. trimer (Banner et 
al. 1993) and a more recent report shows that either TNF-a. or TNF-~ binding 
causes activation of TNFR-l through aggregation of the cytoplasmic domains 
(Naismith et al. 1995). Receptor-specific antibodies can mimic TNF activity 
(Engelmann et al. 1990a) suggesting that clustering of the receptors is sufficient to 
initiate the intracellular signalling mechanisms involved. 
TNFR-l appears to be the main receptor in mediating cell cytotoxicity, LPS 
toxicity (Espevik et al. 1990) and gene induction in epithelial cells (Mackay et al. 
1993). Transgenic mice deficient in TNFR-l are resistant to endotoxic shock when 
treated with bacterial LPS or staphylococcal enterotoxin Band D-galactosamine and 
yet have a reduced ability to fight infection with Listeria monocytogenes (Pfeffer et 
al. 1993) illustrating that TNFR-l is crucial for both toxic and protective effects of 
TNF. 
The role of TNFR-2 is less well defined although it has been implicated in the 
cellular proliferation effects of TNF-a. (Tartaglia et al. 1993a). In addition, in 
association with the function of TNFR-l, both 'ligand-passing' and 'decoy' roles have 
been proposed for TNFR-2 although these mechanisms may not be mutually 
exclusive (Bigda et al. 1994). The 'ligand-passing' model hypothesises that TNFR-2, 
as it has a higher affinity and dissociation rate than TNFR-l, preferentially binds TNF 
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Figure 1.4. Outline of the structure of nerve growth factor receptor (NGFR), TNFRI 
and TNFR2. The extracellular domains of each receptor share 25% homology. 
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at low concentrations and passes it to neighbouring TNFR-1 molecules (Tartaglia et 
al. 1993b). This 'enhancing' role for the receptor is supported by the finding that 
mice deficient in TNFR-2 show an increased, although not complete, resistance to 
TNF-induced death and a reduction in tissue necrosis as a result of subcutaneous 
TNF injection (Erickson et al. 1994). The 'decoy' model hypothesises that TNFR-2 
binds TNF, thus preventing its action through TNFR-l. TNFR-2 may also be 
important in mediating the effects of membrane-bound TNF (Grell et al. 1995). 
Removal of the cytoplasmic domain of TNFR-1 results in a non-functional 
receptor (Tartaglia and Goeddel, 1992) whereas less complete deletions within the 
cytoplasmic region demonstrate a region of about eighty amino acids essential for 
cytotoxicity, antiviral activity and NO synthase signalling (Tartaglia et al. 1993), 
designated the death domain. A TNFR-1 associated death domain protein has been 
identified which interacts with this area and leads to NF-K13 activation. 
Phosphoproteins and a serine protein kinase that interact with the more membrane-
proximal region of the intracellular domain of TNFR-1 have also been isolated (Van 
Arsdale and Ware, 1994). 
Proteins interacting with the intracellular portion of TNFR-2 have been 
identified and designated TRAF proteins (TNFR-2 associated factors) although these 
can also interact with TNFR-1. The precise function of this protein family is not 
known but they have an area characteristic of DNA-binding proteins thus may 
represent cytoplasmic transcription precursors (Vandenabeele et al. 1995). Over-
expression of TRAF2 is responsible for NF -K13 activation (Kaye et al. 1996). 
Vandenabeele and others propose that TNFR2-mediated intracellular signalling 
pathways require the co-operation of other cytokine-receptor-stimulated pathways 
such as the IL-1 pathway (Vandenabeele et al. 1992). 
Human TNF-a has been shown to bind to murine TNFR-1 but not murine 
TNFR-2, indicating that TNFR-2 exhibits more species specificity (Lewis et al. 
1991). 
1.3.4. Soluble TNFRs 
The extracellular portions of both receptors can be cleaved to release soluble 
proteins (sTNFR-1 and sTNFR-2) (Engelmann et al. 1989; Kohno et al. 1990; 
Nophar et al. 1990; Seckinger et al. 1989). These soluble receptors were first 
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identified in urine by their ability to inhibit TNF-a induced cytotoxicity in bioassays 
(Engelmann et al. 1990b). They bind TNF -a in a reversible manner, inhibiting 
activity by preventing its interaction with cells, but also forming a reservoir of TNF-a 
activity (Aderka et al. 1992; Mohler et al. 1993). Soluble TNF receptors have been 
identified in different body fluids of both healthy and diseased patients including urine 
(Novick et al. 1989), serum (Godfried et al. 1993) and synovial fluid (Cope et al. 
1992). 
Viral genes have been isolated from Shope fibroma, myxoma and cowpox 
viruses that encode proteins which interact with TNF -a and thus interfere with the 
host's defence mechanisms (Smith et al. 1991; Smith et al. 1996; Upton et al. 
1991). These proteins are also members of the nerve growth factor receptor family 
and show most homology to the soluble portion ofTNFR-2. 
Diez-Ruiz and others reviewed the use of sTNFR measurement in clinical 
laboratory diagnosis and suggest that their levels in serum show high accuracy in the 
follow-up and prognosis of diseases such as mv infection and sepsis (Diez-Ruiz et 
al. 1995). Increased levels of endogenous sTNFRs reflect activation of the TNF-
aJTNF receptor system and assist quantification of the Th1-type cell-mediated 
immune response. Redl and others have reported on elevation of plasma levels of 
sTNFR-1 (from a healthy mean of 1.7nglml to a mean in affected animals of 
10.4nglml) in a baboon model of bacteraemia (Redl et al. 1995). Since levels of 
sTNFR-1 remained elevated for the eight hours of the experiment but TNF-a 
returned to basal levels within six hours, sTNFR-1 may represent a more useful 
marker of inflammation than TNF-a. 
In patients with human immunodeficiency virus (mV) infection, sTNFR-1 
and -2 levels have been correlated to disease progression (Aukrust et al. 1994; 
Barcellini et al. 1996; Godfried et al. 1993; Hober et al. 1996; Kalinkovich et al. 
1992; Kalinkovich et al. 1993). In addition, measurement of sTNFR-2 in serum has 
been of value in monitoring the efficacy of treatment in asymptomatic mV-1 
infection (Godfried et al. 1995). Low levels of sTNFR in cancer patients have been 
correlated with an increased survival time (Langkopf and Atzpodien, 1994) and 
successful treatment of hairy cell leukaemia is associated with a decrease in sTNFR 
(Digel et al. 1992). In a study of patients with congestive heart failure, measurement 
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of sTNFR, in addition to TNF -a, was found to be essential for evaluation of the role 
of this cytokine and elevated levels of sTNFR-2 correlated with a poor short-term 
prognosis (Ferrari et al. 1995). 
Inhibition of the bioactivity of TNF-a by sTNFR has also stimulated interest 
in the soluble receptors as therapeutic agents (Olsson et al. 1993). Administration of 
sTNFR-1 can prevent the adverse pathologic sequelae caused by the exaggerated 
TNF-a production observed in lethal sepsis in non-human primates (Van Zee et al. 
1992). However, a clinical trial in people has shown an increased mortality in 
patients given TNFR:Fc fusion protein as a treatment for septic shock (Fisher et aI, 
1996) and it may be that ameliorating effects in this condition is only possible in 
experimental infection when the soluble receptor can be given prior to TNF-a 
stimulation. Implantation of mice with copolymers containing human sTNFRl has 
been associated with protection from the development of chronic TNF-associated 
diseases such as lethal wasting and arthritis (Eliaz et al. 1996). 
1.4. Feline Infectious Peritonitis 
1.4.1. Background 
Feline infectious peritonitis (FIP) is an invariably fatal disease of cats caused by 
infection with a feline coronavirus (FCo V) (Horzinek and Osterhaus, 1978). The 
Coronaviridae are pleomorphic viruses with a single stranded ribonucleic acid (RNA) 
genome, surrounded by an envelope with a corona of radiating proteins or peplomers 
which give the virus its name. 
1.4.2. Pathogenesis 
Infection of the cat in the field probably occurs by inhalation or ingestion (Hoskins, 
1993). Replication of the virus in the alimentary tract and subsequent viraemia may 
be asymptomatic or result in mild disease such as enteritis and be followed by 
recovery from infection or, if virus is not cleared by the host, be associated with the 
clinical signs ofFIP (Weiss, 1991). Viraemic cats may shed virus in faeces, saliva and 
urine. 
Whether cats recover from infection with FCo V or develop FIP is thought to 
be determined by a multitude of factors including strain of virus, whether humoral or 
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cellular mechanisms predominate in the host immune response and whether the cat 
is already sensitised from a previous infection (Hoskins, 1993). More recently, it has 
been suggested that increased viral replication in the gastrointestinal tract, such as 
that exhibited when the host is immunosuppressed enhances the mutation rate in the 
viral genome, and makes it more likely for strains of enhanced virulence to arise and 
cause disease (Poland et al. 1996). 
-
Persistent infection with FCo V causes continued stimulation of the immune 
system which results in an immune-stimulated vasculitis and the condition known as 
FIP. Two forms of FIP been described based on the predominant clinicopathological 
findings (Pedersen, 1976). In the classical, effusive presentation, the vasculitis is 
responsible for the characteristic exudative inflammation of the pleural and/or 
peritoneal cavities (figures 1.5. and 1.6.). The other, non-effusive form (figures 1.7. 
and 1.8.) is caused by pyogranulomatous deposits in a variety of organs including the 
eye and the central nervous system and clinical signs are dependent upon the organs 
involved. 
1.4.3. Clinical Biochemistry and Diagnosis 
Diagnosis of FIP can present a considerable problem for the clinician. Clinical 
biochemical and haematological findings in FIP are non-specific although the 
albumin and globulin content (Weiss, 1991) and protein electrophoresis (Shelly et al. 
1987) of effusion samples are considered to be parameters that assist diagnosis. 
Positive antibody titres to FCo V are not diagnostic since cats that have been infected 
with FCoV can develop antibody and then recover from infection (Scott, 1979). The 
only definitive diagnostic test for FIP is histopathological examination of a 
representative biopsy sample, which is an invasive procedure (Addie, 1989). 
Reports on inflammatory cytokines and acute phase proteins during the 
course of FIP are limited. IL-l (Goitsuka et al. 1991) and IL-6 (Goitsuka et al. 
1990) activities have been detected in ascitic fluid samples and serum (IL-6 only) 
from cats with FIP. Gouffaux and others described elevated acute phase proteins and 
reduced albumin levels in experimental and field cats with FIP illustrating an 
inflammatory process (Gouffaux et al. 1975). More recently, Stoddart and others 
studied the acute phase prc!p.in response in experimental cats inoculated with 
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Figure 1.5. The typical appearance of a cat with feline infectious peritonitis and an 
associated abdominal effusion. 
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Figure 1.6. An abdominal radiograph of a cat with effusive FIP. Visceral detail 
within the abdomen is obliterated by the presence of fluid. Only gas within the 
bone and organs within the thorax can be discerned. 
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1.7. An emaciated cat with non-effusive FIP. 
CHAPTER! 32 
Figure 1.8. The gross abdominal pathology of the cat in figure 1.7. Enlarged 
mesenteric lymph nodes can be seen, with multiple granulomata on the small 
intestine and mesentery. 
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coronavirus to produce FIP in an attempt to identify changes useful in the early 
diagnosis of the disease (Stoddart et al. 1988). They used electrophoretic methods to 
examine changes in serum protein levels, found a biphasic response of an initial small 
peak of proteins shortly after inoculation followed by a large negative drop, and 
concluded that the technique was of no value in the diagnosis of FIP. 
1.5. Feline Immunodeficiency Virus Infection 
1.5.1. Background and Epidemiology 
Feline immunodeficiency virus (FIV) is a lentivirus that was first isolated in 1986 
from a colony of cats in which several suffered from an immunodeficiency-like 
syndrome (Pedersen et al. 1987). Lentiviruses, which include human 
immunodeficiency virus (HIV), have an RNA genome and are members of the family 
Retroviridae (Calisher et al. 1992). FIV is genetically distinct from mv although 
both cause a similar clinical disease in their respective hosts (Pedersen, 1995). A 
study of blood samples taken from cats in the UK determined the prevalence of FIV 
infection as 19% in sick cats and 6% in healthy cats (Hosie et al. 1989), emphasising 
the major significance of this pathogen. Both this and further epidemiological studies 
have identified that older, free-roaming male cats are most likely to be infected with 
FIV (Grind em et al. 1989; Gruffydd-Jones et al. 1988; Hosie et al. 1989; Ishida et 
al. 1989; Peri et al. 1994; Yamamoto et al. 1989) which reflects the proposed mode 
of transmission through fighting and biting. Although the virus was only discovered 
in 1986, retrospective analysis of stored serum samples has detected antibody to FlV 
prior to this time (Bennett et al. 1989; Gruffydd-Jones et al. 1988). 
1.5.2. Pathogenesis 
Cats infected with FlV can shed virus in their saliva and this is enhanced by oral 
inflammation, a frequent symptom of FIV infection (Sparkes et al. 1993). 
Consequently, the major mode of transmission of natural infection appears to be 
fighting and biting (Sparger, 1993), although infection from mother to kitten has also 
been reported (Callanan et al. 1991). Transmission in utero and intrapartum can 
occur as well as infection whilst suckling, and vertical transmission is enhanced when 
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the mother has a low CD4+ count, a prolonged duration of infection or clinical signs of 
immunodeficiency (ONeil et al. 1996). 
Recently, it has been demonstrated that some FlV strains use the chemokine 
receptor CXCR4 for entry into the cell (Willett et al. 1997). Once the virus has entered 
a cell, it uncoats and uses its reverse transcriptase enzyme to make a DNA copy of its 
RNA genome. This viral DNA then enters the nucleus and integrates into the host 
DNA, becomes known as the provirus and is translated resulting in the production of 
further virions which are released from the cell. 
Within 6 weeks of experimental infection with FlV, cats enter an acute phase of 
general malaise (Pedersen et al. 1989) which is associated with a lymphadenopathy 
lasting up to 1 year (Callanan et al. 1992). During this period, leukopenia, in particular 
neutropenia, is apparent and cats show an increased susceptibility to infection (Dua et 
al. 1994; Yamamoto et al. 1988). By semi-quantitative analysis using the polymerase 
chain reaction (PCR), Dean and others showed higher levels ofFIV provirus in CD4+T 
cells at this stage of disease than in B cells (CD21 +) and CD8+ T cells (Dean et al. 
1996). Within 10 days of infection, when compared to negative controls, plasma TNF-
a. levels are elevated and the response of peripheral blood mononuclear cells (PBMCs) 
to mitogens is depressed (Lawrence et al. 1992). A strong humoral antibody response 
becomes apparent from 1 to 2 months after infection (Callanan, 1995; Dua et al. 1994) 
and in the acute phase of the infection there is a rapid expansion of CD8+ lymphocytes 
and a more gradual decline in the peripheral CD4+ lymphocyte population (Willett et 
al. 1993). 
After the acute phase, cats enter the asymptomatic phase when, as the name 
suggests, they are free from clinical signs but remain persistently viraemic although 
most of the virus is cell-associated (Sparger, 1993). During this period, an inversion in 
the CD4+:CD8+ ratio has been demonstrated (Ackley et al. 1990; Lawrence et al. 
1995; Novotney et al. 1990), and viral DNA is present in greater numbers ofB cells 
than CD4+ and CD8+ T cells (Dean et al. 1996). PBMCs taken from cats during this 
period exhibit reduced proliferation in response to mitogen stimulation (Ishida et al. 
1992). However, the changes in cytokine levels over this period appear less consistent 
with both an increase in levels ofIL-l, IL-6 and TNF-a. in supernatants from stimulated 
PBMCs (IL-I, IL-6) or plasma (TNF-a.) (Lawrence et al. I995a), contrasting with 
reports of a reduction in TNF-a. and no change in IL-6 production 
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from stimulated cells (Ma et al. 1995). The latter study suggests that the lack of TNF 
stimulation may be due to the absence of secondary disease as it examined 
experimental specific pathogen free (SPF) cats. However the population of cats in the 
first study were also SPF. 
The asymptomatic stage may last for years until, as immunosuppression 
progresses, secondary disease such as opportunistic infection or neoplasia becomes 
apparent. In HIV, progression from the asymptomatic to clinical stages of disease has 
been associated with a shift from predominantly cell-mediated immune responses (via 
Th1-type cytokines) towards a predominance of Th-2 cytokine influences and a 
humoral immune response (Clerici and Shearer, 1994) but this has not been 
documented in FIV. Eventually cats succumb to secondary disease, or more 
commonly, are euthanased when presented to veterinarians as seropositive, sick cats. 
1.5.3. Diagnosis 
Diagnosis of FlV infection is relatively straightforward as most infected cats have 
anti-FIV serum antibodies (Macy, 1994). In addition, immunoassays are available to 
detect the presence of FIV antigen, virus isolation can be performed (Pedersen and 
Barlough, 1991) and FlV nucleic acid sequences can be demonstrated in infected 
samples by the polymerase chain reaction (Tomonaga and Mikami, 1996). 
1.5.4. Treatment and Prognosis 
Treatment is largely palliative and directed towards any secondary infections or other 
diseases that are present, although some anti-viral drugs have been investigated in the 
treatment of FIV. It has been suggested that cytokine-based therapy that enhances 
cell-mediated immunity should be instituted in mv in combination with anti-
retroviral drugs (Clerici and Shearer, 1994) but this avenue remains largely 
unexplored in the cat. Although treatment strategies are currently fairly restricted, it 
is essential that markers of disease progression are identified in FIV so that the effect 
of treatment can be monitored and a prognosis over the prolonged asymptomatic 
period can be given. 
Numerous cellular and serological markers have been monitored in mv 
infection and an attempt made to correlate these with disease progression. The 
parameter said to reflect stage of disease most closely is the CD4+ lymphocyte count 
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(Stein et al. 1992), which gradually declines over the course of infection. The 
serological markers studied and correlated with CD4+ lymphocyte counts and to 
clinical outcome include the cytokine tumour necrosis factor-a. (TNF-a.) (Aukrust et 
al. 1999) and its soluble receptors (see section l.2.7) (Godfried et al. 1993; Hober 
et al. 1996). Although a reduction in CD4+ lymphocyte numbers have been recorded 
in both naturally (Hoffman-Fezer et al. 1992; Novotney et al. 1990) and 
experimentally (Ackley et al. 1990) infected FlV positive cats, with an associated 
inversion in the CD4+:CD8+ ratio, little has been reported on serological markers of 
FlV disease progression. 
1.6. Objectives 
The ultimate aim of the work presented in this thesis was to assist clinicians by 
identifying markers of inflammation in the cat that it might be useful to monitor in the 
clinical situation. This was approached, firstly, by studying the feline acute phase 
protein response in FIP and FlV infection. Thereafter, the possibility of using an in 
vitro bioassay to identify TNF inhibitory activity was investigated. Finally, work was 
directed towards developing species-specific assays for feline soluble tumour necrosis 
factor receptors for use in the management of cats with FlV infection. 
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Chapter 2: 
The Acute Phase Protein Response In The Cat 
2.1. Summary of Chapter 
The aim of the work presented in this chapter was to characterise the feline acute 
phase response by monitoring the levels of two acute phase proteins, a I-acid 
glycoprotein (AGP) and haptoglobin (Hp). Reference ranges for these proteins were 
determined by measuring their concentrations in serum samples from healthy cats. 
Subsequently, levels of AGP and Hp were measured in serum and effusion samples 
from sick cats with a clinical presentation suggestive of feline infectious peritonitis 
(FIP) and in serum samples from cats taken during the initial acute, asymptomatic 
and terminal stages of feline immunodeficiency virus (FlV) infection. It was found 
that these acute phase proteins are present in the serum of healthy cats and their 
concentrations rise during certain periods of these diseases. In particular, AGP 
analysis was of value in differentiating cases of FIP from conditions with a similar 
clinical presentation. 
2.2. Acute Phase Proteins in the Species of Veterinary 
Interest 
2.2.1. General introduction 
A summary of major and moderate acute phase proteins as well as those that are 
most commonly monitored in clinical diagnosis in a number of species is given in 
figure 2.1. The acute phase response has certainly not been as well documented in 
the species of veterinary interest as it has in man. As mentioned briefly in Chapter 1, 
there are considerable interspecies differences in the production of acute phase 
proteins thus conclusions on the response in animals cannot be drawn directly from 
clinical investigations in man. In the veterinary literature, the erythrocyte 
sedimentation rate (ESR) has been acknowledged as providing useful information for 
clinical evaluation and in detecting occult disease, particularly in the dog (J ::tin, 1986) 
and should be of equal benefit in the cat. However horse erythrocytes naturally settle 
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very rapidly in anti-coagulated blood and bovine erythrocytes show little 
sedimentation so the ESR is unreliable in these species (Jain, 1993). Despite the long-
recognised assistance with diagnosis that this test may provide in the assessment of 
small animal cases in the field, it is very seldom used in practice possibly because of 
the dependency of the test on other parameters such as packed cell volume. Instead, 
clinicians have increasingly directed their attention towards the measurement of 
individual acute phase reactants to provide assistance with diagnosis. 
In a review of the acute phase proteins that have been studied and utilised in 
the veterinary species, Gruys and others emphasise the value of testing for these 
proteins in the investigation of both sub-clinical and clinical disease (Gruys et al. 
1994). 
The acute phase protein Hp is an a2-glycoprotein in man which binds 
haemoglobin with high affinity (Cohen-Dix et al. 1973) and is involved in its 
transport around the body. It is thought that through binding to Hp, the harmful 
effects of haemoglobin on the kidneys are avoided, particularly after a haemolytic 
crisis. The binding is 'suicidal' since the Hp-haemoglobin complexes are destroyed by 
the reticuloendothelial system although iron from haemoglobin is recycled. In 
addition to this haemoglobin transport, it is emerging that Hp also plays a role in the 
host defence against infection. The protein binds to antigens on invading pathogens 
(Kohler and Prokop, 1978) and haptoglobin receptors have also been identified on 
leukocytes; Hp binding to these cellular receptors may modify the cell's response (EI 
Ghmati et al. 1996). 
The acute phase protein AGP (also known as orosomucoid) is an al-
glycoprotein, the function of which is largely unknown although it has been reported 
to play a part in immunomodulation (Cheresh et al. 1984) and the promotion of 
fibroblast growth (Sliwinski et al. 1983). It is responsible for binding and 
transporting drugs (McNamara et al. 1986) and endogenous compounds such as 
steroids. 
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Figure 2.1. Acute phase protein changes as a result of inflammation in different 
species, including major and moderate responders and those most commonly 
d in clinical d' 
---"'D------· 
Species Major APP Moderate APP APP generally monitored 
Man CRP, SAA AGP, Hp ESR, CRP, occ SAA 
Mouse SAA SAP,Hp SAA, SAP 
Cow Hp, SAA AGP Hp, occ SAA 
Horse SAA Hp, fibrinogen fibrinogen 
Pig CRP, pig-MAP Hp, ASG CRP,Hp 
Dog CRP Hp CRP 
Cat ?SAA CRP, AGP,Hp 
APP, acute phase protein; CRP, C-reactive protein; SAA, serum amyloid A; AGP, a.l-acid 
glycoprotein; Hp, haptoglobin; ESR, erythrocyte sedimentation rate; pig-MAP, pig major acute 
phase protein; ASG, acid soluble glycoprotein; occ, occasionally. 
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2.2.2. Acute phase proteins in farm animals 
A study in 1986 by Conner and others (Conner et al. 1986) examined the 
bovine acute phase response in cattle with mastitis by comparing the levels of three 
acute phase proteins; Hp, ceruloplasmin and a-I antitrypsin, to levels in healthy 
controls. Although significantly increased concentrations of all 3 proteins were found 
in cattle with infection, the most dramatic change occurred in Hp levels which were 
undetectable in healthy cattle but detectable in most of the mastitis cases. C-reactive 
protein (CRP) does not appear to act as an acute phase reactant in cattle (Maudsley 
et al. 1987) although serum amyloid A (SAA) is a major reactant in this species 
(Boosman et al. 1989; Horadagoda et al. 1993; Yamashita et al. 1994). SAA is 
more sensitive as an indicator of inflammation than Hp in cattle and it is not affected 
by haemolysis which may, through binding to haemoglobin, result in a reduction in 
detectable Hp (Eckersall and Conner, 1988). The assay of SAA, however, is more 
difficult than that of Hp, hence Hp is still the most assayed acute phase protein in 
bovine medicine. 
Pronounced rises in Hp levels have been recorded in sheep with both induced 
(Pfeffer and Rogers, 1989) and naturally-acquired inflammation (Skinner and 
Roberts, 1994) and it has been suggested that in this species protein measurement 
may be of more value than haematological analysis in the diagnosis of tissue injury 
and infectious disease. 
An interesting application of acute phase protein measurement, particularly in 
the pig, is that this technique may be of value in assisting the meat inspection process 
to detect sub-clinical disease. A novel porcine major acute phase reactant has been 
identified, called pig major acute phase protein (pig-MAP) which is homologous to a 
human serum protein denominated PK-120. Serum levels of pig-MAP rose 10 to 30 
times those recorded pre-injection as a result of turpentine injection in pigs 
(Gonzalez-Ramon et al. 1995). CRP, Hp and the acid soluble glycoprotein fraction 
of serum are also elevated as a result of inflammation in pigs and may be of value 
clinically (Eckersall et al. 1996). 
2.2.3. Acute phase proteins in the horse 
Acute phase proteins have been used in the horse to monitor inflammatory 
conditions such as laminitis and colic. Historically, fibrinogen and Hp have been used 
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but more recently SAA has been described as the preferential protein for monitoring 
disease (Pepys et al. 1989). In a similar fashion to the situation in the ruminant, CRP 
does not appear to act as an acute phase protein in the horse. 
2.2.4. Acute phase proteins in the dog 
Canine CRP was first identified using immunological reagents designed to 
detect human CRP (Dillman and Coles, 1966), and the authors observed that, 
although there was considerable individual variability in the CRP response, 
development of an assay for the canine protein might prove useful to the clinician. 
CRP has since been cited as the protein of choice to monitor canine inflammation 
(Caspi et al. 1987) and it has been shown to rise to over 100 times levels found in 
healthy dogs in response to inflammation (Yamamoto et al. 1993) although levels in 
serum samples from healthy dogs were higher than baseline levels recorded in man. 
An immunoturbidimetric assay suitable for routine analysis of canine CRP has been 
developed (Eckersall et al. 1989) and its clinical value has been assessed (Burton et 
al. 1994). 
Hp can be detected in serum from healthy dogs and, on stimulation, responds 
as a moderate rather than a major acute phase reactant (Conner et al. 1988). In dogs 
with experimental acute necrotising pancreatitis, detectable haptoglobin levels were 
reduced at 24 hours after induction of disease, as a result of complex formation with 
haemoglobin, thereafter levels became elevated in parallel with fibrinogen (Feldman 
et al. 1980). The measurement of haptoglobin and a-I antitrypsin was also found to 
be a useful prognostic marker in dogs with chronic liver disease. In severe cases, with 
impaired liver function, levels of these proteins were decreased whereas dogs with 
normal or increased levels had a longer survival time (Sevelius and Andersson, 1995). 
SAA has been monitored in dogs and was found to rise to up to 20 times pre-
inoculation levels as a result of experimental Bordetella bronchiseptica infection 
(Yamamoto et al. 1994). 
2.2.5. Acute phase proteins in the cat 
Analyses of the protein fractions seen in normal cat serum were made over 
thirty years ago using electrophoretic techniques (Groulade et al. 1965; Okoshi et al. 
1968). These papers describe changes in serum protein fractions with age rather than 
CHAPTER 2 42 
with disease and note that total protein levels are lower in the newborn. 
Electrophoresis was later employed to look at protein changes induced during the 
course of FIP when a rise in the a and ~ fraction of plasma proteins, which contain 
the acute phase proteins, was recorded (Gouffaux et al. 1975). Further differentiation 
by comparison of serum and plasma electrophoresis for fibrinogen, by complex 
formation with haemoglobin for haptoglobin and by immunoelectrophoresis for 
transferrin identified that each of these proteins was specifically elevated and could 
also be detected in ascitic fluid samples. In addition, in experimental disease a steady 
increase in an a-I glycoprotein, postulated to be AGP (orosomucoid) was also 
demonstrated. The elevation in transferrin appears to highlight interspecies variation 
in the acute phase reaction as this protein acts as a negative acute phase reactant in 
man (Kushner and Mackiewicz, 1993). 
Feline Hp was studied by Harvey and Gaskin, who noted that whilst levels of 
this protein declined dramatically as a result of haemolysis due to Haemobartonella 
felis infection, it became elevated up to seven-fold during other inflammatory 
conditions such as turpentine injection, surgical intervention, upper respiratory tract 
disease and in FIP (Harvey and Gaskin, 1978). 
In contrast to these two latter reports, a more recent electrophoretic study of 
serum samples from cats with experimentally-induced FIP, which included laser 
densitometric analysis of electrophoresis results, showed a rise in protein bands 
corresponding to AGP (orosomucoid), haptoglobin and possibly transferrin one day 
after inoculation with feline coronavirus followed by a large negative response, 
gradually increasing thereafter to pre-infection levels (Stoddart et al. 1988). As a 
result of this study, the authors concluded that acute phase protein measurement was 
of limited value in the diagnosis of FIP. 
SAA has been monitored in healthy and sick cats by a group investigating 
familial amyloidosis in the Abyssinian breed (DiBartola et al. 1989). Using a radial 
immunodiffusion assay, a mean level of SAA was identified in hospitalised cats (non-
Abyssinian), not necessarily suffering from an inflammatory condition, of ten times 
that in healthy non-Abyssinian cats, although no correlation was made between 
clinical condition and SAA concentration. 
Feline CRP has been isolated and characterised and a reference range for this 
protein in the serum of healthy cats determined (Watanabe et al. 1992). The 
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reference range was found to be higher than both that in man and that in the dog. 
None of the above studies have identified a definitive major acute phase reactant in 
the cat, therefore a need persists to identifY assess markers that may be of value in 
clinical diagnosis and prognosis. 
2.3. Aim of Experimental Studies 
The aim of the work presented in this chapter was to characterise the acute 
phase response in the cat by monitoring levels of haptoglobin and AGP and to 
identifY whether these are useful parameters to measure in clinical cases. 
To this end, both proteins were monitored in samples from cats with FIV 
infection. In the early acute and asymptomatic stages of infection, serial samples were 
obtained which coincided with peaks in serum levels of inflammatory cytokines. As 
such cytokines are known to stimulate acute phase protein production, it was 
expected that analysis of these samples would provide a picture of protein changes in 
cat serum over the course of an inflammatory reaction. 
In addition, Hp and AGP were measured in samples from cats with FIP, and 
from cats with clinically similar disease. Although FIP has a viral aetiology, and thus 
may not be expected to induce maximum acute phase protein levels, it is a disease 
associated with much tissue damage as a result of the associated immune-complex 
based vasculitis, and this tissue damage might be responsible for a strong acute phase 
reaction. As described in section 2.2.5., previous reports of the levels of acute phase 
proteins detected during the course ofFIP have been contradictory. 
2.4. Materials and Methods 
2.4.1. Clinical biochemistry 
2.4.1.1. Haptoglobin 
The ability of Hp to bind haemoglobin was utilised in the method for its 
quantification. The Hp assay employed the colorimetric method of Makimura and 
Suzuki (Makimura and Suzuki, 1982) with the modifications of Eckersall and others 
(Eckersall et al. 1988), which depends on the binding of Hp to haemoglobin, 
preventing the inactivation of the peroxidase activity of haemoglobin in an acid 
environment. Free haemoglobin within a sample interferes with this assay, thus 
CHAPTER 2 44 
haemolysed samples tend to give elevated readings and were excluded from the 
study. A canine serum pool with a high Hp content, quantified using a purified bovine 
haptoglobin preparation, was used as a working standard. The assay results are 
therefore reported in gil (bovine equivalent) based on the assumption that the specific 
activity of Hp in terms of haemoglobin binding capacity per mg of Hp is similar with 
bovine, canine and feline Hp. No differences were found when comparing feline Hp 
binding to cyanmethemoglobin from feline, canine, equine or human sources (Harvey, 
1976). 
A stock solution of methaemoglobin (30gll) was diluted one hundred fold for 
the haemoglobin assay. This was prepared previously from bovine erythrocytes which 
had been washed with saline, haemolysed with a mixture of distilled water and 
toluene, and centrifuged to remove the cell membranes. Oxyhaemoglobin was then 
converted to methaemoglobin in the haemolysate by the addition of potassium 
ferricyanide. The latter reaction was allowed to proceed for ten minutes after which 
the solution was filtered through a Sephadex G-2S column equilibrated with O.ISM 
NaCl to remove potassium and ferricyanide ions. Haemoglobin was quantified by a 
modified Drabkins method using a haemoglobinometer (Coulter Electronics, Luton, 
UK). 
Aliquots of S~l of standards covering a range from 0 to 7g/l Hp, control and 
test samples were pipetted into separate tubes. To each was added 100~l of diluted 
bovine methaemoglobin solution (0.3g/l), and the tubes were mixed. After 10 
minutes, Sml of saline was added, the tubes were mixed and left for 10 minutes at 
room temperature. At the end of this incubation, 12~l of the diluted samples were 
added to 200~l of tetra methyl benzidine solution (0.06g/l) in chromogen buffer 
(1.3mM di-NaEDTA, O.IM NaH2P04.2H20, pH3.8) in separate wells of a 96-well 
microtitre plate. The plate was incubated for 1 hour at 37°C after which SO~l of a 
0.04% H20 2 solution was added. When a strong blue colour had developed in the 
high standards, the reaction was terminated by the addition of SO~l of 2M H2S04. 
Plates were read in an ELISA plate reader (Titertek Multiscan) at 4S0nm. 
The haptoglobin concentrations in the test samples were calculated from the 
standard curve. For each assay, negative samples were prepared with saline replacing 
the sample and these were used as a blank in the plate reader. 
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2.4.1.2. a1-acid glycoprotein 
AGP levels were measured by single radial immunodiffusion using a commercially 
available kit (Saikin Kagaku Institute Co Ltd., Sendai, Japan) which consisted of an 
agarose gel containing specific rabbit antiserum to feline AGP (illustrated in figure 
2.2.). For quantification of results, standards of purified feline AGP are supplied with 
the kit. 
The agarose gel is supplied in plastic plates, each of which has 10 wells. Five 
III of sample or standard were dispensed into each well and the plate was incubated in 
a humid atmosphere at room temperature for 24 to 48 hours. After incubation, the 
size of the precipitant ring was measured and AGP quantified in the test samples by 
comparison to the standard graph. A control feline serum sample was run with each 
batch of samples. 
2.4.1.3. Total protein, albumin and globulin 
Total protein (IP) and albumin concentrations were measured in serum and effusion 
samples from cats in group 5 on an Axon discrete biochemical analyzer (Bayer 
Diagnostics, Basingstoke, UK) using the standard Biuret method for TP and 
bromocresyl green method for albumin with reagents provided by the same supplier 
(Cat nos 01 1301A4 and 011301A4 respectively). Globulin levels were determined by 
subtracting albumin from the total protein concentration. 
2.4.2. Diagnosis of viral diseases 
FlY infection was diagnosed by an enzyme immunoassay for anti-FlY antibody (Reid 
et al. 1991). FIP and the aetiology of clinically similar conditions were confirmed by 
post mortem examination and histopathology (Addie et al. 1995). FCo Y antibody 
tit res were determined by indirect immunofluorescence (Addie and Jarrett, 1992). 
2.4.3. Source of samples 
Serum samples from forty adult, specific pathogen free and clinically healthy cats 
were analysed to determine reference ranges for Hp and AGP. These cats were 
designated Group 1. 
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Figure 2.2. An agarose radial immunodiffusion plate used to calculate the AGP 
concentration of a sample. High and low standards have been applied to wells 1 and 
2 respectively and test samples to the remaining wells. AGP was quantified in the 
samples by comparison of the diameter of their precipitant ring to those of the 
standards. Well 8 contains a sample from a species that does not cross-react with the 
feline-soecific antibodv oresent in the aQarose 
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Samples were taken from cats with FIV infection during the early acute, 
asymptomatic and terminal stages of disease and separated into three groups: 
Group 2 consisted of six experimentally-infected specific pathogen free (SPF) 
12-week old cats. Serum samples had been obtained from these cats over the initial 
period immediately following infection with FIV (Glasgow-8 strain) and had been 
stored for 35 months prior to this investigation. Samples had been harvested at day 
ten for one pair of cats, at days ten and twenty for the second pair of cats and at days 
ten, twenty and thirty for the final pair. Three age-matched kittens maintained as 
controls were sampled simultaneously. Over the course of sampling, these FIV 
infected kittens exhibited decreased mitogen responsiveness of their peripheral blood 
mononuclear cells and elevated plasma tumour necrosis factor levels with respect to 
controls (Lawrence et al. 1992). 
Group 3 consisted of five SPF cats 30 months after experimental infection 
with FIV which were classified as being in the asymptomatic phase of infection. 
Stored serum samples from these cats obtained at monthly intervals over a six month 
period coincident with a previously measured peak in IL-6 production were selected 
for analysis. 
Group 4 consisted of six terminally-ill FIV positive cats with either natural or 
experimental infection which exhibited a variety of clinical signs and from which a 
single serum or effusion sample was obtained. 
Single serum, plasma or effusion samples were obtained from 48 cats 
suffering from naturally occurring FIP (group 5) and 21 cats with similar symptoms 
such as peritoneal and pleural effusions but a different underlying aetiology (group 
6). All of these samples had been sent to the Feline Virus Unit within the Department 
of Veterinary Pathology at the University of Glasgow Veterinary School for 
coronavirus analysis. Forty-five of the cats with FIP had effusive disease, 2 had non-
effusive disease and 1 started with effusive signs and then became non-effusive. 
Samples from cats in groups 5 and 6 were also analysed for total protein, albumin and 
globulin levels and feline coronavirus antibody titres. 
All samples were stored at -20oe until assayed. 
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2.4.4. Statistical analysis 
The inter- and intra-assay coefficients of variation (CV) for both the Hp and the AGP 
assays were determined by repeated analysis of a control sample. The CV was 
calculated as (standard deviation x 100)/mean. 
Statistical analysis was performed using the 'STATISTIX' Version 4.0 from 
Analytical Software, Tallahassee, Florida. Reference values were determined on the 
basis of the 2.5-97.5 percentiles. Inter-group variation was analysed using one-way 
analysis of variance (Tukey's pairwise comparison), with significance determined as 
p<0.05. The cats sampled shortly after infection with FIV and their controls (group 
2) were compared using a two sample t test. 
To determine the potential diagnostic value of AGP and Hp measurement and 
the albumin:globulin ratio as indicators of FIP in the population of cats with FIP-like 
disease, the optimum cut-off or reference value (defined as the optimum value for 
separating negative and positive test results) for each parameter in distinguishing 
groups 5 and 6 was calculated. This was achieved by plotting differential positive rate 
(DPR) curves of DPR against an arbitrarily selected range of cut-off values for each 
parameter. The DPR is the difference between true and false positive values and thus 
is equivalent to (sensitivity-(1-specificity)) where sensitivity is defined as the 
proportion of positive results in diseased individuals and specificity as the proportion 
of negative results in individuals without the specified disease. The DPR curve has 
been used to evaluate and compare diagnostic tests in canine medicine (Jensen and 
Poulsen, 1992). 
2.5. Results 
The Hp assay had an intra-assay coefficient of variation (CV) of 7% (n=16) and an 
inter-assay CV of 29% (n=4) when determined using a sample with a Hp 
concentration of 2.3g11. The AGP assay had an intra-assay CV of 3% (n=8) and an 
inter-assay CV of 13% (n=6) when determined using a sample with an AGP 
concentration of 0.668 gil. 
The haptoglobin and AGP results for all groups are illustrated in figures 2.3. 
and 2.4. respectively. 
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Figure 2.3. Concentrations ofHp in serum, plasma or effusion samples from healthy 
cats, cats with FlV infection and cats with FIP and clinically similar disease. Each 
column shows the range of Hp results in a clinical group with the red bars 
representing the median values of each group. 
Group 1, healthy cats (n=40); Group 2a, cats in the early stage of FlV infection 
(n=6); Group 2b, control cats for group 2a (n=3); Group 3, cats with asymptomatic 
FlV infection (n=5); Group 4, cats terminally ill and FlV positive (n=6); Group 5, 
cats with FIP (n=48); Group 6, cats with disease clinically similar to FIP (n=21). 
Hp gllitre 
14 
12 • 
• 
10 
• 8 
6 • I 
• I • 4 + ... • I • • • 2 + II1II I I I • I • I o I ... 
1 2a 2b 3 4 5 6 
Group 
CHAPTER 2 50 
Figure 2.4. Concentrations of AGP in serum, plasma or effusion samples from 
healthy cats, cats with FIV infection and cats with FIP and clinically similar disease. 
Each column shows the range of AGP results in a clinical group with the red bars 
representing the median values of each group. Group 2 is split into infected cats (2a) 
and controls (2b). 
Group 1, healthy cats (n=40); Group 2a, cats in the early stage of FIV infection 
(n=6); Group 2b, control cats for group 2a (n=3); Group 3, cats with asymptomatic 
FIV infection (n=5); Group 4, cats terminally ill and FIV positive (n=6); Group 5, 
cats with FIP (n=48); Group 6, cats with disease clinically similar to FIP (n=21). 
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2.5.1. Group 1 
Analysis of the samples from healthy cats gave a reference range for Hp of 0.04-
3.84g11. and for AGP ofO.1-0.48g11. 
2.5.2. Group 2 
The cats sampled shortly after infection with FlV had a range of Hp values from 
0.77g11 to 3.3g11 and their uninfected controls had a range from l.4g11 to 2.04g11. 
AGP values in these FlV positive cats ranged from 0.19 to 0.615 gil and those in the 
controls from 0.29 to 0.547g11. There was no statistically significant difference 
between the infected cats and their controls for either AGP or Hp. 
2.5.3. Group 3 
The samples taken from cats during the asymptomatic stage of FlV infection 
exhibited a range of Hp values from l. 7 to 3.1 gil and of AGP values from 0.165 to 
0.28g11. There was no significant difference between this group and the reference 
group (group 1). 
2.5.4. Group 4 
Cats with FlV-associated terminal disease had Hp values from l.34 to 12.04g11, the 
latter being over three times the maximum reference value, and AGP values ranging 
from O. 18-4. 44g11, the latter being almost ten times the maximum healthy value. Both 
AGP and Hp results in this group of cats were significantly different from those of 
the healthy group. 
2.5.5. Groups 5 and 6 
In cats with FlP (group 5), Hp concentrations ranged from 0.29 to 8.65g11, the latter 
being over two times the maximum value in healthy cats and AGP concentrations 
ranged from O. 15 -4.8 gil the latter being ten times greater than the maximum 
reference value. Both ranges were significantly different from those of the healthy 
group. By contrast, cats with FIP-like disease (group 6) exhibited a lower range of 
Hp and AGP concentrations from 0.26 to 4.81 gil and O. 02-1.46g11 respectively, 
which did not differ significantly from the healthy group. However, in the majority of 
cats with FIP-like disease, pleural or ascitic effusions were analysed and these would 
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not necessarily have the same protein content as serum, so may not be directly 
comparable to serum samples from healthy cats. 
From figure 2.4., it is apparent that the median AGP level in cats with FIP is 
distinct from that in cats with FIP-like disease, suggesting that this test might be of 
value in the diagnosis of FIP. The pathological, serological and biochemical findings 
of the cases with FIP and clinically similar diseases (groups 5 and 6 respectively) are 
given in figures 2.5. and 2.6. Albumin:globulin ratios are commonly used as an aid to 
the diagnosis of FIP and the effectiveness of measurements of AGP, Hp and 
albumin:globulin ratios in differentiating FIP from clinically similar diseases was 
compared. 
The DPR curves used to calculate the optimum cut-off points for these 
parameters in distinguishing groups 5 and 6 are plotted in figure 2.7. The optimum 
cut-off point corresponds to the maximum DPR value. For the Hp assay, the 
maximum DPR value (0.29) was obtained when a cut-off value of>2g/1 was used as 
a positive test for FIP. For the AGP assay, the maximum DPR value (0.85) was 
obtained when a cut-off value of>1.5g/1 was used as a positive test for FIP. A cut-off 
value of <0.7 was determined to be optimal value for the albumin: globulin ratio as an 
indicator ofFIP in this population of cats with a DPR value of 0.72. 
In this sample of the population of cats with FIP and FIP-like disease, the 
prevalence ofFIP was 70%. Using the cut-off points described above, the sensitivity, 
specificity and overall efficiency for each of the parameters were determined and are 
given in figure 2.8. AGP had the greatest overall efficiency (90%) in distinguishing 
cats with FIP from those with clinically similar disease with a sensitivity of 85% and a 
specificity of 100%. The albumin:globulin ratio had a similar overall efficiency (87%) 
and sensitivity (87%), but a somewhat lower specificity (85%) and Hp had a much 
lower overall efficiency (54%) and sensitivity (40%), although a comparable 
specificity (86%). 
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Figure 2.5. Concentrations of AGP, Hp, total protein (TP) and albumin:globulin ratio 
(A:G) and the titre of anti-feline coronavirus antibody (anti FCoV Ab) in serum, 
plasma and effusion samples from cats with FIP (group 5). 
Case no. sample AGP gil Hp gil TP gil A:G anti FCoV Ab Diagnosis 
1 af 4.80 2.43 112 0.47 1280 wet FIP 
2 af 4.44 4.77 61 0.74 160 wetFIP 
3 af 3.60 haem 69 0.47 1280 wetFIP 
4 af 3.60 3.73 102 0.59 40 wet FIP 
5 af 3.60 4.64 45 0.61 320 wet FIP 
6 af 3.60 3.60 50 0.67 320 wet FIP 
7 af 3.60 6.49 70 0.71 1280 wet FIP 
8 pi 3.40 5.26 108 0.38 l280 wet FIP 
9 af 3.38 5.47 64 0.42 320 wet FIP 
10 ser 3.32 6.51 91 0.42 1280 dry FIP 
11 af 3.28 6.19 70 0.35 >1280 wet FIP 
12 af 3.16 6.58 40 0.67 160 wet FIP 
13 af 3.04 1.83 52 0.53 l280 wetFIP 
14 af 3.00 3.11 70 0.59 40 wetFIP 
15 ser 3.00 haem 78 0.81 nJa wet FIP 
16 pi 2.98 1.06 53 0.56 l280 wet FIP 
17 af 2.90 6.06 87 0.36 >1280 wet FIP 
18 pi 2.88 haem 91 0.44 1280 wet FIP 
19 af 2.86 2.85 73 0.38 1280 wet FIP 
20 ser 2.85 5.47 64 0.78 1280 dry FIP 
21 af 2.80 2.31 57 0.84 640 wet FIP 
22 pf 2.62 3.30 79 0.23 nJa wet FIP 
23 af 2.62 5.96 46 0.53 160 wet FIP 
24 ser 2.60 8.65 80 0.36 1280 wet FIP 
25 af 2.60 1.75 64 0.39 nJa wet FIP 
26 pf 2.58 3.23 50 0.52 1280 wet FIP 
27 pf 2.47 2.17 46 0.28 >1280 wet FIP 
28 af 2.47 1.49 60 0.43 1280 wet FIP 
29 af 2.45 3.20 70 0.32 160 wet FIP 
30 af 2.44 3.09 70 0.30 1280 wet FIP 
31 af 2.44 0.29 68 0.31 nJa wet FIP 
32 af 2.44 1.49 33 0.32 640 wet FIP 
33 af 2.38 2.84 47 0.62 80 wet FIP 
34 af 2.26 1.89 67 0.26 80 wet FIP 
35 af 2.26 4.34 51 0.46 640 wet FIP 
36 af 2.26 0.85 60 0.36 640 wet FIP 
37 pi 2.13 3.89 60 0.33 160 wet FIP 
38 af 2.13 3.53 66 0.35 320 wet FIP 
39 af 2.00 1.61 42 0.40 1280 wet FIP 
40 af 2.00 4.66 57 0.46 >1280 wet>dry FIP 
41 af 1.80 2.04 80 0.31 nJa wet FIP 
42 pf 1.42 4.04 106 0.31 >1280 wet FIP 
43 af 1.26 1.40 56 0.37 1280 wet FIP 
44 pf 1.22 1.65 64 0.23 >1280 wet FIP 
45 af 0.96 haem haem haem 0 wet FIP 
46 af 0.74 0.42 58 0.32 1280 wet FIP 
47 af 0.40 3.17 41 0.64 160 wet FIP 
48 af 0.15 0.79 30 0.88 0 wet FIP 
af, ascitic fluid; pi, plasma; ser, serum; pf, pleural fluid; nJa, not available; haem, haemolysed 
sample; wet, effusive; dry, non-effusive. 
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Figure 2.6. Concentrations of AGP, Hp, total protein (TP) and albumin:globulin ratio 
(A:G) and the titre of anti-feline coronavirus antibody (anti FCoV Ab) in serum, 
plasma and effusion samples from cats with clinical signs suggestive ofFIP (group 6). 
Case no. sample AGP gil Hp gil TP gil A:G anti FCoV Ab Diagnosis 
af 1.46 3.75 43 1.05 0 biliary adenocarcinoma 
2 af 1.25 4.81 56 0.81 0 lymphosarcoma 
3 af 1.08 1.83 38 1.00 20 choloangitis and cirrhosis 
4 pi 1.04 3.92 25 0.79 nla cardiomyopathy 
5 af 1.02 haem 51 0.65 0 adenocarcinoma 
6 af 1.00 3.09 43 0.72 320 chronic nephritis 
7 af 0.96 1.82 65 0.91 nla cirrhosis 
8 ser 0.92 haem 92 0.67 40 adenocarcinoma 
9 af 0.88 1.28 19 0.73 nla not FIP 
10 af 0.74 1.45 49 0.96 nla cardiomyopathy 
11 af 0.54 1.56 43 1.10 0 small intestinal adenocarcinoma 
12 af 0.40 1.45 47 0.96 nla cardiomyopathy 
13 af 0.40 haem haem haem nla not FIP 
14 af 0.36 3.43 40 1.35 nla cardiomyopathy 
15 af 0.22 2.32 38 0.73 0 chronic cholangitis 
16 pf 0.20 0.57 23 0.77 0 cardiomyopathy 
17 af 0.16 1.11 6 1.00 0 renal lymphosarcoma 
18 af 0.16 2.79 68 l.06 320 pericarditis 
19 af 0.16 1.46 47 1.24 0 cardiomyopathy 
20 pf 0.12 haem 47 0.81 0 cardiomyopathy 
21 Ef 0.02 0.26 29 0.53 160 cardiom~oEathl 
af, ascitic fluid; pi, plasma; ser, serum; pf, pleural fluid; nla, not available; haem, haemolysed 
sample; wet, effusive; dry, non-effusive. 
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Figure 2.7. Calculation of the optimum cut-off values for AGP, Hp and 
albumin:globulin ratio using a differential positive rate (DPR) curve to differentiate 
the cats with FIP or clinically similar disease. The value of the optimum cut-off 
point is marked at the maximum DPR value for each parameter. The table 
underneath illustrates the individual cut-off values for AGP, albumin:globulin ratio 
and Hp at which the sensitivity, specificity and, subsequently, DPR were calculated. 
DPR = sensitivity - (1 - specificity) 
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Figure 2.8. Sensitivity, specificity and efficiency of AGP, Hp and albumin:globulin 
in differentiating cats with FIP and clinically similar conditions. 
Biochemical Sensitivity Specificity Overall efficiency 
parameter % % % 
AGP > 1.5g/l 85 100 90 
*Hp >2g/l 70 59 67 
talbumin:globulin 87 85 87 
<0.7 
*Eight cases missing from Hp analysis owing to haemolysed samples 
tTwo cases missing from albumin:globulin analysis due to haemolysed samples 
56 
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Whilst an insufficient number of blood samples was available to perform a 
detailed analysis on the difference between blood and effusion samples, the mean 
total protein (TP) concentrations in both types of samples were calculated and 
compared (TP concentrations are given in figures 2.S. and 2.6.). The mean effusion 
TP concentration in the FIP group (n=39) was 62g/1 and the mean blood TP 
concentration in the same group was 78g/1 (n=8). In the cats with clinical signs of 
different aetiologies, the mean TP content of effusion samples was 42g/1 (n=18). 
However, only 2 blood samples were analysed in this group, one of which had a very 
low level (2Sg/I) so the mean TP level was also low (S8g/1). 
2.6. Discussion 
For any diagnostic test it is important to establish the expected values in a healthy 
population. Accordingly, the reference ranges for AGP and Hp in the blood of 
healthy cats were determined. Previous studies where feline Hp was quantified, 
reported the results in units of cyanmethemoglobin binding capacity which makes the 
comparison ofresults difficult (Harvey, 1976; Harvey and Gaskin, 1978). This lack of 
standardisation between laboratories is a major problem which prevents international 
harmonisation of acute phase protein assays and has been highlighted by Eckersall 
and others (Eckersall et al. 1997). Development of international standards for 
calibration of these assays would be a major achievement. 
The inter-assay CV described for the Hp assay in this study is considerably 
poorer than that described for AGP. This may help to explain why levels of Hp were 
not as useful as levels of AGP in distinguishing FIP from clinically similar disease. 
The assay has since been automated to a biochemical analyser (MIRA, Roche 
Diagnostics) by other workers and has a lower inter-assay CV using this method. It 
would be of interest to repeat this investigation using the improved technique to 
determine whether an improvement in precision leads to a greater diagnostic value. 
The reference range described here for AGP (O.I-0.48g/1) is similar to that 
quoted by the manufacturers of the kit (O.27-0.47g/1), which was determined in 23 
cats from six months to 11 years of age. The range found in this study has an 
extended lower limit, possibly because the samples tested came from specific 
CHAPTER 2 58 
pathogen free animals which are likely to have less immunological stimulation than 
cats in the field. 
In eight samples the Hp measurement was not recorded as the samples were 
grossly haemolysed and in two of these, it was impossible to analyse albumin and 
total protein levels but this had no effect on the AGP immunodiffusion assay. 
AGP and Hp levels were highest in cats with FIV associated illness and FIP. 
The maximum concentrations recorded suggest that in the cat these proteins are only 
moderate acute phase reactants with an increase of three to tenfold over the 
maximum values in healthy cats. No acute phase protein response was detected in the 
kittens shortly after infection with FIV or in the sequential samples taken from cats 
during the asymptomatic stage of the disease, despite previously recorded alterations 
in inflammatory cytokines (TNF-a and IL-6 respectively) in both groups of cats. 
Although sampling was rather infrequent for acute phase proteins detection, it might 
still be expected that some samples would have exhibited raised acute phase proteins 
levels had they fluctuated in parallel with the cytokines. Indeed, because they are. 
generally elevated for a longer time period, acute phase proteins are normally 
regarded as more reliable markers of inflammation than cytokines (Whicher et al. 
1993). 
It may be that inhibitors such as soluble receptors are also circulating and 
prevent the interaction of cytokines with the appropriate cells. Further research is 
required to elucidate the discrepancy between inflammatory cytokine and acute phase 
protein levels during the early stages of FIV infection described here. Although the 
terminally-ill FlV -positive cats exhibited elevated acute phase proteins, their 
measurement in cats with FIV infection is likely to be of limited value as assistance 
with diagnosis is not required since specific immunoassays for anti-FlY antibody are 
available. As in HIV infection, acute phase protein measurement may be useful during 
the clinical stage of FIV infection when monitoring secondary infection (Husebekk et 
al. 1995). 
In previous retrospective studies to identifY serological, biochemical and 
haematological markers ofFlP, there were differences in the way that the data were 
evaluated and in the prevalence of disease in the populations examined (Rohrer et al. 
1994; Shelly et al. 1987; Sparkes et al. 1991; Sparkes et al. 1994; Weiss, 1991). In 
the present study, we selected cases in which FlP was considered a major differential 
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diagnosis so that the prevalence was high (70%). This does not affect the sensitivity 
or the specificity calculations, but alters the efficiency of the tests so that only the 
former two can be compared with previous results. The most frequent diagnoses 
made in the non-FIP cases were cardiomyopathy (8 out of21 cases) and neoplasia (6 
out of 21 cases) which is similar to that found in previous studies (Shelly et al. 1987; 
Weiss, 1991). There have also been variations in the 'cut-off' values quoted for AG 
in the diagnosis of FIP. Shelly and others (Shelly et al. 1987) selected the optimal 
value to differentiate FIP and effusions of other origins by visual assessment of all the 
results on a histogram. They elected to use a cut-off value of 0.81 which is similar to 
0.7, the optimum value calculated in our population by plotting a DPR curve. 
Both blood and effusion samples were included in the overall comparison 
between FIP and clinically similar disease. Since the effusion in FIP is exudative in 
nature, the protein content of the effusion should reflect blood levels. This is 
supported in this study by the similarity of the mean total protein levels in blood and 
effusion samples in cats with FIP. In cats with effusions of different aetiologies, 
protein levels would be expected to be lower if the effusion were a transudates or 
modified transudate. Indeed, a lower mean total protein concentration in effusion 
samples is recorded here in cats with FIP-like disease. Consequently, although 
protein levels in effusions from cats with transudates do not necessarily reflect blood 
levels, the value of AGP in differentiating these from exudative effusions should be 
enhanced. 
Cats with conditions that might be confused with FIP may be less likely to be 
have elevated serum AGP levels as the pathology involved is generally less pro-
inflammatory e.g. cardiomyopathy. The FIP-like conditions are often chronic and not 
associated with an infectious agent. In addition, in this study, the cats with neoplastic 
disease had lower acute phase protein responses than cats with FIP. 
Although the samples from cats with FIP that had a normal AGP result were 
effusions, two of the samples which gave false negative albumin:globulin results were 
sera and one of the latter was a serum sample from a case of non-effusive FIP. This 
finding suggests that AGP measurement might be of particular benefit in cases where 
no effusion sample is available. 
A previous study monitoring acute phase protein changes by electrophoresis 
concluded that this method of analysis was of little value in the diagnosis of FIP 
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(Stoddart et al. 1988). As the results of electrophoresis were quantified by 
densitometry, absolute changes in individual proteins would be less easily assessed by 
this method than by the specific assays used here. Stoddart and others analysed 
samples taken from cats immediately after inoculation with feline coronavirus until 
the onset of clinical signs suggestive of FIP, when the cats were euthanased (17 to 28 
days after inoculation). The samples in the study presented here were from cats with 
established clinical signs and this may also help to explain the observed differences. 
However, even in samples taken at the end of their study, Stoddart and others only 
detected protein levels returning to their pre-inoculation values and not becoming 
elevated. An earlier study of cats experimentally infected with feline coronaviruses 
described elevated Hp levels from the 4th day after inoculation (Gouffaux et al. 
1975). As this was also an electrophoretic study, the reasons for these discrepancies 
remain unclear. A reduction in acute phase protein concentration has been described 
immediately after the initiation of inflammation due extravasation of protein into 
tissues but this was only detected in the first few hours (Olsen, 1993). 
Our results indicate that AGP is a reliable aid in the diagnosis ofFIP when the 
clinical picture is suggestive of this disease. The assay is readily performed and it is 
now used routinely in the Feline Virus Unit as part of an 'FIP profile' in conjunction 
with measurement of albumin and globulin levels and antibody titres to FCo V. 
2.7. Further Studies 
Although not possible in this study due to the lack of availability of samples, analysis 
of effusion and blood samples from the same animal would identify the similarity in 
their protein content in cats with FIP and those with clinically similar disease. 
It would be interesting to investigate the glycosylation pattern of the 
AGP produced in the course of disease using electrophoretic techniques. During acute 
inflammation, less complex structures are seen, designated Type 1 changes which 
lead to an increased reactivity with concanavalin A (Con A). However, in the 
prolonged inflammation seen in cats with FIP, it might be expected that changes in 
glycosylation would be those of chronic change, or Type 2 when more complex 
structures are created with reduced Con A reactivity (Fassbender et al. 1991). 
Although AGP has an effect on immunomodulation, chronically raised levels during 
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FIP do not appear to limit the immunoglobulin response to any extent as 
hypergammaglobulinaemia is one of the characteristic clinical biochemistry findings in 
cats with FIP. Indeed, immune complex formation is the basis of the underlying 
pathology of the disease. Analysis of circulating cytokine levels might determine the 
driving influence behind the antibody response. 
Analysis of other acute phase proteins such as SAA may also prove to be of 
benefit in the diagnosis of FIP. The more sensitive major acute phase responders, 
however, may be less effective at discriminating diseases of such a chronic nature. 
For clarification of the discrepancy between cytokine and acute phase protein 
levels in the early stages of FIV, it would be most interesting to investigate 
concentrations of cytokine inhibitors such as soluble receptors, if suitable assays for 
these were available. 
2.8. Conclusion 
Moderately elevated levels of acute phase proteins were demonstrated in the serum 
of cats during two infectious diseases, FIV infection and FIP. These results indicate 
that, whilst not a specific test for FIP, AGP measurement is of considerable value in 
the diagnosis of this disease, particularly in conjunction with clinical signs, antibody 
titre and albumin:globulin ratio. 
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Chapter 3: 
Bioassay For Feline Anti-Tumour Necrosis Factor 
Activity 
3.1. Summary of Chapter 
62 
This chapter presents work designed to investigate activity against tumour necrosis 
factor-a. (TNF-a.) in culture fluids from feline splenic cells. The work in Chapter 2 
demonstrated that the measurement of acute phase proteins in cats with asymptomatic 
FIV infection had no prognostic value. Measurement of levels of soluble tumour 
necrosis factor receptors (sTNFRs) has given useful prognostic information in human 
patients with asymptomatic HIV infection, and it is likely that a similar situation exists 
in cats. The work described in this chapter was directed towards the detection of 
sTNFRs by their inhibition of the cytotoxic activity of TNF-a. in a bioassay. Splenic 
tissue isolated from healthy cats was incubated for varying lengths of time, either with 
or without mitogenic stimulation. At the end of the incubation period, culture fluids 
were harvested, concentrated and analysed by bioassay for their TNF activity and their 
ability to inhibit the TNF-induced killing of the murine fibroblast cell line, L929. TNF 
activity was detected in only two of the samples. Inhibition of TNF activity was 
demonstrated in most samples, and this was not affected by mitogenic stimulation or 
length of incubation. 
3.2. Background 
3.2.1. Investigating anti-TNF activity 
Anti-TNF activity was initially described in concentrated urine from both healthy 
(Engelmann et al. 1989) and fevered (Seckinger et al. 1989) human patients. Each of 
these studies demonstrated inhibition of the cytotoxic effects ofTNF-a. in bioassays by 
the addition of concentrated urinary fractions and suggested that this effect was a 
consequence of a urinary constituent binding TNF thus preventing its interaction with 
membrane-bound receptor. Further analysis of these urinary fractions revealed two 
immunologically distinct proteins that were responsible for the inhibitory effect 
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(Engelmann et al. 1990b). Even at that early stage, the suggestion was raised that 
there might be a therapeutic potential for these proteins as TNF inhibitors. 
Partial amino acid sequencing of the urinary proteins soon led to the 
development of probes for screening cDNA libraries and the complete nucleotide and 
amino acid sequences for both inhibitory proteins were elucidated. They were 
identified as tumour necrosis factor receptor 1 (TNFR-l, p55) (Gray et al. 1990; 
Loetscher et al. 1990; Nophar et al. 1990) and tumour necrosis factor receptor - 2 
(TNFR-2, p75) (Kohno et al 1990). The TNFR-2 sequence was derived 
simultaneously from screening an expression library for TNF-a binding (Smith et al. 
1990). Further analysis showed that the urinary proteins consisted of the extracellular 
portion of the membrane-bound TNF receptors and are most probably derived by 
proteolytic cleavage of the latter rather than alternative mRNA splicing (Schall et al. 
1990; Kohno et al. 1990). These proteins became known as the soluble receptors or 
sTNFR-1 and sTNFR-2. 
A variety of physiological and pharmacological mechanisms have been found 
to induce the cleavage of soluble receptors from the cell surface (Porteu and Nathan, 
1990) including inflammation as a result of endotoxin administration (Van Zee et al. 
1992) and mv infection (Kalinkovich et aI1992). The role of the soluble receptors in 
binding to circulating TNF appears to be twofold, both protecting against the harmful 
effects of TNF and creating a reservoir of the cytokine and sustaining the effects of its 
release (Aderka et al. 1992). 
TNF receptors have not been described in the cat although a study on adult 
feline myocardial cells suggested that TNF-induced release of a heat shock protein 
was mediated through a TNFR-1like receptor (Nakano et al. 1996). Identification of 
sTNFR in the cat will allow development of assays to determine their diagnostic 
value in different clinical situations and may have therapeutic potential. In the 
absence of cross-reacting antibody, an assay that is not immunologically based is 
required to identify sTNFR activity in feline derived fluids. TNF bioassays can be 
used in the assessment of TNF inhibitory activity as an indirect means of identifying 
sTNFRs. 
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3.2.2. TNF bioassay 
The use of cell lines to measure TNF-related cytotoxicity was documented by Carswell 
and others in 1975 (Carswell et al. 1975). The same authors found that three cell lines 
displayed different susceptibilities to the cytokine. Modifications to an assay employing 
the tumorigenic murine fibroblast line, L929, including adaptation to a 96-well 
microtitre plate format (Ruff and Gifford, 1981) and the addition of actinomycin D 
(Ostrove and Gifford, 1979), resulted in a sensitive method of monitoring serum 
tumoricidal activity (Flick and Gifford, 1984). The WEill 164 line has also been used 
in a similar way to detect TNF activity (Burke and Balkwill, 1991). 
A major disadvantage of bioassays is that they do not distinguish between 
molecules with similar effects on susceptible cells (Thorpe et al. 1992). Although 
interleukin (IL )-1 shares many biological activities with TNF, L929 cells are not 
affected by IL-1. A bioassay has the advantages that it only detects biologically active 
cytokines and tends to be less species-specific than immunoassays. The use of 
neutralising antibody is recommended in bioassay regimes to ensure that the detected 
activity is due to the molecule of interest. However, such antibody may not be 
available against the cytokine and species being investigated. 
Molecules, such as soluble receptors, which interfere with the biological 
availability of cytokines, can result in different values for cytokine levels being obtained 
with bioassays compared to other techniques (Van Zee et al. 1992), as can the 
presence of inactive cytokine forms such as monomeric TNF (Corti et al. 1994). The 
component antibodies of an immunoassay determine its specificity for the form of 
cytokine that it can detect (Bird et al. 1991). The purification of TNF -u has led to the 
development of sensitive immunological assays which have largely replaced bioassay 
techniques in the analysis of human (Michie et al. 1988) and laboratory animal 
samples. Radiolabeled TNF receptors have also been used to develop a very sensitive 
assay for TNF (Poltorak et al. 1994). 
A further technique which is becoming widely used in experimental disease to 
quantitate cytokine production is assessment of cellular transcript levels by reverse 
transcription followed by the polymerase chain reaction (RT -PCR). Transcript levels 
do not necessarily reflect cellular cytokine release, but they can give an indication of 
changes in rate of production. Relatively little starting material is required and multiple 
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cytokines can be investigated in the same sample if a suitable protocol is prepared 
although the technique is considered, at best, semi-quantitative (Benveniste et al. 
1996). Real time PCR is a recent development where the amount of product is 
monitored continuously during the reaction and allows accurate quantification of the 
starting levels ofmRNA (Orlando et al. 1998). 
Serum levels of TNF have been monitored in cattle using species-specific 
antibody (Horadagoda et al. 1994; Sileghem et al. 1994) and bovine TNF transcripts 
have been quantified in RNA derived from alveolar macrophages by RT-PCR 
(Bienhoff and Allen, 1995). The gene sequence of feline TNF-a has been published 
(McGrawet al. 1990) and the protein has been expressed (Otto et al. 1995). Despite 
these advances, analysis of feline serum TNF levels has generally been performed 
using a murine cell line bioassay (Lawrence et al. 1992; Lawrence et al. 1995b; Ma 
et al. 1995) or immune-based methodology with anti-human TNF antibody (Kraus et 
al. 1996; Lehmann et al. 1992). In addition, TNF transcript levels in feline peripheral 
blood mononuclear cells have been analysed using quantitative RT-PCR (Rottman et 
al. 1995; Dean et al. 1995) and feline cytokine expression has been measured using 
real time PCR (Leutenegger et al. 1998). 
3.2.3. TNF receptor assay 
As described in section 3.2.1., the L929-based bioassay was used initially to 
demonstrate sTNFR in urine (Seckinger et al. 1989; Engelmann et al. 1989). 
Compared to TNF-a, the effects of TNF-P are only slightly affected by the soluble 
receptors. A cross-linking assay, where sTNFR in cell culture supernatants are 
detected by binding to radioactive TNF-a has also been described (Gatanaga et al. 
1991). More recently, with the development of appropriate reagents, assays using a 
combination of antibody capture and radioiodinated TNF binding (Digel et al. 1992) 
and enzyme linked immunosorbent assays (ELISAs) (Higuchi and Aggarwal, 1992) 
have been utilised for sTNFR measurement. Indeed ELISAs are now commercially 
available for the measurement of human and murine sTNFRs (R&D Systems). 
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3.3. Aim of Experimental Study 
The aim of the work presented in this chapter was to determine whether the L929 cell 
bioassay can be used to detect anti-TNF activity in supernatants from cultured feline 
splenic cells. This assay has already been developed for analysis of TNF in feline 
plasma samples and a polyc1onal anti-human TNF antibody was used to neutralise 
feline TNF activity by the same method (Lawrence 1995). 
Initial western blots performed as described in chapter 5, using anti-human 
sTNFR-l antibody (lmglml, R&D Systems) as the primary antibody at a concentration 
of 1: 1000 did not show any reaction with the feline splenic cell supernatant samples 
described in sections 3.4.1. and 3.4.2. Therefore an immunoassay was not feasible and a 
bioassay was selected as a means of detecting anti-TNF activity because of its lack of 
species-specificity. TNFR-l is considered to be less species specific than TNFR-2 
(Zola, 1992) so that any feline anti-TNF activity detected in a bioassay using murine 
TNF is likely to be due to the presence of sTNFR -1. 
3.4. Materials and Methods 
All cell culture media, reagents and Nunc microtitre plates were obtained from Gibco 
(Paisley, UK) unless otherwise stated. Polypropylene tubes and tissue culture flasks 
were purchased from Greiner (UK) and petri dishes and universals from Sterilin (UK). 
3.4.1. Source and preparation of samples 
Immediately post mortem, the spleens were collected aseptically from three healthy 
specific pathogen free cats designated H41, H42 and H46. The tissue was deposited in 
sterile 50m} polypropylene tubes containing Dutch modification RPMI 1640 medium, 
supplemented with 2% heat inactivated foetal calf serum (HI-FCS), 2mM L-glutamine, 
5 x 1O-5M 2-mercaptoethanol" lOOIU/ml penicillin, lOOJlglml streptomycin and lOmM 
Hepes and kept on ice. 
Once in the tissue culture hood, the spleens were placed in sterile petri dishes 
and overlain with further medium. Two scalpels were used to dice and tease apart the 
tissue, with initial cells being harvested after five minutes of maceration. Fresh medium 
was used to overlay the remaining tissue which was then dissected in a similar fashion 
for a further five minutes. At the end of this time. 15ml aliauots of cell susoension 
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were decanted into polypropylene tubes and carefully underlain with an equal volume 
ofHistopaque 1077 (Sigma, UK). 
After centrifugation for 15 minutes at 3000rpm, cells at the interface were 
removed with a pipette and diluted 1:2 with fresh medium to wash the cells. The 
resultant suspensions were re-centrifuged for 5 minutes at 1500rpm, the supernatant 
discarded and the cell pellet re-suspended in 5mls of medium. After determining cell 
numbers by counting in a haemocytometer, splenocytes were diluted to a concentration 
of 2. 5 x 106mr1 and replicate cultures of 20ml of cell suspension set up in 80cm2 tissue 
culture flasks. Spleens from each of the three cats were prepared in the same way. 
3.4.2. Incubation procedure 
Cultures were incubated at 37°C in a humidified atmosphere containing 5% CO2. 
Supernatants were harvested at time 0 and after 4, 8, 12, 24, and 42 hours. For each 
time point after time 0, duplicate flasks were incubated per cat, and one culture was 
stimulated with concanavalin A (Sigma) at a final concentration of7.5~gmrl. 
At the end of the incubation period, any adherent cells were released with a cell 
scraper and the medium from each flask was centrifuged for 5 minutes at 1500rpm. 
The cell-free supernatants were collected and stored at -20°C. 
3.4.3. Concentration of supernatants 
Samples were concentrated in an ultrafiltration unit (8050 Stirred Cell, Amicon, UK) 
using a filter membrane with a molecular weight cut off of lOkDa (Diaflo PMI0, 
Amicon). Prior to use, the membrane was soaked for at least an hour in sterile distilled 
water (dH20) during which time the water was changed three times, and flushed with 
dH20 once in the ultrafiltration chamber before applying the sample. Supernatant 
fractions of> 1 OkDa were concentrated fourfold. The membrane was restored between 
samples with O.IM NaOH then thoroughly flushed with dH20. No single membrane 
was used to concentrate more than ten samples. 
Supernatants both greater than and less than 10kDa molecular weight and 
unfiltered supernatants were collected and stored at -20°C until analysed. 
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3.4.4. Initiation and maintenance of L929 cell line 
Murine fibroblast L929 cells were obtained in a lml aliquot from the European 
Collection of Cell Cultures (ECACC no 85011425). The transported cells were 
washed in lOml of complete medium (Dutch modification RPMI 1640 with 10% ill-
FCS, 2mM L-glutamine, 5 x 1O-5M 2-mercaptoethanol, 100IU/ml penicillin and 100J.l 
glml streptomycin) to remove any dimethyl sulphoxide (DMSO) present in the 
transport medium and centrifuged for 5 minutes at 1000rpm. The cell pellet was -re-
suspended in 12ml of complete medium and incubated in an 80cm3 flask at 37°C, 
5%C02 in a humidified atmosphere until the cells were confluent. At confluency, cells 
were removed from the flask by the action of 0.01% trypsin in EDTA (Gibco, UK). 
After trypsinisation, primary culture cells were washed in complete medium 
(CM), centrifuged, diluted tenfold in CM, and 10 replicate cultures of the diluted cells 
were set up. When these secondary cultures became confluent, cells were trypsinised, 
counted and stored in liquid nitrogen as secondary cultures in aliquots of 1ml in 
freezing down medium (45% ill-FCS, 45% CM, 10% DMSO, latter from Sigma) at a 
concentration of 2 x 107 cells/ml. The aliquots were frozen at -80°C for four hours 
before being transferred to liquid nitrogen. 
At the same time as preparing the cells for storage, a 1: 10 dilution of a 
secondary culture was set up in CM in an 80cm3 flask to maintain the cell line as a 
working stock. Maintained cells were trypsinised weekly, diluted 1:10 and grown up 
in new flasks, for use as required in the bioassay. 
3.4.5. L929 bioassay - TNF activity 
The bioassay for TNF was performed as described by Wadhwa and others (Wadhwa et 
al. 1991) with slight modifications. L929 cells were taken in the log phase of growth, 
trypsinised, and diluted to 2 x 105 cells/ml in CM prepared as above. Aliquots of 
100J.lI of cell suspension were put into each well of a 96 well microtire plate and the 
plates incubated at 37°C, 5% CO2 in a humidified atmosphere for 24 hours. At the end 
of this time, the medium was replaced with 100J.lI of either sample or standard 
prepared in CM containing actinomycin D (Sigma, UK) at a concentration of 1 J.lglml. 
Recombinant murine TNF-a (Cat no 41O-MT, R + D Systems, UK) at an initial 
concentration of 1.25nglml was used for the standards. Serial twofold dilutions of 
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both standard and sample were made vertically down the microtitre plate. All 
standards, samples and positive and negative controls were plated in triplicate. The 
positive control was rmTNF-a. in 6 two-fold serial dilutions from 2.5ng/ml in medium 
containing actinomycin D and the negative control was actinomycin D medium alone, 
as described in the original protocol. Plates were incubated at 37°C, 5% CO2 in a 
humidified atmosphere for 24 hours. 
After the second incubation, the medium was decanted and 1 00~1 of naphthol 
blue black (NBB) stain (0.1% NBB, Sigma, 9% acetic acid, O.lM sodium acetate) was 
added to each well. After 30 minutes, plates were fixed with 100~1 fixative (9% acetic 
acid, 0.1 M sodium acetate) per well for a further 15 minutes. After decanting stain and 
fixative, plates were washed with water and inverted till dry. The absorbance at 620nm 
was determined on a microtitre plate reader (MRX Microplate Reader, Dynex 
Technologies Inc., V A) using the 'endpoint' program after addition of 100~1 of O.lM 
NaOH per well and gentle shaking. 
3.4.6. L929 bioassay - anti-TNF activity 
The bioassay for TNF described in section 3.4. 5. was adapted to detect anti-TNF 
activity. Twenty-four hour cultures of L929 cells grown in 96-well microtitre plates 
were prepared as above. Serial two-fold dilutions of supernatants were pre-incubated 
with rmTNF-a. at a concentration of 0.0625ng/ml in CM supplemented with 
actinomycin D for 1 hour at 37°C. For this assay, rhsTNFR-l (Cat no 225-BI-025, R 
+ D Systems, UK) was used as a standard in two-fold dilutions from 1.25~g/ml to 
0.02~g/ml and was also pre-incubated with rmTNF-a.. After pre-incubation, 100~1 
aliquots of the incubated samples and standards were used in triplicate to replace the 
medium overlying the cells. A negative control was prepared with rmTNF-a. at a 
concentration of 0.125ng/ml in CM with actinomycin D. The positive control was a 
sample that exhibited anti-TNF activity when used in this assay. 
Prepared plates were incubated at 37°C, 5% CO2 in a humidified atmosphere 
for 24 hours. At the end of this time, the medium was decanted and the plates were 
stained, fixed, dried and analysed as above. Soluble TNFR-1 levels were measured in 
~g/ml (human equivalent) based on the assumption that the cytotoxic activity detected 
was a result of sTNFR-1 activity. 
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3.4.7. Analysis 
The Dynex Revelation 3.2 software (Dynex Technologies Inc, VA) was used to 
provide standard curves for both TNF and anti~TNF assays using the rmTNF~a and 
rhsTNFR~l standards respectively. Each curve was plotted with logarithmic scaling on 
the x-axis and linear scaling on the y-axis using a sigmoid curve fit type. 
Statistical analysis was performed using 'STATISTIX' Version 4.0 from 
Analytical Software, Tallahassee, Florida. Inter-group variation was analysed using 
one-way analysis of variance (Tukey's pairwise comparison), with significance 
determined as p<O.OS. Unstimulated and stimulated groups of samples were compared 
using a two sample t test. 
3.5. Results 
3.5.1. TNF bioassay 
L929 cells cultured with and without the presence of rmTNF-a are illustrated in 
figures 3.1.a. and 3.1.b. respectively. The standard curve obtained when using rmTNF-
a in the bioassay is displayed in figure 3.2. with three sample curves superimposed. 
The standards produced a curve with a sigmoid best fit determined by the Revelation 
software (r2=0.9693). 
Only 2 of the 96 supernatant samples tested showed evidence of cytotoxic 
activity using the bioassay (illustrated in figure 3.2.). Both of these supernatants were 
from stimulated cultures and were unfiltered samples; one was from cat H41 and was 
taken after 24 hours of incubation, the other was from cat H42 and was taken after 42 
hours of incubation. These samples gave a reduced absorbance consistent with 
cytotoxicity and their serial dilution curves showed some evidence of being parallel to 
the standard curve. When calculated from the least diluted results, the positive 
samples gave TNF concentrations of 0.037ng/ml and 0.08Sng/ml. Recombinant 
human sTNFR-l (R&D Systems), which was used in the anti-TNF assay, was also 
tested in the TNF assay and had no cytotoxic activity. 
3.5.2. Anti-TNF assay 
The standard and three sample curves for the anti-TNF assay are given in figure 3.3. 
The standards produced a curve with a sigmoid best fit determined by the Revelation 
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Figure 3.1. Photomicrograph of L929 cell monolayer cultured in complete medium 
a) without the addition of rmTNF-a and b) in the presence of rmTNF-a. The 
monolayer is disrupted as the cells die. 
a) 
b) 
¥ 
, 
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Figure 3.2. Standard curve for recombinant murine TNF-a using the L929 cell line 
(r2 =0.9693). The titration curves of three samples have been superimposed on the 
standard curve. The standard (rmTNF-a) ranges in concentration from 0.0195ng/ml 
to 1.25nglml. Sample 1; negative sample, H46, stimulated, 24 hours and <10000, 
sample 2; positive sample, H42, 42 hours, unconcentrated and ConA stimulated, 
sample 3; positive sample, H41, 24 hours, unconcentrated and ConA stimulated. 
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Figure 3.3. Standard curve (r2=0.9945) for the anti-TNF activity of recombinant 
human soluble TNFR-l using the L929 cell line. The titration curves of three 
samples have been superimposed on the standard curve. Note that the actual values 
on the x-axis apply only to the standard curve, other samples are plotted according 
to their dilution. Sample 1; H41 , 4.5 hours, > 10000 and unstimulated; sample 2; 
H41 , 24 hours, <10000 and unstimulated; sample 3; H46, 12 hours, unstimulated 
and unconcentrated. 
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software (~=O.9945). The samples illustrated show evidence of high (O.55~glml), 
medium (0.15~glml) and low (O.073~glml) activity. Anti-TNF activity was 
demonstrated in all except 2 of the samples tested. Results are given as ~glml (human 
equivalent) and the assumption is made that the detected activity is due to the 
presence of feline sTNFR-I. The maximum value recorded was greater than the 
maximum standard of 1.25~glm1. 
Groups of samples were analysed for differences between each time point, 
between unstimulated and stimulated supernatants and between concentrated and 
unconcentrated samples. There was no significant difference between results for any 
of the incubation times or between stimulated and unstimulated samples (figure 3.4.a 
and 3.4.b). However, a significant difference was detected between samples with a 
molecular weight cut off greater than lOkDa (median value O.352~glml) and samples 
with a molecular weight cut off less than lOkDa (median value O.116~glml). Although 
the median value of the unfiltered samples was intermediate between these two groups 
(O.2955~glml), this was not significantly different from either group (figure 3.4c.). 
3.S. Discussion 
The standard curves obtained in the assay for cytotoxicity illustrate the sensitivity of 
murine L929 cells to rmTNF-a. It is known that this cell line is sensitive to rhTNF-a 
(Wadhwa et al. 1991) and has been used to demonstrate cytotoxic activity in feline 
samples (Lawrence et al. 1995). However, little cytotoxic activity associated with 
TNF-a was demonstrated in the samples by this assay. It is likely that this was due to a 
combination of a lack of sensitivity to the very small concentrations of TNF-a that 
may be present, and the presence of soluble receptors that interfere with the bio-
availability of TNF, rather than unresponsiveness of the murine cells to feline 
cytokines. 
Previous studies measuring TNF-a activity using the L929 bioassay found 
detectable levels in plasma (Lawrence et al. 1992; Lawrence et al. 1995) rather than 
cell supernatants, although TNF-a activity has been detected in supernatants of LPS-
stimulated feline monocyte cultures by ELISA and using the WEHl-164 bioassay 
(Lehmann et al. 1992). The latter study reported concentrations 
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Figure 3.4. a-c Graphs illustrating the distribution of results of anti-TNF activity 
(reported as j.!g1ml human equivalent) in different groups of cell culture supernatant 
samples. In each group the median values are represented by a red bar. a) Samples 
grouped into different time points, b) samples grouped into ConA stimulated and 
unstimulated, c) samples grouped into <10kDa, unconcentrated and> 1 OkDa. 
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of <10pglml to around 100pg/ml which is consistent with the level of cytotoxicity 
detected in the standards and two positive samples in this study. However the results 
reported here cannot be compared easily with those of Lawrence et al as they report 
TNF levels in international units. The use of concanavalin A rather than LPS to 
stimulate the cells may explain why so few samples displayed TNF activity. 
Cross-reactivity between feline TNF-a. and human anti-TNF-a. antibody has 
been described, resulting in a neutralisation of the cytotoxic effect seen in the bioassay 
(Lehmann et al. 1992; Lawrence et al. 1995). Demonstration of inhibition of the 
activity described in the two positive feline splenocyte supernatants in this study by 
pre-incubating them with anti-human antibody might be used to confirm that the 
cytotoxicity detected was specific to this cytokine. The lack of cytotoxic activity of 
recombinant human sTNFR-l confirms that this receptor is suitable for use as a 
standard in the assay of anti-TNF activity. 
This is the first report of the demonstration of feline TNFR activity in feline cell 
culture supernatants. The protocol employed for the detection of anti-TNF activity in 
the supernatant samples was similar to that described previously for the assessment of 
the effect of the addition of sTNFR-l purified from human urine (Engelmann et al. 
1990) to the TNF bioassay. 
There was no detectable difference between cultures stimulated with ConA and 
unstimulated cultures. Similarly, the length of incubation did not make a significant 
difference to levels of soluble receptor. TNFR-1 gene expression is thought to occur in 
a constitutive manner, with any increase in the soluble receptor resulting from cleavage 
from the cell surface rather than up-regulation of transcription and translation 
(Aggarwal and Reddy, 1994). The preparation of the splenic cell cultures may have 
induced the cleavage of receptors from cell membranes so that they were already 
present in supernatants removed at time O. Subsequently, ConA may not have been a 
suitable stimulator of further receptor release or there may have been no membrane 
bound receptors remaining for cleavage. In human subjects after surgery levels of 
sTNFRs became elevated for at least 24 hours to a maximum of three-fold when 
compared to pre-operative levels (Neilson et al. 1996) which suggests that a decrease 
in receptor levels might not have been expected throughout the course of this 
experiment. 
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A significant difference was detected between the ultrafiltrate samples 
containing molecules smaller than 10kDa and concentrated samples that were retained 
by the PMIO filter and contained only larger molecules. This is consistent with the 
functional, soluble TNFR being retained during ultrafiltration as human sTNFR has a 
molecular mass of around 30kDa (Engelmann et al. 1990). The retention of some 
activity in the filtrate samples may reflect leakage through the PMlO membrane of 
molecules greater than 10kDa. This could have been investigated by the analysts of 
supernatant fractions by SDS-PAGE. Alternatively, there may be a different substance 
present that is exhibiting some anti-TNF activity. However, since the standard and 
sample curves are parallel, it is likely that the activity in each is due to the same 
molecule. Pre-incubation of samples with an inhibitory antibody to feline TNFR-1 
would confirm that the detected activity was due to the soluble receptor. However an 
antibody reacting with the feline protein is not available. 
The concentrations of receptor detected here (range 0.046 - > 1. 25 Ilg/ml) were 
far greater than those previously described in human serum samples (range 0.86 -
3.54nglml) measured by enzyme-linked binding assay (Godfried et al. 1993) and 
monocyte culture supernatants (range 27 - 36pg/ml) measured by ELISA (Rimaniol et 
al. 1994). This result suggests that the binding of recombinant human sTNFR-1 and 
feline receptor in the supernatant samples to murine TNF-a are not directly 
comparable. In addition, using the results for two samples that were measured over 
repeated assays, the inter-assay coefficient of variation was calculated as over 50%, 
highlighting gross inconsistencies with the quantitative values provided by the 
bioassay. There was more consistency in the qualitative analysis of results, as samples 
that gave high readings compared to other samples on one assay date, produced a 
similar relative picture at a later date although the absolute value was quite different. 
The two samples that had evidence of TNF activity had moderate anti-TNF 
activity which presumably was artificially low because of the presence of endogenous 
TNF. 
3.7. Further studies 
Following the study presented in this chapter, further work directed towards developing 
a species-specific immune based assay is likely to provide a more consistent 
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method of monitoring levels of feline sTNFR-l. Development of a neutralising 
antibody to feline sTNFR-l would also allow confirmation that the anti-TNF activity 
detected by the bioassay is, indeed, attributable to feline sTNFR-l. Perhaps the most 
straightforward way to approach this would be to clone and sequence the cDNA 
encoding feline sTNFR-l, generate recombinant protein and raise antibody to it. 
PCR-based methods of quantifying receptor expression are unlikely to be of 
value because serum levels of sTNFR-l fluctuate as a result of protease activity on 
membrane bound receptors. Since human TNFR-I is considered to be constitutively 
expressed in the manner of a house keeping gene, evaluating mRNA levels of the 
receptor in blood cells by real time RT-PCR will not provide a reflection of serum 
levels (Aggarwal and Reddy, 1994). 
3.8. Conclusion 
The L929 assay has been used here successfully to demonstrate the presence of anti-
TNF activity in feline samples. This activity is likely to be due to the presence of feline 
sTNFR-l but lack of neutralising antibody meant that this conclusion could not be 
confirmed. The inconsistency encountered with the quantitation of results means that 
the development of immune-based assays for feline TNFR-l would be highly 
advantageous. As TNFR-2 is considered more species-specific, immune based 
methodology is also required for the analysis of feline sTNFR-2. 
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Chapter 4: 
Cloning and Sequencing of Feline Tumour Necrosis 
Factor Receptors 
4.1. Summary of Chapter 
This chapter presents work designed to clone and sequence complementary DNA 
(cDNA) encoding tumour necrosis factor receptors 1 and 2 in the cat (TNFR-1, 
TNFR-2). The polymerase chain reaction (peR) was used to amplifY regions of the 
sequences coding for feline receptors using cDNA prepared from cat splenic tissue. 
peR products were cloned into a standard TA-vector and sequenced. The expression 
of feline coding sequences homologous to both receptors for TNF that have been 
described in man were identified by this technique. The amplified regions 
demonstrated 85% and 77% homology at the nucleic acid level and 83% and 67% 
homology at the amino acid level to the corresponding regions of the human 
sequences for TNFR-l and 2 respectively. 
4.2. Background to Techniques Used 
4.2.1. The polymerase chain reaction 
The technique of peR was originally described in the mid 1980's (Saiki et at. 1985) 
as an enzymatic means of amplifying regions of DNA by the extension of annealed 
primers. Initially the process was limited because the elevated temperatures required 
in the reaction denatured the enzyme, and fresh enzyme had to be added continually. 
With the incorporation of a thermostable polymerase into the protocol (Saiki et at. 
1988), the enormous potential of peR began to be realised. Simply, peR is used to 
amplifY a segment of DNA located between two areas of known sequence - the 
'priming sites'. 
Figure 4.1. illustrates a simple peR protocol. In peR, the double stranded 
DNA template is first denatured by heating, then the reaction temperature is reduced 
to permit the binding to each single DNA strand of a short oligonucleotide primer. 
Two oligonucleotides are used in each peR, each complementary to opposite strands 
of template DNA, flanking the region to be amplified. They are added in molar excess 
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Figure 4.1. Diagrammatic representation of the polymerase chain reaction 
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of the template DNA to favour primer binding rather than template re-annealing. The 
annealed primers are then extended through the incorporation of deoxynucleoside 
triphosphates (dNTPs) by the action of a thermostable DNA polymerase to form a 
DNA strand complementary to the template. The temperature-dependent cycles of 
denaturation, annealing and extension are repeated around thirty times. The product 
doubles at every cycle until eventually a plateau of product is achieved mainly as a 
result of enzyme limitations and re-annealing of template in preference to primer 
binding. For the first few rounds of amplification, products are not of a distinct 
length, as only one end is determined by primer. In subsequent rounds, initial 
products with a primer-defined end become the template, so that a population of 
DNA products of specific length arises (see figure 4.1.). 
PCR has been used for many different applications since its introduction. 
These include mutation detection, diagnosis of disease, generation of large amounts 
of DNA for probe production, cloning or sequencing, quantification of expression 
levels and identification of novel sequences, although this latter application requires a 
small amount of sequence or related sequence data to be available. The early problem 
of base mis-incorporation has been reduced by the development of the polymerases 
with 'proof-reading' or exonuclease activity which excise mis-matched nucleotides. 
It is important to optimise each new PCR reaction for the primers being used. 
Primer design is perhaps the most critical parameter but the magnesium ion 
concentration and the annealing temperature employed during the reaction can also 
alter results dramatically. The balance is always to achieve maximum levels of the 
desired product with the minimum amplification of non-specific products. Magnesium 
ions allow dNTP incorporation, stimulate polymerase activity and increase the 
melting temperature of double stranded DNA and primer-template binding. Any 
change in dNTP concentration alters the availability of Mg2+. The optimal annealing 
temperature for each primer is related to its length and its 
guanine/cytosine:adenine/thymine (G/C:AlT) content and should be similar for each 
primer pair designed. 
4.2.2. Using peR to determine novel sequence 
PCR can be used to amplify previously unknown sequence using primers designed 
according to regions of homology in related sequences. Primers are either based on 
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one of the comparative sequences or incorporate degeneracy at sites where differences 
exist in the related sequences (Compton, 1990). Less stringent PCR conditions can be 
employed, although this practice may increase non-specific amplification, and bands 
of the desired size can be isolated, cloned and sequenced. 
4.2.3. TNFR sequences in other species 
Once the proteins TNFR-1 and TNFR-2 had been identified in man by their abilitY to 
inhibit the toxic effects of the cytokine, researchers began to unravel the cDNA 
encoding them. The nucleotide sequence for human TNFR -1 was originally described 
by different groups after detection using molecular techniques based on the amino 
acid sequence of the purified protein. These techniques included screening cDNA 
libraries with oligonucleotide probes to identify clones containing the appropriate 
insert (Engelmann et al. 1990b) (Schall et al. 1990) and designing degenerate 
primers for use in a reverse transcription-polymerase chain (Loetscher et al. 1990). 
The nucleotide sequence for human TNFR-2 was determined by expression screening 
of a cDNA library with radiolabeled TNF-a (Smith et al. 1990). 
Cloning and sequencing of the murine TNF receptors and rat TNFR-l soon 
followed using probes based on the human sequences to screen murine and rat cDNA 
libraries (Goodwin et al. 1991; Himmler et al. 1990; Lewis et al. 1991). Homologous 
regions between the human and mouse TNFR-1 sequences were used subsequently to 
design PCR primers for amplification of porcine TNFR-2 cDNA (Suter and Pauli, 
1995). 
The human TNFR-1 amino acid sequence shows 73% homology to the mouse 
and 74% homology to the rat, and the human TNFR-2 sequence shows 73% homology 
to the mouse. Murine and rat TNFR-I sequences are 88% homologous. 
4.3. Aim of Experimental Studies 
The aim of the work presented in this chapter was to identify whether receptors for 
tumour necrosis factor homologous to those that have been described in man and the 
mouse are expressed in the cat. It was intended to use PCR to amplify fragments 
encoding the receptors in cDNA extracted from feline tissues and subsequently to 
characterise the amplified products by sequence analysis. 
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4.4. Materials and methods 
4.4.1. Source of tissue 
Feline splenic tissue was collected and prepared for cell culture as described in 
section 3.4. 1. Cell cultures were incubated for 8 hours with ConA at a final 
concentration of7.5~gmrl. Any adherent cells were released into the culture medium 
with a cell scraper (Nunc, Gibco) and the medium was collected and centrifuged to 
provide a cell pellet for RNA extraction. 
4.4.2. RNA extraction 
All non-RNase free plasticware for RNA extraction was treated with diethyl 
pyrocarbonate (DEPC, (Sigma, UK» and re-autoclaved prior to use. After 
quantifYing the number of cells present in a haemocytometer, the pellet prepared in 
section 4.4.1. was lysed by the addition of 0.2ml RNAzoITMB (AMS Biotechnology 
(Europe) Ltd.) per 106 cells. RNA extraction was performed according to the 
protocol supplied by the manufacturers. Briefly, O.2ml of chloroform was added per 
2ml of cell homogenate and the samples were shaken for 15 seconds, after which they 
were placed on ice for 5 minutes. The suspensions were centrifuged at 4°C for 15 
minutes at 12000g in a refrigerated microfuge (Eppendort), then the upper aqueous 
phase was removed to a fresh eppendorf tube, an equal volume of ice-cold 
isopropanol was added to precipitate the RNA and the samples were stored at 4°C 
for 15 minutes. 
Precipitated RNA was collected by centrifugation at 4°C for 15 minutes at 
12000g, washed with 75% ethanol and centrifuged for 8 minutes at 7500g at 4°C. All 
traces of ethanol were removed by pipette and the RNA pellet was allowed to dry in 
air. The dry pellet was dissolved in DEPC-treated dH20 (0.5ml DEPC per 500ml 
dH20, autoclaved before use to destroy the DEPC) and its RNA concentration and 
quality assessed by spectrophotometry (GeneQuant, Pharmacia Biotech, UK) and by 
visualisation on a standard 1.5% agarose gel (see section 4.4.6.) after diluting 1:10 in 
dimethyl formamide and adding 2~1 loading dye (0.25% bromophenol blue, 0.25% 
xylene cyanol, 40% sucrose). If the RNA was not to be reverse transcribed 
immediately, it was not reconstituted in dH20, but instead stored at -20°C under 
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ethanol. Following a similar protocol, murine RNA was extracted from L929 cells for 
use as a positive control. 
4.4.3. Reverse transcription 
Reverse transcription was performed in a total reaction volume of 25)l1 with a final 
concentration of SOmM Tris-HCI (pH8.3), 75mM KCl, 10mM dithiothreitol (DTT), 
3mM MgCh, 0.5mM each dGTP, dATP, dTTP and dCTP, 0.25)lI RNAisin 
(Promega) and 0.09 OD26o units of random primers (Gibco). Each reaction contained 
2/lg of total RNA which had been treated previously by heating to 65°C for 5 
minutes and quenched on ice prior to addition to the reaction. Finally, 400 units of 
Moloney murine leukemia virus reverse transcriptase (M-ML V RT) enzyme (Gibco, 
UK) were added to the reaction mix. 
Reverse transcription was allowed to proceed at 37°C for 30 minutes and 
then at 42°C for one hour, after which the enzyme was denatured by heating to 95°C 
for 5 minutes. Aliquots of cDNA were stored at -20°C prior to use and at 4°C while 
in use. Murine RNA was reverse transcribed in the same way. 
4.4.4. Primer design 
Primers for use in PCR were designed according to regions of homology in 
previously published cDNA sequences in other species. At the time of primer design, 
human (Godfried et al. 1993; Loetscher et al. 1990; Schall et al. 1990), mouse 
(Lewis et al. 1991) and rat (Himmler et al. 1990) sequences were available for 
TNFR-l, and human (Smith et al. 1990) and mouse (Goodwin et al. 1991) 
sequences for TNFR-2. Sequence comparisons to identity regions of homology were 
performed using the Genetics Computer Group (GCG) software (see section 4.4.10). 
Figures 4.2 and 4.3 illustrate the primers that were designed to amplity feline TNFR-
1 and TNFR-2 respectively. After successful amplification and sequencing of at least 
part of the feline TNFR-I and TNFR-2 sequences, feline-specific primers were 
designed to use as positive controls when assessing further cDNA aliquots for the 
presence of the appropriate transcripts. For TNFR-l, these were eco-60 
(5' gcatcgaattcatgggcctccccacc3 ') as the upstream primer and xba-60 
(5'gctcatctagagaaccccgcgtggca3') as the downstream primer. Restriction sites were 
included in these primers for ease of cloning into an expression vector. 
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Figure 4.2 Siting and species homology of primers designed to amplify feline 
TNFR-l. The human cDNA sequence (Accession no. X55313) is shown by the blue 
line, with leader, extracellular (BCD), transmembrane (t-m) and intracellular (lCD) 
regions as indicated by the red bars. Primers were designed according to the human 
sequence (shown in blue) and nucleotide differences between that and the mouse 
sequence (M59377, shown in red) and the rat sequence (M63122, shown in green) 
are given. Upstream primers are marked f and downstream primers r and all are 
presented in 5' -3' orientation. 
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Figure 4.3 Siting and species homology of primers designed to amplify feline 
TNFR-2. The human cDNA sequence (Accession no. M32315) is represented by the 
blue line, with leader, extracellular (ECD), transmembrane (t-m) and intracellular 
(rCD) regions as indicated by the red bars. Primers were designed according to the 
human sequence (shown in blue) and nucleotide differences between that and the 
mouse sequence (M59378, shown in red) are given. Upstream primers are marked! 
and downstream primers r and all are presented in 5' -3 ' orientation. Primer 80-6r is 
feline specific; see section 4.4.4. for sequence. 
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primer 80-5f 
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For TNFR-2, only one feline specific primer was designed, 80-6/ 
(5'tctgagctgctggagctggc3'), a downstream primer which was used in conjunction 
with 80-3 (see fig 4.3.). 
Primers based on the human Abelson tyrosine kinase (ABL) housekeeping 
gene were used to check the quality of each cDNA aliquot. These primers were 
designed to span an intron in the genomic sequence and were designated ABL-l (5' 
cagcggccagtagcatctgactt 3', position 452-474 in Genbank Accession number 
M14752) and ABL-2 (5' tgtgattatagcctaagacccggag 3' position 626-650). 
Optimal melting temperatures (T M) for each primer were calculated using the 
formula [TM = (2xNT) + (4xG/C)], and the initial annealing temperature used was 
calculated as 5°C lower than the T M (Roux, 1995). A magnesium chloride titration 
was performed to determine the optimal magnesium ion concentration for each PCR 
reaction. 
4.4.5. peR 
PCR was performed in thin-walled 0.5ml microcentrifuge tubes using a thermocycler 
(DNA Thermo Cycler 480, Perkin Elmer) in a total reaction volume of 50~1 with a 
final concentration of 10mM Tris-HCI (pH8.8), 1.5mM MgCh (or as otherwise 
suggested by MgCl2 titration), 50mM KCI, 0.1% Triton X-100, 0.2mM of each 
dNTP and O.4~M of each primer. After exposure of the reaction tubes to ultraviolet 
light for 10 minutes, 1 unit of thermostable DNA polymerase (DNAzyme, Finnzymes 
Oy, Finland) was added to each. Negative control reactions without template were 
prepared as above for each primer pair used. To the other tubes, 2.5~1 of the cDNA 
template prepared as in section 4.4.3. was added. A drop of mineral oil was applied 
to the top of each reaction mix prior to application to the thermo cycler. 
PCR consisted of an initial denaturation step of 5 minutes at 95°C, followed 
by 35 cycles consisting of I minute each of denaturation at 94°C, annealing at the 
optimal temperature determined for the primers involved (see section 4.5.2.), and 
extension at 72°C. A final extension step of 30 minutes at 72°C was performed to 
facilitate cloning by ensuring the addition of' A overhangs' (see section 4.4.8.). 
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4.4.6. Analysis of products by agarose gel electrophoresis 
A 10111 aliquot of each PCR product was mixed with 2111 gel loading dye 
(composition as in section 4.4.2.), electrophoresed at 100V for 1 hour on 1.5% 
agarose gels in TBE buffer (90mM tris, 90mM boric acid, 2mM EDT A) in a minigel 
system (Hoefer HE 33 Mini Submarine Electrophoresis Unit, Pharmacia Biotech) and 
stained with ethidium bromide (3111 of 10mg/ml stock added to 100ml gel). Standard 
molecular weight markers were run in parallel with samples (Gibco BRL, Paisley, 
UK). Gels were examined over an ultraviolet light (T2201, Sigma or UVT 28-M, 
Herolab) and photographed using either a Polaroid camera or a digital imaging 
system (Cohu high performance charge coupled device (CCD) camera connected to a 
Sony monitor (SSM-930CE) and video graphic printer (UP 890CE», recording onto 
film (Polaroid 665, Sigma) or printing paper (Sony Superior Density, UPP 1l0HA) 
respectively. 
4.4.7. Purification of PCR products 
If PCR yielded a single band of the expected size, the PCR product was removed 
from underneath the mineral oil layer and cleaned by chloroform: isoamyl alcohol 
(ClAA) extraction. A volume of ClAA (24: 1) equal to the reaction volume was 
added, the tube vortexed and then centrifuged at 12000g for 1 minute. The aqueous 
phase containing the DNA was collected and 2111 added to the ligation reaction. 
When a single band was not observed after PCR, the remainder of the 
products was electrophoresed on an agarose gel and individual bands at the expected 
size were cut out with a sharp, clean scalpel blade, in as small a gel volume as 
possible. DNA was eluted from gel slices using a gel extraction kit (Qiaex II kit, 
Qiagen, UK) and quantified by spectrophotometry (GeneQuant, Pharmacia Biotech). 
4.4.8. Cloning of PCR products 
Purified PCR products were cloned into a standard T A-cloning vector (pT7Blue T-
Vector, Novagen, Wisconsin) supplied as part of a kit (pT7Blue T-Vector Kit, 
Novagen, Wisconsin) containing all the reagents necessary for the cloning procedure. 
The vector is supplied pre-digested with EcoR Vand with 3' dT residues at each end 
(figure 4.4.) so that PCR products obtained after amplification with a DNA 
polymerase that leaves 3' A-nucleotide overhangs can be readily ligated. Interruption 
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Figure 4.4 Diagram showing sequence flanking the cloning site of the pT7 vector 
(Novagen). The positions of the T7 and U19 primer binding sites and the cloning site 
are illustrated. 
R-20mer primer #69835-1 
~ 
T7 promoter primer #69348-1 
.. 
Sail 
Sse8387 I Hinc I 
1 T7 promoter.. Hind III Sph I Pst I Ace I Xba I lacZ start ______________ _ Spe I 
ATGACCATGATTACGCCAAGCTCTAATACGACTCACTATAGGGAAAGCTTGCATGCCTGCAGGTCGACTCTAGAGGATCTACTAGT 
Met 
Sma I 
Ava I 
Nde III EcoR V BamH I Kpn I Sac I EcoR I 
CATATGGATATCGGATCCCCGGGTACCGAGCTCGAATTCACTGGCCGTCGTTTTAC~CGTCGTGACTGGGAAAACCCT 
~ U-19mer primer #69819-1 
... tatggatT atcggat .. . 
. . . ataccta Ttagccta .... . 
TA cloning site present 
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of the plasmid with insert disrupts an encoded S-galactosidase gene so that positive 
colonies appear white on medium containing the chromogenic substrate 5-bromo-4-
chloro-3-indolyl S-D-galactopyranoside (X-gal, Sigma), whereas negative colonies 
appear blue. 
The ligation reaction was prepared with SOng vector, 0.2pmol PCR product 
(or 2111 of CIAA cleaned product), 5mM DTT, 0.5mM ATP and 0.5111 T4 DNA 
ligase (2-3 Weiss units) in ligase buffer (20mM Tris-HCl, pH 7.6, 5mM MgCh) in a 
total volume of 10111 and incubated overnight at 16°C. At the end of incubation, 1 III 
of the reaction was used to transform 20111 of NovaBlue competent cells (supplied 
with the kit) taken from -70°C and thawed on ice. Tubes were stirred gently, left on 
ice for 30 minutes, heated for 40 seconds at 42°C and returned to the ice for a further 
2 minutes. After addition of 80111 of SOC medium (see Appendix 1) at room-
temperature to each reaction, tubes were incubated in an orbital shaker at 37°C and 
spun at 200rpm for 1 hour. 
Half (50111) of each transformation reaction was spread on LB-agar (see 
Appendix 1) 82mm plates containing 50Ilg/ml ampicillin, 151lg/ml tetracycline, 35111 
of 50mg/ml X-Gal and 20111 of 100mM isopropyl-S-thiogalactoside (IPTG, Sigma). 
Once the liquid had been absorbed, the plates were inverted and incubated overnight 
at 37°C. 
The following morning, 10 white and one blue (control) colonies were picked 
off using a sterile pipette tip and dispersed in 2ml LB broth (see Appendix) with 
ampicillin at 50Ilg/ml (LB-amp). Colonies were incubated overnight at 37°C in an 
orbital shaker at 200rpm. Tubes showing evidence of growth (cloudiness) at the end 
of this incubation were tested for the presence of insert by PCR as follows. Fifty 
microlitres of culture medium were boiled for 5 minutes to lyse the cells which were 
then centrifuged at 12000g for 1 minute. Ten microlitres of the resultant supernatant 
were used as the template in a 50111 PCR reaction with 1 unit of thermostable DNA 
polymerase (DNAzyme, Finnzymes Oy, Finland), 10mM Tris-HCl (pH8.8), 1.5mM 
MgC12, 50mM KC1, 0.1% Triton X-I00, 0.2mM of each dNTP and O.4IlM of each 
plasmid primer (upstream, T7 promoter primer 5 'taatacgactcactataggg3', 
downstream U -19 primer 5' gttttcccagtcacgacgt3 " see figure 4.4.). Without an insert, 
these primers are situated to give a product of 139 base pairs in length. If an insert is 
present, the primers amplify a product equivalent to the insert length plus 139 base 
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pairs of plasmid sequence. PCR products were analysed as described above (section 
4.4.6.). 
Stocks were made with 15% glycerol of any colony with evidence of an insert 
of the correct size and stored at -20°e. Plasmid DNA from the same colonies was 
purified using a kit (Plasmid Miniprep Kit, Qiagen, UK) with spin columns to bind 
the DNA. DNA was eluted from the columns in 40~1 of dH20. 
4.4.9. Sequencing 
Three clones and 2 PCR products of the amplified region were sequenced bi-
directionally using T7 and U19 primers or the PCR specific primers respectively. 
Samples were sent to the DNA Sequencing Service (King's College, London) for 
sequencing on an automated ABI DNA sequencer (Perkin Elmer, USA). 
4.4.10. Analysis of results 
Analysis of results was performed using the Wisconsin Sequence Analysis Package 
(Devereux et at. 1984) (Genetics Computer Group, Madison, Wisconsin). 
Sequencing data were analysed using' SeqEd' and 'BestFit' (Smith and Waterman, 
1981) programs and confirmation that the appropriate sequence had been amplified 
was achieved by comparison to a database (GenEMBL nucleotide sequence 
database) using the 'BLAST' and 'FastA' (Pearson and Lipman, 1988) programs. 
Novel sequence data were submitted to Genbank for release onto the database. 
4.5. Results 
4.5.1. RNA Assessment 
A gel illustrating the products of two standard RNA extractions is illustrated in figure 
4.5. By comparison to the size marker, the 28S and 18S ribosomal RNA bands can 
be visualised at 1500bp and 750bp respectively, with less intense, diffuse ethidium 
bromide staining between and around these bands. Generally, the extraction 
technique produced total RNA with an A26o:A28o greater than 1.6. 
The reverse transcription step and DNA contamination of RNA were assessed 
by amplification of the cDNA with ABL primers. In cDNA these primers produced a 
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Figure 4.5. Agarose gel following electrophoresis of the products of 2 RNA 
extractions using the RNAzolTM B method. Lane 1: 1kb marker, lanes 2 and 3: 
products of two separate RNA extractions. Both RNA products were diluted 1:10 
with formamide and 2111 loading mix added prior to running on the gel. 
123 
bp 
1018 
506 
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band of 198 base pairs, whereas in samples with genomic DNA contamination, an 
additional band of 800 base pairs was seen. Samples with genomic contamination or 
poor amplification with the control ABL primers were discarded. 
4.5.2. peR Amplification 
Initial amplification was performed with primer pairs designed to amplify the majority 
of feline TNFR-1 and TNFR-2 sequences (60-1 and 60-2, 80-1 and 80-2) but these 
failed to yield any products. Subsequently primers were designed to amplify smaller, 
internal fragments of each sequence. Successful amplification was achieved with 
primer pairs 60-1 and 60-4, and later with ec060 and xba60 (figure 4.6.), and 80-3 
and 80-4 (figure 4.7.). Both of these amplifications were optimal in the presence of 
2.5mM MgCl2 and with an annealing temperature of 58°C. 
A feline specific primer (80-6 situated at bases 1175 to 1195 of the human 
sequence 5'3') was designed after sequencing of the 80-3 and 80-4 product. This 
produced the correct band as a single product when used for amplification with 80-3 
(figures 4.7. and 4.8.) and gave a band of around 900bp when used in combination 
with 80-5. However, cloning and sequencing of the 80-5 and 80-6 product revealed 
80-6 primer sequence followed by unknown sequence which showed no homology to 
other TNFR-2 sequences when run in the GCG FastA program. 
A nested PCR approach was attempted by designing two further primers (80-
7 and 80-8) where amplification with 80-7 and 80-6 was followed by amplification 
with 80-5 and 80-8, but this did not produce any bands of the desired size. 
Figure 4.8. illustrates an MgCh titration where higher concentrations of 
MgCh are associated with an increase in non-specific bands. Addition of DMSO and 
formamide appeared to make little difference to the reaction whereas addition of 
glucose results in loss of the product altogether. 
4.5.3. Analysis of sequence data 
Consensus sequence information for the amplified regions of feline TNFR-1 
and TNFR-2 is given in figures 4.9. and 4.10. The novel feline sequences were 
deposited in the GenBank database and given Accession numbers U72344 (TNFR-1) 
and U51429 (TNFR-2). 
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Figure 4.6. Agarose gel following electrophoresis of the products of peR 
amplification of feline cDNA with primer pair 60-1 and 60-4. Lane 1: 100bp marker 
with bright band corresponding to 600bp, lane 2: 542bp fragment amplified with 
feline TNFR-1-specific primers eco-60 and xba-60, lane 3: 620bp fragment 
amplified with 60-1 and 60-4. 
1 2 3 
bp 
600 
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Figure 4.7. Agarose gel following electrophoresis of the products of peR 
amplification of feline cDNA with primer pair 80-3 and 80-4. Lane 1, 100bp marker; 
lanes 2 and 3, 284bp fragment amplified from murine (lane 2) and feline (lane 3) 
cDNA with 80-3 and 80-4; lane 4, negative control with 80-3 and 80-4 primers; 
lanes 5 and 6, 130bp product and non-specific bands amplified from murine (lane 5) 
and feline (lane 6) cDNA with 80-3 and feline specific 80-6; lane 7: negative control 
with 80-3 and 80-6 primers, lanes 8 and 9: 180bp product amplified from murine 
(lane 8) and feline (lane 9) cDNA with ABL-1 and ABL-2; lane 10, negative control 
with ABL-1 and ABL-2 primers. 
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Figure 4.8. Agarose gel showing the effects of changing reaction conditions on PCR 
of feline cDNA with 60-3 and 60-6 primer pair. Lane 1, molecular weight marker; 
lanes 2-5 increasing concentrations of MgClz in the reaction mix; lanes 6-8, 
formamide, DMSO and glucose respectively added to reaction mix; lane 9, positive 
control with ABL primers; lane 10, negative control. The arrow indicates the product 
of interest. 
2 3 4 5 6 7 8 9 10 
bp 
300 
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Figure 4.9. Nucleotide sequence and predicted translation of the amplified region of 
feline cDNA homologous to part of human TNFR-1, GenBank Accession number 
U72344. The coding region starts at nucleotide 14 and the sequence is flanked by 
60-1 (uDstream) and 60-4 ( downstream). 
60 
120 
180 
240 
300 
360 
420 
480 
540 
CAACTGGCCGGACATGGGCCTCCCCACCGTCCCTGGCCTGCTGCAGCCACTGGTACTTCT 
1 ---------+---------+---------+---------+---------+---------+ 
GTTGACCGGCCTGTACCCGGAGGGGTGGCAGGGACCGGACGACGTCGGTGACCATGAAGA 
MetG1yLeuProThrVa1ProGlyLeuLeuGlnProLeuValLeuLe 
M G L P T V P G L L Q P L V L L 
GGCTCTGTTGGTGGAAATATACCCATTAAGGGTTACTGGACTGGTCCCTCACCTCAGGGA 
61 ---------+---------+---------+---------+---------+---------+ 
CCGAGACAACCACCTTTATATGGGTAATTCCCAATGACCTGACCAGGGAGTGGAGTCCCT 
uAlaLeuLeuValGluIleTyrProLeuArgValThrGlyLeuValProHisLeuArgAs 
ALL V ElY P L R V T G L V P H L R D 
CCGGGAGAAGAGAGCTATTCCATGTCCCCAAGGAAAATATATTCACCCTCAAGATAATTC 
121 ---------+---------+---------+---------+---------+---------+ 
GGCCCTCTTCTCTCGATAAGGTACAGGGGTTCCTTTTATATAAGTGGGAGTTCTATTAAG 
pArgGluLysArgAlaIleProCysProGlnGlyLysTyrIleHisProGlnAspAsnSe 
R E K R A I PCP Q G K Y I H P Q D N S 
CATTTGCTGTACGAAGTGCCACAAAGGGACCTACCTGTACAATGACTGTGAGGGCCCAGG 
181 ---------+---------+---------+---------+---------+---------+ 
GTAAACGACATGCTTCACGGTGTTTCCCTGGATGGACATGTTACTGACACTCCCGGGTCC 
rIleCysCysThrLysCysHisLysGlyThrTyrLeuTyrAsnAspcysGluGlyProGl 
ICC T K C H K G T Y L Y N D C E G P G 
GCTGGACACGGACTGCAGAGAATGTGAAAATGGCACATTTACTGCTTCAGAGAACTACCT 
241 ---------+---------+---------+---------+---------+---------+ 
CGACCTGTGCCTGACGTCTCTTACACTTTTACCGTGTAAATGACGAAGTCTCTTGATGGA 
yLeuAspThrAspcysArgGluCysGluAsnGlyThrPheThrAlaSerGluAsnTyrLe 
L D T D C R E C ENG T F T A SEN Y L 
CAGACAGTGCCTTAGCTGCTCCAAATGCCGAAAAGAAATGTACCAGGTGGAGATATCTCC 
301 ---------+---------+---------+---------+---------+---------+ 
GTCTGTCACGGAATCGACGAGGTTTACGGCTTTTCTTTACATGGTCCACCTCTATAGAGG 
uArgGlnCysLeuSerCysSerLysCysArgLysGluMetTyrGlnValGluIleSerPr 
R Q C L S C S K C R K E M Y Q v E I S P 
TTGCACAGTGTACCGGGACACCGTGTGTGGCTGCAGGAAGAACCAGTACCGGTATTACTG 
361 ---------+---------+---------+---------+---------+---------+ 
421 
481 
AACGTGTCACATGGCCCTGTGGCACACACCGACGTCCTTCTTGGTCATGGCCATAATGAC 
oCysThrValTyrArgAspThrValCysGlyCysArgLysAsnGlnTyrArgTyrTyrTr 
C T V Y R D T V C G C R K N Q Y R Y Y W 
GAGTGAAACCCATTTCCAGTGCCTAAACTGCAGCCTCTGCCTCAACGGCACGGTGCAGAT 
CTCACTTTGGGTAAAGGTCACGGATTTGACGTCGGAGACGGAGTTGCCGTGCCACGTCTA 
pSerGluThrHisPheGlnCysLeuAsnCysSerLeuCysLeuAsnGlyThrValGInIl 
SET H F Q C L N C S L C LNG T V Q I 
CTCCTGCAAGGAGACACAGAATACTGTATGCACCTGCCACGCGGGGTTCTTTCTAAGAGG 
---+----- -+--- -----+ 
GAGGACGTTCCTCTGTGTCTTATGACATACGTGGACGGTGCGCCCCAAGAAAGATTCTCC 
eSercysLysGluThrGlnAsnThrValCysThrCysHisAlaGlyPhePheLeuArgGl 
S C K E T Q N T V C T C HAG F F L R G 
GAATGAATGCGTCTCTTGTGTTAACTGTAAGAAAAACACAG 
541 ---------+---------+---------+---------+- 581 
CTTACTTACGCAGAGAACACAATTGACATTCTTTTTGTGTC 
yAsnGluCysValserCysValAsnCysLysLysAsnThr 
N E C V S C V N C K K N T 
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Figure 4.10. Nucleotide sequence and predicted translation of the amplified region of 
feline cDNA homologous to part of human TNFR-2, GenBank Accession number 
U51429. The sequence is flanked by 80-3 (upstream) and 80-4 (downstream). 
60 
120 
180 
240 
CTCAGGCAGCACCGCAGACGGGAGGGCGCCCACCGGGACCCGGCTGCCCGCACCAGGCAC 
1 ---------+---------+---------+---------+---------+---------+ 
GAGTCCGTCGTGGCGTCTGCCCTCCCGCGGGTGGCCCTGGGCCGACGGGCGTGGTCCGTG 
SerG1yserThrAlaAspGlyArgAlaProThrGlyThrArgLeuproAlaProGlyTh 
S G S TAD G RAP T G T R L PAP G T 
GGAGAAGGCCGCCGGGTCTGGGGAGGCCTGGGCCAGCTCCAGCAGCTCAGAGCCTTCCTC 
61 ---------+---------+---------+---------+---------+---------+ 
121 
181 
CCTCTTCCGGCGGCCCAGACCCCTCCGGACCCGGTCGAGGTCGTCGAGTCTCGGAAGGAG 
rGluLysAlaAlaGlySerGlyGluAlaTrpAlaSerSerSerSerSerGluproSerSe 
E K A A G S G E A WAS S S SSE P S S 
TGGCAGCCACGGGACCCAGGTCAACGTCACATGCATCGTGAATGTGTGCAGCGCCTCCGA 
--+----- -+---------+---------+ 
ACCGTCGGTGCCCTGGGTCCAGTTGCAGTGTACGTAGCACTTACACACGTCGCGGAGGCT 
rGlySerHisGlyThrGlnValAsnValThrcysIleValAsnValCysSerAlaSerAs 
G S H G T Q v N V T C I V N V C S A S D 
CCACGGCTCTCAGTGCGCCTCCCAGGCCAGCTACACGATGGGGGACGTGGATGCCAGCTC 
---+---------+---------+---------+---------+---------+ 
GGTGCCGAGAGTCACGCGGAGGGTCCGGTCGATGTGCTACCCCCTGCACCTACGGTCGAG 
pHisGlySerGlnCysAlaSerGlnAlaSerTyrThrMetGlyAspValAspAlaSerSe 
H G S Q CAS Q A S Y T M G D V D ASS 
CTCCGGC 
241 ------- 247 
GAGGCCG 
rSerGly 
S G 
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When amplified products were compared to the GenBank database using the 
FastA program, the products from PCR with the TNFR-1 based primers showed most 
homology to human, pig, cow, mouse and rat TNFR-1 sequences, whereas those from 
peR with TNFR-2 based primers showed most homology to cow, mouse, human and rat 
TNFR-2 sequences, confirming that the PCR products were homologues of the 
appropriate human protein. Homology in nucleotide and derived amino acid sequences 
between the cat and other species for which the corresponding part of the receptpr has 
been published is illustrated in figures 4.11. and 4.12. For the regions amplified, TNFR-1 
shows more inter-species homology than TNFR-2. 
4.6. Discussion 
The work presented in this chapter illustrates that part of the coding sequences for feline 
TNFR-1 and -2 have been successfully amplified by PCR. Comparison of the amplified 
region of feline TNFR-1 with soluble human TNFR-1 confirmed that a protein 
homologous to that in man exists in the cat with conservation of the cysteine rich areas 
which identify the human protein as a member of the nerve growth factor receptor super-
family. Three disulfide cysteine bridges have been described in each cysteine rich 
domain of the human receptor which help to form a relatively rigid elongated structure 
(Banner et al. 1993). Optimal TNF binding is achieved when three of these receptors 
interact with the TNF trimer, holding the transmembrane and intracellular regions of 
neighbouring receptors in close proximity (Hilton, 1994). Here, three of the four areas 
with 6 cysteine residues have been completely amplified in the cat, as has the majority of 
the fourth. 
In man, TNF receptors are fairly ubiquitously expressed, having been detected on 
all nucleated cells examined for their presence. For this reason, the starting material was 
assumed not to be critical and stimulated splenic cells were selected, as they were readily 
available and TNFR-2 predominates on activated leucocytes. Although failure to produce 
the correct band in a PCR might be due to lack of expression in the starting tissue, this 
was confirmed not to be the case by using the successful primers as positive controls. 
One of the problems encountered when performing RNA extractions IS 
contamination with RNases which are naturally rich in splenic tissue. This was 
minimised by using RNase-free disposable equipment or treating with DEPC. Total 
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Figures 4.1 1. and 4.12. Homology of nucleotide (nt) and derived amino acid (aa) 
sequences of the amplified regions of feline TNFR-l and TNFR-l and the 
corresponding regions in the other species in which they have been published. 
Table 4.1. Table 4.2. 
Species and TNFR-l TNFR-l Species and TNFR-2 TNFR-2 
Accession no. nt (%) aai_(%) Accession no. nt (%) aa(%) 
human X55313 85 83 human M32315 
mouse M59377 78 74 mouse M59378 
rat M63122 78 72 rat U55849 
cow U90937 80 74 cow AF031589 
pig U19994 842 79 ! 
1 aa sequence is compared for the coding region only 
2 the pig nt sequence starts 4 bases later than the amplified cat sequence 
3 amplified cat and rat sequences only overlap over 172 base pairs 
77 
73 
763 
785 
4 homology between cat and rat derived aa sequence was assessed over 28 aa 
residues (BestFit program) 
5 this region of the bovine sequence is 3 nts (1 aa) shorter than the cat sequence 
67 
60 
464 
66 
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Figure 4.13. Aligned predicted amino acid sequences for much of the extracellular 
domains of feline TNFRI and the complete extracellular region of the human 
receptor. Residues where the feline sequence differs from the human are indicated. 
The four conserved cysteine rich repeat areas are under- or over- lined, the cysteine 
residues shown in red and the putative site for cleavage of the hwnan soluble 
receptor shown in green type. (~ represent areas of the extracellular domain of feline 
TNFRI not amplified and sequenced.) 
1 50 
feline ---P---G-- Q-----A--- E---LR-T-- ----R----- AIP - ------
human MGLSTVPDLL LPLVLLELLV GIYPSGVIGL VPHLGDREKR DSVCPQGKYI 
51 100 
feline ---D--- --- - - -------- - - E---L--- - -- - -N-T-- ----Y--Q- -
human HPQNNSI CCT KCHKGTYLYN DCPGPGQDTD CRECESGSFT ASENHLRHCL 
101 150 
feline - - -- - ----Y -----P- --Y ---- - - - --- ---Y----TH -- - L- - -- - -
human SCSKCRKEMG QVEISSCTVD RDTVCGCRKN QYRHYWSENL FQCFNCSLCL 
151 200 
feline 
----QI- - K- T---- - - - -- -----G-- - - - - V- - --NT- ----------
human NGTVHLS CQE KQNTVCTCHA GFFLRENECV SCSNCKKSLE CTKLCLPQIE 
201 211 
feline "'''''"'''''''''''''''''''V'''''-' '" 
human NVKGTEDSGT T 
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RNA was extracted in preference to messenger RNA because of the ease of the 
technique. The A26o:A280 of total RNA after extraction should generally be between 
1.8 and 2. Lower ratios make the quantification of RNA more difficult and suggest 
contamination with glyco-polysaccharides, or an RNA pellet that is not totally 
soluble. High ratios suggest that the RNA has become degraded. 
Although RNA extraction was straightforward, DNA contamination was 
regularly detected despite exercising great care when removing the aqueous phase 
containing the RNA from the interphase and organic phase which contain DNA and 
protein. This is a recognised problem with RNA extraction protocols (Bauer et al. 
1997) and is best tested for by performing a reverse transcription reaction without 
enzyme. Any product after subsequent PCR must be due to genomic DNA 
contamination of RNA which can be removed by treatment with DNase I. DNA 
contamination is a serious problem particularly when assessing selective expression or 
quantifying expression levels. In this work, samples with contamination were 
discarded to prevent genomic DNA interfering with PCR amplification of cDNA. 
Despite designing multiple primers for both receptors, attempts to amplify 
either of the complete cDNA transcripts were disappointing. After initially trying to 
obtain each transcript in a single PCR, internal primers were designed to amplify 
shorter, overlapping stretches of each receptor. Primers were unlikely to have been 
exactly complementary to the feline template but any discrepancies between the 
available sequences were not permitted towards the 3' end of designed primers. In 
addition, complementarity of the 3' prime ends was avoided both inter and intra 
individual primers to reduce the formation of 'primer-dimers'. 
While some of these internal primers were successful, many were not, 
although it is not completely clear why not. Several explanations were considered. 
Because there was complete homology between human and murine sequences for 
primer 80-5, it was assumed that this was likely to apply to the cat sequence, but this 
may not be true and lack of homology may have been a causative factor in primer 
failure. In some cases, inequality of each of the bases in a primer may help to explain 
the problems encountered. For instance, primer 60-2 was fairly homologous 
throughout the species but had a G/C content of 70%. For the product derived from 
amplification with the 80-5 and 80-6 primer pair, sequencing showed that 80-6 acted 
as both forward and reverse primers. 
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Although not the ideal positive control because the primers were based upon 
human sequences, murine cells were readily available and murine cDNA was useful for 
testing new primer pairs. Altering the reaction conditions through magnesium ion 
concentration or the addition of DMSO, formamide or glucose did not improve the 
performance of primers that failed to amplify the correct product. 
By the end of this project, TNFR-1 sequences from the pig and cow and TNFR-2 
sequences from the rat and cow had been released onto the database. Alignment (}f all 
known sequences may identify further conserved regions for which primers can be 
designed. Introducing degeneracy into these primers to cover base differences across 
the species might be a way of amplifying more of the sequences. Alternatively, because 
partial sequence information is now available for the cat, a rapid amplification of 
cDNA ends (RACE) protocol could be employed (Frohman et al. 1988) or a feline 
cDNA library screened with a feline-specific probe to elucidate the remainder. RACE is 
a PCR-based technique in which gene-specific primers are designed on the sequence 
data available and used in combination with primers that anneal to oligonucleotides 
ligated to each end of the cDNA transcript (Fig 4.14.). The products ofPCR can then be 
sequenced by a standard method. 
Three clones and 2 PCR products for each transcript were sequenced in an 
attempt to filter out any PCR mis-incorporations or sequencing errors that may have 
arisen. Whereas degeneracy of the genetic code caused by wobble at the third position 
of the triplet codon suggests that amino acid sequence might be more conserved 
between species than nucleotide sequence, it can be noted that the opposite is true in 
the sequences presented here with less homology at the amino acid level. This has also 
been described for feline IL-2 when compared with human, bovine, rat and murine IL-2 
but is not true for feline TNF which is 91 % homologous to human TNF at the 
nucleotide level and 92% homologous at the amino acid level (comparison using 
BestFit program of sequences with Accession nos. M92061 and M10988). The high 
level of homology found between feline and human TNFR sequences, particularly 
TNFR-1, suggests that these proteins are likely to have a similar function in the cat to 
that in the human. 
In this study, the cDNAs encoding the extracellular regions of the receptor were 
of particular interest because it is these portions which are released from cells and exist 
as soluble proteins. This region of feline TNFR-1 has been amplified 
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successfully and the information gained can be used to generate antibody for the 
development of a species-specific assay to allow quantification of the soluble receptor 
in clinical samples. Antibody production may be undertaken in a number of ways 
including DNA vaccination and expression of recombinant protein or peptide 
synthesis for inoculation into a foreign host. 
In contrast, the only part of feline TNFR-2 that was amplified is located within 
the intracellular region so further sequence has to be elucidated before work- to 
develop an assay for this soluble receptor can progress. It is desirable to continue this 
work because the value of human soluble TNFR-2 as a marker of disease progression 
in HIV is clear (Aukrust et al. 1996) and the situation is likely to be similar in flY. 
4.6. Conclusion 
The majority of the extracellular region of feline TNFR-l was successfully amplified 
by peR, sequenced and cloned. This success will allow work to progress on the 
development of an assay for the protein, feline soluble TNFR-l. The ultimate 
objective is to be able to monitor levels of the protein in serum samples from cats 
infected with FlY. Although part of feline TNFR-2 has also been amplified, sequenced 
and cloned, this is situated in the intracellular region and further work is required to 
elucidate extracellular sequence before progression in the development of an assay for 
this receptor can be made. 
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Figure 4.14. Diagrammatic representation of RACE 
----------- AAAA 
reverse transcription ~ NNT10### 
t oligo (dT) primer 
2nd strand synthesis NNT30### 
NN'\ ,oil.'fH 
+ 
ligation of adaptor 
------------ NNT10### -
-
------- NNA 10#1I# -
5' RACE / ~ 3' RACE 
+- GSP1 NNT30###- -
GSP2 ~ NNAlOlf## 
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- adaptor 
GSP gene specific primer 
AP adaptor primer 
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Chapter 5: 
Expression of Feline Soluble TNFR-1 
5.1. Summary of Chapter 
This chapter presents work designed to express, as a recombinant protein, feline 
soluble tumour necrosis factor receptor type 1 (sTNFR-1). Complementary DNA 
encoding feline sTNFR-1 as determined in chapter 4 was ligated into two different 
bacterial expression vectors (pGEX 4T-3, Pharmacia Biotech and pET33b(+), 
Novagen). Although both systems gave disappointing results when synthesising 
recombinant protein, the system expressing the receptor as a fusion with glutathione-
S-transferase yielded sufficient protein for antibody production in a sheep. 
5.2. Introduction to Protein Expression 
Previous work using Western blotting failed to detect any cross-reactivity between 
commercially available anti-human TNFR-1 antibody and feline samples (see section 
3.3). Consequently, species-specific antibody was required for the development of an 
immunological assay for feline TNFR-1. To this end, expression of feline sTNFR-1 
was undertaken to provide recombinant protein to immunise a sheep for polyclonal 
antibody production. 
Cell-free and cell-associated systems are available for protein expression. The 
technique of cell-free protein synthesis has the advantage of producing protein with a 
minimum of background from translation of endogenous RNA and can be very rapid, 
but is limited by the quantity of protein that it can produce. The in vivo expression of 
cloned gene products is an important method of protein production on a larger scale 
for use in research. It is used in the study of protein structure and function, protein-
protein and protein-nucleic acid interactions, antibody production and mutagenesis. 
Both eukaryotic and prokaryotic in vivo expression systems can be used to 
provide protein for subsequent antibody production. Bacterial expression is generally 
the most straightforward and least costly method and can give high yields with 
closely regulated expression (Goeddel, 1990). Although eukaryotic systems can also 
give high yields and are more likely to allow the post-translational modifications 
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necessary to make the protein functional, this is generally not required for antibody 
production. One of the problems associated with prokaryotic systems is the tendency 
to over-express protein, resulting in it being stored in insoluble inclusion bodies 
which hampers purification. However, since bacterial expression is generally 
straightforward, it remains a very attractive technique when the initial goal is 
antibody production. 
In studies to examine the functional properties of recombinant human (Schall 
et al. 1990), murine (Lewis et al. 1991) or rat (Rimmler et al. 1990) TNFR-1, 
expression was performed in either mammalian or insect (Moosmayer et al. 1994) cell 
systems. However, commercially available assays for human and murine TNFR-1 
utilise antibody raised against recombinant protein expressed in E coli (R&D 
Systems, Minneapolis, USA) and recombinant feline TNF produced in a bacterial 
expression system (FLAG, International Biotechnologies Inc) was used successfully 
to inoculate chickens for subsequent antibody production (Otto et al. 1997). 
5.2.1. Bacterial Expression Systems 
5.2.1.1. Glutathione-S-transferase fusion proteins 
The glutathione S-transferase (GST) gene fusion system (pGEX vectors, Pharmacia 
Biotech) has been designed to allow protein expression where the recombinant 
protein is fused to GST from the parasite Schistosoma japonicum (Smith, 1993). 
Such fusion proteins can be rapidly purified by chromatography because of the high 
affinity that GST has for glutathione (Smith et al. 1986) and are also easily detected 
by exploiting the biochemical or immunological reactions of GST which is important 
when expressing a novel protein for which no other reagent exists. GST -protein 
fusion systems have been used successfully in molecular immunology (Toye et al. 
1990), vaccine production (Johnson et al. 1989) and in the study of DNA-protein 
(Chittenden et al. 1991) and protein-protein (Kaelin et al. 1992) interactions. The 
pGEX system has also been used to express the cytokine, feline stem cell factor 
(Dunham, 1997) as a functional protein. 
The pGEX vectors carry the tac promoter which is induced by the lactose 
analogue isopropyl f)-D-thiogalactopyranoside (IPTG), and allows transcription to be 
readily regulated. The tac promoter is a hybrid of two promoters, lac and trp, and is 
more efficient than either parent. It is controlled by the lac repressor which is readily 
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de-repressed by IPTG, resulting in high level expression (Wong, 1996). Expressed 
proteins often, though not always (Frangioni and Neel, 1993), remain soluble and do 
not require to be denatured during their purification (Smith and Johnson, 1988) so 
are more likely to retain their antigenicity (Smith and Corcoran, 1997). The GST 
moiety generally does not interfere with the antigenicity of the expressed protein 
(Toye et al. 1990). 
5.2.1.2. His-tag fusion proteins 
The pET system (Promega) is a powerful method of producing recombinant proteins 
in which expression is under transcriptional control of a bacteriophage T7 promoter 
(Studier and Moffatt, 1986). Vector transcription remains silent until expression of a 
chromosomal copy of T7 RNA polymerase is induced by IPTG activation of the lac-
controlled T7 RNA polymerase gene promoter (Rosenberg et al. 1987). Cells 
carrying the pLysS plasmid inhibit background expression prior to induction because 
they express low levels of T7 lysozyme which is a natural inhibitor of T7 RNA 
polymerase (Novagen, 1995). Upon induction, the overwhelming production of T7 
RNA polymerase counteracts the effects of lysozyme. This stringent regulation of 
expression ensures that toxic inserts can be established in the BL21(DE3)pLysS host 
and still be expressed to high levels (Promega, 1996). 
The pET33b(+) vector encodes both N- and C- terminal histidine-tag 
sequences allowing easy purification of expressed protein by metal chelation 
chromatography. The vector also carries a kanamycin rather than an ampicillin 
resistance gene to allow selection. Ampicillin selection can be lost in cultures as the 
drug is degraded by secreted p-lactamase or by a reduction in pH as a result of 
bacterial fermentation. 
5.3. Aim of Experimental Studies 
When the sequence for the extracellular portion of feline TNFR-! had been 
elucidated (chapter 4), the goal became to raise antibody against it to allow the 
development of an immunological assay for the protein. To this end, the aim of the 
work described in this chapter was to use the available sequence to express the 
protein in a bacterial expression system, and subsequently to inoculate sheep with 
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purified expressed fusion protein to generate antiserum for use as a reagent in the 
assay. 
5.4. Materials and Methods 
5.4.1. Glutathione-S-transferase fusion protein 
Construction of the plasmid and insert for expression is illustrated in figure 5.1. 
5.4.1.1. Preparation of insert DNA 
A glycerol stock (designated clone 2av) of the pT7Blue T-Vector (Novagen, 
Wisconsin) containing the PCR product obtained after amplification with primers 60-
1 and 60-4 as an insert (see section 4.4.S.) was used to inoculate 5rnl LB broth 
containing 5011g/ml of ampicillin (LB-amp, Appendix 1). The culture was grown 
overnight at 37°C in an orbital shaker at 200rpm. At the end of incubation, the cells 
were collected by centrifugation at lS00rpm for 10 minutes and plasmid DNA 
purified using a commercial kit (Qiagen). Purified DNA was quantified (GeneQuant, 
Pharmacia Biotech) and sequenced bi-directionally with T7 promoter (5' 
taatacgactcactatagg) and U19 (5' gttttcccagtcacgacgt) primers (DNA Sequencing 
Service, Kings College, London) to detect orientation of the insert and ensure an 
open reading frame throughout. 
Ten llg of plasmid DNA were digested for 1 hour at 37°C in a total reaction 
volume of l00111 with a final concentration of 50mM Tris-HCl (pHS), 10mM MgCh 
and 100mM NaCI and with 50 units each of the restriction enzymes EcoRI and Sail 
(GibcoBRL, Paisley, Scotland). Digestion products were electrophoresed on a O.S% 
agarose gel at 100V for 1 hour and the 6S0bp insert band was excised. DNA was 
electro-eluted from the gel in dialysis tubing (Cellulose membrane, Sigma) for 10mins 
at 150V and precipitated in O.lM sodium acetate and 50% ethanol. After storage at -
20°C overnight, DNA was collected by centrifugation and washed with 70% ethanol 
prior to drying. Lyophilised DNA was dissolved in 2011l dH20. 
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Figure 5.1. Diagrammatic representation of cloning procedure. DNA insert encoding 
feline sTNFR-l is shown in black, whereas that encoding GST is shown in red. The 
pT7 and pGEX 4T-3 vectors are coloured green and blue respectively. Selection of 
the appropriate vector for expression ensures the insert is ligated in-frame. The 
construct was used initially to transform JM109 cells. 
~ 't o 
l;g,lIon : p"rifi,' 
insert and 
expression vector 
1 
o 
construct ready for expression of GST 
and feline sTNFR-1 fusion protein 
pGEX 4T-3 
digested with 
ECO~ fd Sail 
o 
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5.4.1.2. Preparation of pGEX vector 
Two ~g ofpGEX 4T-3 plasmid DNA (Pharmacia Biotech) were digested for 1 hour 
at 37°C in a total reaction volume of 20~1 with a final concentration of 50mM Tris-
HCI (pH8), 10mM MgCI2 and 100mM NaCI and with 5 units each of the restriction 
enzymes EcoRI and Sal I. The products of digestion were electrophoresed and linear 
plasmid DNA was excised and purified as above (section 5.4.1.1.). 
5.4.1.3. Ligation of insert to pGEX plasmid 
Linearized pGEX DNA and insert DNA were ligated at a molar ratio of 1:5 in a total 
reaction volume of 20~1 with ImM ATP, 10mM Tris acetate, 10mM magnesium 
acetate, 50mM potassium acetate and 10 units of T4 DNA ligase (all reagents from 
Pharmacia Biotech). Ligation was allowed to proceed for 2 hours at room 
temperature. 
5.4.1.4. Preparation of competent cells 
Both JM109 (Promega) and BL21 (Pharmacia Biotech) strains of E. coli were 
purchased; the former for maintenance of the plasmid and the latter for expression. 
To make the cells competent, they were grown in 5ml cultures of LB broth without 
antibiotic and incubated overnight in an orbital shaker at 200rpm. The following 
morning a 1 :50 dilution of the overnight culture was prepared in broth and growth 
was continued until the ~50 reached 0.6 (Beckman spectrophotometer). At this time, 
the cells were collected by centrifugation at 2000rpm for 10 minutes at room 
temperature and re-suspended in a half volume of ice-cold O.IM CaCho After 
incubation on ice with occasional shaking for 20 minutes, the cells were centrifuged 
as before and suspended in a tenth of the former volume of ice-cold O.IM CaCho If to 
be used immediately, competent cells were kept on ice until required. Alternatively, 
an equal volume of sterile 50% glycerol was added and the cells were stored in 
aliquots at -70°C. 
5.4.1.5. Transformation reaction 
Ten ~I of the ligation mix were added to 500~1 of competent JMI09 cells and kept 
on ice for 30 minutes. Cells were heated to 42°C for 2 minutes and quenched on ice 
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for a further 2 minutes. Five hundred III of SOC medium (Appendix 1) were added 
and the tubes were incubated in an orbital shaker for 1 hour at 37°C. At the end of 
this time, the cells were collected by centrifugation for 10 minutes at lS00rpm and 
re-suspended in 0.5ml LB-amp broth before being plated onto LB-amp agarose plates 
and incubated overnight at 37°C. Negative control plates with cells transformed with 
undigested and digested vector with no insert were also prepared. 
5.4.1.6. Recovery of plasmid DNA 
Single colonies were picked off and used to inoculate 3ml aliquots ofLB-amp broth. 
These cultures were incubated at 37°C overnight. The following morning 15% 
glycerol stocks were made of each culture and plasmid DNA was recovered using a 
standard mini prep (Qiagen, UK). To check for the presence of an insert, 5111 of each 
colony was digested with EcoRI and Sail in a total reaction volume of 20111 as 
described in section 5.4.1.2. Glycerol stocks were stored at -SO°c. 
5.4.1.7. Transformation of BL21 cells 
Cells were transformed with plasmids with and without the TNFR-l insert. Aliquots 
of 200111 of BL21 cells were transformed as described in section 5.4.1.5. with 0.5111 
of plasmid DNA as prepared in section 5.4.1.6. Transformed cells were plated onto 
agarose, colonies grown in LB broth with ampicillin and glycerol stocks made as 
described previously. Again, integrity of an open reading frame was confirmed by 
sequence analysis using the primers 5'pGEX Sequencing Primer (S69 
5' gggctggcaagccacgtttggtg 3 ') and 3' pGEX Sequencing Primer (1040 
5' ccgggagctgcatgtgtcagagg 3') (Pharmacia Biotech). 
5.4.1.8. Screening for protein expression 
Glycerol stocks were used to inoculate 10mls ofLB-amp broth and the cultures were 
incubated overnight at 37°C with vigorous agitation. The following morning, cultures 
were diluted 1:3 and grown under the same conditions until reaching an ~oo of 0.6-
O.S. At this time, IPTG was added to a final concentration of 0.2mM, and the 
incubation continued for a further 2 hours. Duplicate cultures were maintained with 
no added IPTG. Different incubation times (1, 2, 4 and 6 hours), IPTG 
CHAPTERS 113 
concentrations (0.1, 0.2, 0.5 mM) and incubation temperatures (37°C and room 
temperature) were used and the effect on expression levels was monitored. 
Post-induction, 1ml of each culture was collected, the bacteria were pelletted by 
centrifugation and the pellet was re-suspended in 167,.d phosphate buffered saline and 
33111 treatment buffer (0.06M Tris-HCI, 1.7%SDS, 6% glycerol, O.lM dithiothreitol, 
0.002% bromophenol blue). Each sample was boiled for 5 minutes before analysing by 
sodium dodecyl sulphate-polyacrylamide gel electrophoresis (SDS-PAGE) (see section 
5.2.1.9.). 
5.4.1.9. 50S-PAGE 
SDS-PAGE was performed using a mini-gel system (BioRad) with 12.5% 
polyacrylamide gels (Laemmli, 1970) (Appendix 2). Ten microlitres of each sample 
were loaded into wells in the gels and electrophoresis carried out in tank buffer (25mM 
Tris, 192 mM glycine, 0.1% w/v SDS, pH 8.3) at 20mA per gel until the dye front 
reached the bottom. The gels were stained overnight with 0.025% Coomassie Brilliant 
Blue R-250 in 40% methanol and 7% acetic acid and de-stained in the same solvents. 
Molecular weight standards were run simultaneously (Wide Range Color Markers, 
Sigma, St Louis, USA). 
Stained gels were photographed using a digital imaging system (Cohu high 
performance charge coupled device (CCD) camera connected to a Sony monitor (SSM-
930CE) and video graphic printer (UP 890CE)) and recorded onto printing paper (Sony 
Superior Density, UPP 110HA) or dried between cellulose sheets (Pharmacia Biotech) 
in a warm air drier (Hoeffer). Gels used for Western blotting were left unstained. 
5.4.1.10. Western blotting 
Proteins were transferred from polyacrylamide gels to nitrocellulose membrane in 
Towbin transfer buffer (25mM Tris, 192mM glycine, 20% methanol and 0.1 %SDS) 
using a Trans-Blot Cell (Bio-Rad) with cold water cooling at 200mA for 2 hours. After 
transfer, nitrocellulose membranes were blocked overnight by incubating in 5% (w/v) 
dried skimmed milk powder in 50mM Tris-HCI buffered saline (TBS), pH7.4. The 
blocked membrane was incubated with goat anti-GST antibody (Pharmacia Biotech) 
diluted 1: 100 in TBS with 1 % dried skimmed 
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milk powder and 0.05% Tween-20 (TBS-Tween-milk) for 1 hour at room 
temperature and washed 3 times for 10 minutes in TBS-Tween-milk. 
Donkey anti sheep/goat IgG conjugated to horseradish peroxidase (Scottish 
Antibody Production Unit, Law Hospital) was used as the second antibody at a 
concentration of 1: 1000 in TBS-Tween-Milk, and the membrane was incubated in 
this buffer for a further hour. After 3 washes carried out as before, the membrane was 
stained with 3,3' -diaminobenzidine (Sigma Fast DAB tablets, Sigma) before washing 
with dH20. 
5.4.1.11. Large scale protein expression 
Large scale protein expression in 5 litres of culture medium was performed three 
times. Two litres of LB-amp broth were inoculated with 100J,t1 glycerol stock and 
incubated overnight as 500ml aliquots in 2 litre flasks. The following morning the 
aliquots were diluted 1:3 and induced with IPTG when an At;oo of 0.6-0.8 was 
reached in a similar manner to smaller volumes. After induction, the culture was 
transferred to 500ml centrifuge containers and centrifuged at 7700 x g for 10 minutes 
at 4°C (Beckman JAlO rotor in a centrifuge). Bacterial pellets were re-suspended in 
0.01 volume of ice-cold PBS containing protease inhibitors (Protease Inhibitor 
Cocktail, Sigma) and the cells disrupted by sonication for three bursts of 30 seconds. 
To assist solubilization of the fusion protein, 20% Triton X-I 00 was added to the 
sonicate to a final concentration of 1 % before mixing gently for 30 minutes. At the 
end of this time, the supernatant was collected after centrifugation at 12000 x g for 
10 minutes at 4°C (Beckman JA-20 rotor). 
Aliquots of the pre-sonicate suspension and the post-sonicate solution and 
cell debris pellet were taken for analysis by SDS-P AGE. 
5.4.1.12. Purification of expressed proteins 
Expressed proteins were purified by binding to glutathione sepharose slurry prepared 
according to the accompanying protocol (Pharmacia Biotech). For 5 litre cultures, 
the sonicate was allowed to flow through a column of 2mls (bed volume) of 
glutathione sepharose. Bound protein was washed with lOx bed volumes of PBS and 
then eluted by three additions of 2mls of Elution Buffer (10mM glutathione, 
Pharmacia). 
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5.4.1.13. Thrombin cleavage 
Thrombin cleavage was performed by adding 10j.!1 of thrombin solution (10 cleavage 
units, Pharmacia Biotech) per mg of fusion protein in the eluant and the mixture left 
at room temperature overnight. The following morning the reaction was dialysed 
against 2000 volumes of PBS with stirring for 2 hours and then purified on a 
glutathione column as in section 5.4.1.12. Aliquots of eluant immediately after 
addition of thrombin and prior to dialysis were saved for analysis along with the 
products of purification. 
5.4.1.14. Quantification and preparation of expressed proteins 
Purified expressed protein was analysed by SDS-P AGE and quantified by scanning 
densitometry of stained gels at 600nm (Chromoscan, Joyce-Loebel) and by assay 
with Bradford reagent (Sigma) for total protein. The eluants from the three 5 litre 
cultures were pooled and concentrated in a stirred cell concentrator (Ami con 8050 
mini-system) with a 43mm PMlO membrane pre-soaked in dH20. Concentrated 
protein was electrophoresed on an SDS-PAGE gel, stained with Coomassie blue and 
the appropriate band was cut out and macerated with a scalpel. Four aliquots of 100j.! 
g of protein contained in the gel were used by the Scottish Antibody Production Unit 
(SAPU, Law Hospital, Lanarkshire) for injection into a sheep at 4 four-weekly 
intervals. 
5.4.1.15. Analysis of antiserum 
Pre-immune serum and antiserum taken after the second, third and fourth injections 
of antigen were returned from SAPU and examined by western blotting as described 
above. Prior to use in the blot, any cross-reaction with E. coli proteins had to be 
removed from the antiserum by absorption. For this, E. coli cells containing vector 
without an insert were cultured, re-suspended in PBS and then ruptured by 
sonication. Antiserum was added to this suspension at a ratio of 1 ml antiserum to 9ml 
culture and the mixture was left at 4°C overnight. Cell debris was removed by 
centrifugation and sodium azide was added to a final concentration of 10mM. 
Absorbed antiserum was diluted 1: 5 in TBS-T -M for use as the initial antibody in a 
western blot. 
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5.4.2. Expression in pET33b(+) 
The vector pET33b(+) (Novagen, US) was also used to express feline TNFR-l. In a 
similar manner to that described for pGEX, both pET33b and the 2av clone were 
digested with EcoRi and Sail and the purified insert was ligated into the expression 
vector. The vector was maintained in pMOS blue cells (Amersham,) and expressed in 
BL21 DE3 pLys(S) (Promega) cells. Aliquots of 20mls of LB broth with kanamycin 
and chloramphenicol were inoculated with culture which was induced with 1 mM 
IPTG for 1, 2, 3 and 4 hours when the Atioo reached 0.6. Analysis of celllysates was 
performed on SDS-PAGE gels as in section 5.4.l.9. 
5.5. Results 
5.5.1. Glutathione-S-transferase system 
5.5.1.1. Preparation of plasmid with insert 
Digestion of plasmid DNA from clone 2av and pGEX 4T-3 plasmid with 
EcoRI and Sail produced a 680 base pair insert and linear plasmid (figure 5.2.) with 
cohesive ends. Insert and plasmid were readily ligated and the ligation reaction 
successfully transformed E coli cells. Positive clones were identified by the presence 
of an insert after re-digestion (figure 5.3.). The 4T-3 plasmid allowed the insert to be 
ligated in-frame and this was confirmed by sequence analysis. Numerous colonies 
grew after transformation of JMI09 cells with vector ligated to insert. When digested 
vector alone was used in the transformation reaction, 3 colonies grew. It is likely that 
these 3 colonies arose from re-ligated vector after digestion with only one enzyme. 
5.5.1.2. Protein expression 
Analysis of the bacterial lysates prepared by boiling showed induction of GST in the 
colonies that contained vector alone, but no evidence of fusion protein expression in 
colonies containing vector with the insert. Purification identified a weak band of 
about 50kDa which was produced by the colonies containing vector with an insert 
but not in the colonies containing vector alone (figures 5.4. and 5.5., column 2). 
Confirmation that this band represented the fusion protein was obtained by its 
disappearance after thrombin cleavage (figure 5.5.) and also by its reaction with anti-
GST antibody in a western blot (figure 5.6.). 
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Figure 5.2. Agarose gel following electrophoresis showing pGEX 4T-3 and plasmid 
DNA from clone 2av after digestion with EcoRl and SaIl. Lane 1, lkB marker; lane 
2, 680bp insert from 2av DNA; lane 3, linear 4T-3. 
bp 
3054 
506 
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Figure 5.3. Negative image of an agarose gel showing successful ligation of 4T-3 
and insert. Plasmid DNA from transformed BL21 cells has been digested with 
EcoRi and Sal! and the presence of an insert demonstrated by electrophoresis. Lane 
1, IkB marker; lanes 2-5, 680bp insert from different clones after digestion of 4T-3; 
lane 6 negative control sample of vector without insert that has been digested in a 
similar manner. The upper arrow shows digested plasmid and the lower arrow 
shows insert. 
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Figure 5.4. SDS-PAGE gel stained with Coomassie blue illustrating bacterial 
expression of GST. Lane 1 molecular weight marker; lane 2, cell lysate from a 
colony of cells containing pGEX 4T-3 plasmid without an insert; lane 3, purified 
lysate used in lane 2. The arrow indicates the GST protein band (29kDa). 
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Figure 5.5. SDS-PAGE gel stained with Coomassie blue illustrating loss of fusion 
protein band after thrombin cleavage. Lane 1, molecular weight marker; lane 2, 
purified cell lysate from a colony of cells containing plasmid with feline TNFR-1 
insert; lane 3, purified lysate from lane 2 after thrombin cleavage; lane 4, fusion 
protein cleaved with thrombin after GST had been removed by purification on a 
glutathione column. The arrow indicates the band that is present in colonies 
containing vector with an insert but not in colonies containing vector only that 
disappears after thrombin cleavage. 
3 4 
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Figure 5.6. Western blot using anti-GST antibody illustrating breakdown of fusion 
protein. Lane 1, purified GST from 4T-3 without an insert; lane 2, purified fusion 
protein from pGEX 4T-3 with feline TNFR-l insert. The upper band (solid arrow) is 
around 50kDa and represents intact protein whereas the smaller bands (broken 
arrows) reflect protein cleavage. 
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Quantification of the fusion protein after electrophoresis using a scannmg 
densitometer by comparison with dilutions of albumin (figure 5.7.) showed that 400ll 
g had been produced from the three 5 litre cultures and, after separating from 
contaminating E coli proteins on a polyacrylamide gel (fig 5.S.). This material was 
divided into 4 equal aliquots and sent to SAPU for antibody production. 
Alterations in time or temperature of incubation, or in the concentration of 
IPTG did not improve the production of fusion protein. Analysis of the post-sonicate 
pellet and glutathione column washes showed that expressed protein was not lost at 
either of these stages. 
5.5.1.3. Analysis of antiserum 
Pre-immune sera from the inoculated sheep showed no cross reaction with 
recombinant protein when examined by western blotting. Analysis of antiserum 
returned after the fourth inoculation with antigen showed binding to the expressed 
protein from a colony containing the vector with insert but not one containing vector 
alone (fig 5.9.). Two bands stained on the western blot at 25kDa; both about half the 
size of the expected 50kDa and staining was weak. Expressed protein from colonies 
containing vector with or without insert reacted with anti-GST antibody, although 
again the bands in both were around the same size (fig 5.9.). 
The antiserum did not react with any proteins in the region of the size of the 
protein band excised for inoculation and the reaction between the antiserum and the 
smaller band could not be reproduced consistently. 
5.5.2. Expression in the pET33b system 
The pMOS blue cells used for maintenance were readily transformed with the 
ligation reaction and plasmid prepared from these cultures successfully transformed 
the BL21 cells as confirmed by plasmid digestion and sequence analysis. However, 
there was no evidence of expression of protein by the pET33b vector when induced 
celilysates were analysed by SDS-PAGE. 
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Figure 5.7. SDS-PAGE gel stained with Coomassie blue used to quantify fusion 
proteins. Lane 1 molecular weight marker; lanes 2 and 3, sample of fusion protein 
after purification from two 5 litre cultures, with the arrow indicating the band of 
interest; lanes 4-8, 10, 25, 50, 75 and 1001lg/ml samples of bovine serum albumin 
respectively. 
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Figure 5.8. SDS-PAGE gel stained with Coomassie blue illustrating the band 
excised for inoculation of a sheep. The molecular weight marker can be seen on the 
left and concentrated purified fusion protein has been run in the other lanes. The 
arrow shows where the band identified by Western blotting and thrombin cleavage 
has been excised from the gel. 
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Figure 5.9. Western blots using anti-GST antibody (blot a) and antiserum taken from 
the sheep after the fmal inoculation and absorbed with E coli proteins (blot b). Lanes 
1 and 4 contain purified fusion protein and lanes 2 and 3 contain purified expressed 
GST. Protein of around 25kDa in lanes 1 and 4 has reacted with both anti~GST 
antibody and the antiserum suggesting breakdown of the fusion protein whereas 
GST alone only reacts with specific anti-GST antibody. 
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5.S. Discussion 
The work presented in this chapter describes the cloning and expression of the 
amplified region of feline TNFR-l described in chapter 4. Expression in E. coli as a 
GST fusion protein produced only sufficient protein for the inoculation of one sheep. 
Although the vector for expression was readily ligated to the feline TNFR-l 
sequence, the amount of fusion protein recovered after purification was 
disappointing. Only 400llg of protein were obtained from 15 litres of culture, 
considerably less than the 1-10 mg/litre suggested by other reports of use of the 
pGEX gene system (Dunham, 1997). Although only a small amount was obtained, 
this protein was used to inoculate a sheep which provided sufficient antiserum for use 
in the development of an assay for the protein in clinical samples. To eliminate the 
possibility of an idiosyncratic response in a single animal, it may have been preferable 
to use the small amount of protein to inoculate two rabbits (Harlow and Lane, 
1988b) and accept the accompanying reduction in antiserum produced. 
Small yields from expression systems may be a result of either poor protein 
expression or loss of protein during purification. It is suggested that a pre-purification 
yield may be in the order of 10-1 OOllg of fusion protein per ml of culture (Frangioni 
and Neel, 1993), although 60-70% of protein may be lost at the elution step. With 
larger proteins the saturation binding level of glutathione agarose is much reduced so 
that proteins greater than 100kDa are extremely poorly bound. The fusion protein 
expressed here was only 50kDa, so should be retained by the column. SDS-P AGE 
analysis of post-sonicate supernatant and column fractions did not detect significant 
amounts of fusion protein. 
The lack of protein expression was unlikely to be due to the protein being 
insoluble and in inclusion bodies since it could be detected in neither cell lysate nor 
purified fractions. Analysis of pre-sonicate and post-sonicate cell debris, the wash 
phases and glutathione column post-elution did not reveal a stage at which the 
protein might have been lost during these procedures. Attempting to improve protein 
recovery by selecting a smaller portion of feline receptor for expression, perhaps 
omitting the hydrophobic or highly charged regions might have been a useful 
alternative strategy if solubility had been a problem. This approach was not attempted 
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because there was no evidence of expressed protein in cell lysate fractions when 
analysed by SDS-P AGE. 
It has been reported that fusion protein expression may be toxic to cells (Otto 
et al. 1995). If this were true, and ~-lactamase production by cells carrying the 
plasmid depleted ampicillin in the culture, then antibiotic selection would be disrupted 
resulting in overgrowth by cells from which plasmid had been lost. This could explain 
the continued turbidity of the culture concurrent with the lack of protein expression. 
It may have been possible to test for this by performing a plasmid stability test in 
which log phase culture of transformed cells are plated onto plates containing 
antibiotic only, antibiotic and IPTG, IPTG only and no additives, and subsequent 
growth is analysed. A small proportion only of the cells (2%) should not contain 
plasmid and grow on the plate containing IPTG. If overgrowth had been identified by 
this method, addition of 2% glucose to the pre-induction culture medium may have 
been sufficient to limit basal expression in further cultures. 
A plasmid turbidity test was not carried out, however changing to expression 
in JMI09 cells or altering the induction time, temperature or concentration of IPTG 
did not affect expression levels. In cells containing the pET33b(+) plasmid with 
kanamycin selectivity, there should be a reduced incidence of overgrowth of cultures 
by cells that have lost the plasmid (Novagen, 1995). 
Purification on a glutathione column did not result in a single protein band 
detectable by SDS-PAGE as there was simultaneous purification of E. coli proteins. 
This may be due to over-zealous use of the sonicator. Definitive analysis of the 
purified proteins was required. No antibody specific to feline TNFR-l was available 
to check the production of expressed protein by Western blotting. Instead, anti-GST 
antibody was used to identifY protein containing the GST sequence and a band of 
around 50kDa was detected consistent with the fusion protein. The anti-GST 
antibody also reacted with some smaller bands, suggesting some breakdown of the 
fusion protein. Subsequently, anti-proteases were added to cultures during 
purification. 
The only feline TNFR-l available to test the antiserum for cross-reactivity 
was expressed protein. As the level of expression was very poor, this was not entirely 
satisfactory, and results from the last aliquot of antiserum suggested that some 
proteolysis of the fusion protein had occurred. Excessive sonication can result in 
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protein disruption as well as the simultaneous purification of E coli proteins, so this 
may also have occurred. BL21 cells used for expression are protease deficient and 
thus should not contribute to protein degradation. 
Protein expression by the GST fusion system was poor and it made 
identification of the expressed protein difficult since bacterial proteins were present 
even after purification. Determination of molecular radius by SDS-P AGE, 
identification by Western blotting with anti-GST antibody and disappearance after 
thrombin cleavage were relied on as identification techniques. However, it was 
intended to confirm protein production by amino acid sequencing. This did not prove 
possible because of the low quantities of protein generated and because of the loss 
after thrombin cleavage. The GST moiety was expressed on the N-terminus and thus 
has to be cleaved before any useful sequence information can be gained. Protein loss 
after thrombin cleavage may have been as a result of thrombin degradation of the 
expressed protein as well as release of the GST moiety (Sun and Budde, 1995) or 
due to such small amounts being present originally. 
The aim of raising antiserum to soluble feline TNFR was to develop a species-
specific assay for the receptor. Although the antiserum did detect expressed protein 
in Western blots, the result was poor and inconsistent. The development of an assay 
based on this antiserum is likely to give unreliable results. Consequently, the sheep 
used in this experiment was maintained without further inoculation whilst other 
methods of antibody production were assessed. 
Since expression in the bacterial system had been poor, it became necessary to 
consider other methods of antibody production. One possibility was expression of 
protein in a mammalian system which, in addition to providing protein, is likely to 
produce functional receptor. However this was not undertaken due to lack of time. A 
further possibility, as sequence but not protein was available for the receptor of 
interest, was to raise antibody to peptides based on the known sequence. It would 
also be possible to vaccinate an animal with naked DNA of the cloned sequence of 
interest to provide antiserum in a similar manner to that used for protection from 
disease (Johnson et al. 1989). One of the problems with this latter approach is that 
although the host's immune response may be protective, cell mediated immunity is 
likely to dominate and antibody production may be minimal. This may be overcome 
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by the simultaneous injection of DNA encoding a cytokine selected to drive a 
humoral response. 
5.7. Further Studies 
The results of expression of feline TNFR-l in two bacterial expression 
systems were disappointing. However, the sequence of feline sTNFR-l is now 
available and the clear way forward is to immunise animals with appropriate peptides 
based on the sequence. An alternative would be to re-boost the sheep, or other 
animals with recombinant protein perhaps after expression in a mammalian system. 
This is a more time-consuming option, as would be DNA vaccination. In addition, 
peptide synthesis provides a source of antigen to assess specific antibody production 
in the inoculated animal. Further analysis of the antiserum raised in the current sheep 
is difficult because of the poor expression of recombinant protein and the lack of 
reactivity between the antiserum and rhTNFR-l. 
5.8. Conclusion 
Feline sTNFR-l was purified after expression in E. coli using the pGEX 4T-3 
vector. Antibody raised against the purified receptor reacted weakly with 
recombinant feline but not recombinant human protein. This reaction was inconsistent 
and the antiserum was therefore not used in the development of an assay for the 
protein. 
CHAPTER 6 130 
Chapter 6: 
Immunological Detection of Feline Soluble TNFR-1 
6.1. Summary of Chapter 
This chapter presents work designed to detect feline soluble tumour necrosis factor 
receptor type 1 (sTNFR-l) by immunological assay. Feline-specific antisera were 
generated by inoculating sheep with synthetic peptides based on the feline TNFR-l 
sequence described in chapter 4. Cross-reactivity of the antisera with the peptides, 
human sTNFR-l and feline TNFR-l was assessed using western blotting, enzyme-
linked immunosorbent assay (ELISA) and immunocytochemistry. An attempt was 
also made at the development of the ELISA to detect sTNFR-l in feline samples. 
6.2. Introduction 
Attempts to generate antiserum to recombinant feline sTNFR-l expressed in E. coli 
were very disappointing because of poor protein production by clones containing the 
gene for this receptor (see Chapter 5). However a specific antibody was required 
before an effective assay for the receptor could be developed. To this end, antiserum 
was produced against synthesised peptides based on the feline sTNFR-l sequence. 
An advantage of this approach is that a plentiful supply of antigen is available to 
assess antisera. 
6.2.1. Selection of antigenic peptides 
Antigenic determinants are surface features of proteins and are frequently found on 
exposed areas of the molecule. Stretches of charged, hydrophilic amino acid side 
chains are common features of antigenic regions which tend to have few hydrophobic 
residues (Hopp and Woods, 1981). These properties have been used to devise 
computer programs which will predict the location of regions of antigenicity in 
proteins (Hopp and Woods, 1983) and their hydropathic character (Kyte and 
Doolittle, 1982). 
When designing peptides for antibody production, it is obviously important to 
select an area of the protein predicted to be immunogenic. In addition, it is wise to 
CHAPTER 6 131 
choose a region that has poor homology with the homologous protein of the species 
used for raising antibody so that the animal recognises the peptide as foreign. For these 
reasons, a number of peptides are often synthesised to increase the chance of detecting 
one that elicits a good immune response. To improve their immunogenicity, peptides 
are either conjugated to a carrier protein, often keyhole limpet hemacyanin or bovine 
serum albumin, or are constructed into a larger molecule prior to inoculation. These 
larger molecules are known as multiple antigenic peptides (MAPs) and have a simple 
scaffolding of a low number of sequential levels of an amino acid as the core matrix on 
the C-termini of copies of the peptide, forming a macromolecule with a high density of 
peptide antigens (figure 6.1.) (Tam, 1988). Although the amino acid core is non-
immunogenic, the immunoreactivity of MAPs has been found to be superior to that of 
monomeric peptides conjugated to a protein carrier (Tam and Zavala, 1989). 
Linear peptides can be synthesised independently in a single chain to provide 
antigen for analysing the immune response in an animal inoculated with a MAP when 
recombinant or purified protein is not available and to assist with purification of the 
resultant antiserum if required. Thus, anti-peptide activity can be detected readily 
although this will not necessarily reflect activity against the native protein. The absence 
of activity against the native protein is one of the major problems encountered with 
anti-peptide antibodies (Harlow and Lane, 1988). 
MAPs have been used successfully to generate antiserum in sheep to peptides 
based on the third variable (V3) loop of FIV (Rigby et al. 1996) and to generate 
antiserum in rabbits to feline y-interferon (Argyle, 1995). In these studies, inoculations 
were made with complete Freund's adjuvant for the initial vaccination and incomplete 
Freund's adjuvant thereafter. Adjuvants are non-specific stimulators of the immune 
response and are particularly necessary when using soluble antigens to induce an 
immune response. Freund's adjuvant contains mineral oil which creates a depot and 
protects the antigen from rapid catabolism (Burrin and Newman, 1991) and killed 
Mycobacterium tuberculosum for immune stimulation (Harlow and Lane, 1988). 
Incomplete Freund's adjuvant does not contain the bacteria and is used for boosting 
vaccinations to avoid the side effect of persistent granuloma. 
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Figure 6.1. Structure of an octameric MAP/peptide complex with a poly-lysine core. 
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6.2.2. ELISA protocol 
The construction of an ELISA for the assay of antibody generally relies on antigen 
immobilised on a solid phase (antibody capture) (Achord et al. 1991), whereas an 
ELISA for the assay of antigen relies on immobilised antibody. An inhibition ELISA 
uses antigen immobilised on a solid phase, and antigen in test samples is measured by 
inhibition of antibody binding (figure 6.2.). 
6.3. Aim of Experimental Studies 
The aim of the work presented in this chapter was to develop an immunoassay for 
feline soluble TNFR-1 using antiserum generated against peptides based on the 
predicted amino acid sequence for the receptor. 
6.4. Materials and Methods 
6.4.1. Peptide design 
The 'Peptide Structure' program of the Genetics Computer Group (GCG, Wisconsin, 
USA) was used to predict antigenic regions within the derived amino acid sequence 
for feline TNFR-1 (Accession no. U72344, see chapter 4). This programme shows 
potential glycosylation sites, determines hydrophilicity, surface probability, chain 
flexibility, secondary structure and provides an antigenicity index for each amino acid 
(Wolf et al. 1988). Appendix 3 shows the 'PeptideStructure' output demonstrating 
the antigenic profile of the available feline TNFR-1 sequence. 
Two areas with high antigenicity indices that did not contain potential 
glycosylation sites were selected for peptide synthesis. The synthesised peptides were 
designated peptide A and peptide B. Peptide A contained 16 amino acid residues 
(residues 28-43, Accession number U72344) and peptide B contained 15 (residues 
175-189, Accession number U72344). Each differed from human, mouse and cow 
sequences as indicated in figures 6.3. and 6.4. Peptide A was located close to the 
leader sequence and peptide B was at the N-terminal end of the known sequence, in 
the region immediately upstream from the transmembrane domain. 
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Figure 6.2. Diagram illustrating the principle of the ELISA with capture antigen or 
antibody bound to the solid phase. a) the antibody capture ELISA designed to detect 
the presence of antibody, b) the antigen capture ELISA designed to detect the 
presence of antigen and C) shows the antibody capture ELISA where inhibition of 
antibody binding is caused by the presence of free antigen in test samples. 
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a) antibody capture ELISA 
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b) antigen capture ELISA 
A primary antibody 
A labelled secondary antibody 
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Figure 6.3. Diagram showing feline, human, murine and bovine amino acid sequences 
for the region represented by peptide A. The dashes represent consensus residues 
between the cat and other species. 
TGLVPHLRDREKRAIP 
I------G-----DSV 
-----S-G-----DSL 
Q-----PG-L---ES-
cat 
human 
mouse 
cow 
Figure 6.4. Diagram showing feline, human, murine and bovine amino acid sequences 
for the region represented by peptide B. The dashes represent consensus residues 
between the cat and other species. 
RGNECVSCVNCKKNT 
-E------S-----E 
S----TP-SH----E 
K-AK-T--HD--NKE 
cat 
human 
mouse 
cow 
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6.4.2. Peptide synthesis 
Both linear (1S0mg) and MAP (15 Ilmole) peptides with N-terminal acetylation were 
synthesised commercially (Alta Bioscience, University of Birmingham, UK). To 
remove impurities, MAPs were purified by solubilising in Sml of 10% acetic acid-8M 
urea, and dialysing against 5 changes of 5% acetic acid over 48 hours using a 
membrane with a 2000 Da cut-off (D7884, Sigma). After dialysis, the peptide was 
recovered by Iyophilising and was re-dissolved in 4ml of saline. 
6.4.3. Inoculation of sheep 
The protein concentration of each solution was determined on an Axon discrete 
biochemical analyser (Bayer Diagnostics, Basingstoke, UK) using the standard Biuret 
method. Four aliquots of O.Smg (O.Sml) were submitted to the Scottish Antibody 
Production Unit (SAPU, Law Hospital, Lanarkshire) for each sheep to be inoculated. 
Inoculations were made on 4 occasions at intervals of 4 weeks. Blood 
samples were taken prior to initial inoculation and 7 days after subsequent injections. 
The serum was collected after coagulation and stored at _20DC prior to use. Peptide 
A was injected into sheep A, peptide B into sheep B and both A and B into sheep C, 
which had previously been used to raise antibody against recombinant GST -feline 
sTNFR-1 fusion protein (see chapter 5). Initial inoculations of sheep A and B were 
made with complete Freund's adjuvant. All subsequent inoculations and inoculations 
of sheep C were made with incomplete Freund's adjuvant. 
6.4.4. Assessment of antiserum by western blotting 
The linear peptides proved very difficult to dissolve, despite attempts using various 
buffers of different composition and pH. Consequently, for western blotting, peptides 
were dissolved in dimethyl sulphoxide (DMSO) before the gradual addition of 
treatment buffer and loading onto the gels. Antiserum at a dilution of 1: 100 in TB S-
Tween-milk was used as the first antibody but otherwise the western blots were 
prepared as previously described (chapter 5) except that the percentage of acrylamide 
in the gels was increased to 15% to improve the separation among the lower 
molecular weight peptides. 
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6.4.5. ELISA 
A kit providing a starter buffer pack was used for the ELISA (Pierce, Rockford, 
Illinois). A two dimensional serial dilution protocol was used to optimise the assay 
(figure 6.5.). This protocol is designed so that primary antibody is diluted serially 
across the plate and secondary antibody is diluted serially down the plate, allowing 
the optimal combinations of both reagents to be determined. All incubations were 
performed at room temperature. 
Linear peptide was applied to microtitre plates at a final concentration of 
10Ilg/ml by adding 9SIlI of coating buffer (1 packet of BupIfTM Carbonate in SOOml 
distilled water) to Sill of peptide at a concentration of 0.2mg/ml in DMSO. The 
antigen was allowed to bind to the plate for 1 hour, after which each well was 
washed 3 times with 100lli wash buffer (2.5ml Surfact-AmpsTM Tween® 20, 5ml 
BlockerTM BSA in PBS and 1 packet BupIfTM Dulbecco's PBS made up to 500m! with 
distilled water). The plate was then incubated with lOOll1 blocking buffer (10m! 
Blocker™ BSA in PBS made up to 100mi with BupIfTM Dulbecco's PBS) per well for 
1 hour. After blocking, 100lli of primary antibody diluted in blocking buffer was 
applied to each well and the plate was incubated for a further hour. 
When analysing the binding of antisera to the peptides, the optimal 
concentration was determined by performing serial two-fold dilutions of primary 
antibody across the plate. To achieve this, 100lli wash buffer was added to all wells 
and 100lli antibody solution at a dilution of 1: 500 in blocking buffer was added to 
each well in column 1. The contents of column 1 were mixed by filling and emptying 
the wells with a pipette 4 times, then transferring lOOll1 from each well in column 1 
to the adjacent well in column 2, mixing and repeating across the plate. The final 
column was left free of primary antibody as a negative control. 
After incubation with the primary antibody, the plate was emptied and each 
well was washed 3 times with 100111 wash buffer. A horseradish peroxidase-labelled 
secondary antibody (anti sheep/goat IgG, SAPU, Scotland, UK) diluted 1: 500 in 
blocking buffer was applied in a similar manner to the primary antibody with the 
dilutions being made from row to row rather than between columns. The final row 
was left without any secondary antibody as a negative control. Incubation with 
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Figure 6.5. Diagrammatic representation of the two-dimensional serial dilution ELISA 
protocol used to optimise primary and secondary antibody concentrations. 
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secondary antibody was terminated after 1 hour, the wells were washed 3 times 
with 1 00~1 wash buffer and 1 00~1 wash buffer was left in the wells for S minutes. The 
plate was then emptied by inversion and any residual fluid was removed by tapping 
the plate on a paper towel. 
The enzyme substrate solution was made by dissolving one 3,3',S,S'-
tetramethylbenzidine dihydrochloride tablet (lmg TMB tablets, Sigma) in 10mi of 
O.OSM phosphocitrate buffer (2S.7ml 0.2M dibasic sodium phosphate, 24.3ml O.IM 
citric acid and SOml de-ionised water, pHS) and adding 2111 fresh 30% hydrogen 
peroxide immediately prior to use. One hundred microlitres of this solution was 
added to each well and the plate was left until a strong blue colour developed in the 
wells with the highest antibody concentrations (about 20 minutes). The reaction was 
stopped by the addition of SOIlI 2M H2S04, which caused the chromogen to change 
to yellow and the absorbance was read at 4S0nm using a microtitre plate reader 
(MRX Microplate Reader, Dynex Technologies Inc, V A). 
6.4.6. ELISA with rhsTNFR-1 
To determine the presence of any cross-species reactivity, the ELISA was repeated 
as described using recombinant human sTNFR-l (rhsTNFR-l) as the capture antigen 
at a concentration of IOIlg/ml in coating buffer. 
6.4.7. Inhibition ELISA 
An inhibition ELISA was developed to detect any reaction between the antiserum 
and rhsTNFR-I or feline sTNFR-l in clinical samples. Peptide A was bound to the 
microtitre plate at IOIlg/ml as described. The primary antibody was pre-incubated 
with recombinant human soluble TNFR-l (rhsTNFR-l) or feline clinical sample for 2 
hours in a separate micro titre plate at room temperature before transfer to the ELISA 
plate. Initially, varying concentrations of anti-peptide A antiserum and rhsTNFR-l 
were analysed to determine the optimal concentrations of each to detect inhibitory 
activity. 
6.4.8. Immunocytochemistry 
Immunocytochemistry was performed by the Department of Veterinary Pathology at 
the University of Glasgow. Antiserum to peptide A was used as the primary antibody 
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and biotinylated rabbit anti-goat IgG (E0466, DAKO, Cambridge, UK) as the 
secondary antibody. Sections of healthy feline liver were stained using multiple 
dilutions of primary antibody to determine the optimal concentration to give minimal 
background yet retain specific staining. The optimal concentration of primary 
antibody was then used to stain slides which had been treated with trypsin and by 
microwave and pressure cooking in an attempt to enhance antigen retrieval. Slides 
prepared without the addition of a primary antibody were used as negative controls. 
6.5. Results 
6.5.1. Western blotting 
Although difficulty was encountered in dissolving the linear peptides, western 
blotting demonstrated that antisera from sheep A and sheep C reacted with peptide A 
with bands stained over a range less than 29kDa in size. Pre-immune serum taken 
from sheep A and C prior to inoculation with peptide did not react. Antisera from 
sheep B and sheep C reacted with peptide B with bands staining over a similar range 
to peptide A. The reaction of both peptides with antiserum from sheep C is shown in 
figure 6.6. This illustrates that both peptides induced an immune response in the 
inoculated sheep which resulted in the production of peptide-specific antibody. 
6.5.2. ELISA - Serial dilution protocol for antiserum from sheep A 
Figure 6.7. shows the antibody dilution curves using peptide A as the capture antigen 
and antiserum from sheep A taken after the final inoculation of peptide. The 
antiserum showed strong binding activity against linear peptide A when tested by 
ELISA. This activity was not detected when pre-immune serum from sheep A was 
used as the primary antibody. After performing the two dimensional serial dilution 
protocol, it was found that a primary antibody dilution of 1 :8000 and a secondary 
antibody dilution of 1: 1000 gave an A450 reading of approximately half of the 
maximum value on the microtitre plate reader, (1.157 compared to 2.008). These 
antibody dilutions were considered optimal and were used subsequently in the 
ELISA. 
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Figure 6.6 Digital image of western blot showing the reaction of antiserum taken 
from sheep C against the linear peptides. Lane 1; peptide A, lane 2; peptide B. 
lane 1 2 
kDa 
66 
~. 
....t. ~ 
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Figure 6.7. Antibody dilution curves for the ELISA using peptide A as the capture 
antigen and antiserum from sheep A as the primary antibody. Serial dilutions of 
primary and secondary antibody were used in the assay. The key shows reciprocal 
dilutions xl 03 of secondary antibody for each curve. 
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6.5.3. ELISA - Serial dilution protocol for antiserum from sheep 8 
Antiserum from sheep B taken after the final injection of peptide showed little 
increase in activity against peptide B above background levels (determined by wells 
coated with DMSO or coating buffer without capture antigen). For this reason, 
further assessment of antiserum from sheep B was not pursued. 
6.5.4. ELISA for rhsTNFR-1 
Antiserum from sheep A that had anti-peptide activity showed a strong reaction 
against rhsTNFR-1. However pre-immune serum from sheep A also demonstrated 
this activity (figure 6.8.). 
6.5.5. Inhibition ELISA 
Initial results of the inhibition ELISA demonstrated that pre-incubation of anti-
peptide A antibody with rhsTNFR-1 resulted in interference with primary antibody 
binding to the capture antigen (figure 6.9.). However, this reduction in antibody 
binding could not be reproduced consistently and reduction of the concentration of 
capture peptide to 2.51lg/ml or increase of rhsTNFR-1 concentration to 51lg/rnl did 
not improve the results. In addition, no inhibition could be demonstrated by pre-
incubation of anti-peptide A antiserum with feline splenic supernatant samples that 
exhibited sTNFR-1 like activity detected by bioassay (chapter 3) prior to use in the 
ELISA. 
6.5.6. Immunocytochemistry 
Titration of primary antibody determined that a dilution of 1 :3000 was 
optimal to demonstrate specific activity with no background staining. Pre-treatment 
of the liver sections by microwave cooking or by incubation with trypsin for 30 
minutes gave the best demonstration of anti-peptide A antiserum binding to receptor 
on hepatocytes (figure 6.10.). 
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Figure 6,8, Graph illustrating the reaction of pre-immune and post-inoculation anti-
sera with bound rhsTNFR-l when used in the ELISA. 
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Figure 6.9. Dilution curves for the inhibition ELISA using peptide A as the capture 
antigen and antiserum from sheep A as the primary antibody. Serial dilutions of 
primary antibody were pre-incubated with serial dilutions of recombinant human 
soluble TNF receptor -1 (rhsTNFR-l) from 0.018 to 1.25/-Lg/ml. The key shows 
reciprocal dilutions xl03 of primary antibody for each curve . 
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Figure 6.10. Immunocytochemistry slide of a liver slice which has been pre-treated 
by microwave cooking then stained with anti-peptide A antiserum. Magnification = 
x500. The arrows highlight some areas of positive staining. 
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6.6. Discussion 
The work presented in this chapter demonstrates that antiserum raised in sheep to 
peptides A and B contained within feline sTNFR-l recognised the corresponding 
peptides in western blot (peptides A and B) and ELISA (peptide A only). However, 
development of an immunoassay system was not possible in the time available. 
Although the antiserum recognises linear peptide when that is used as an antigen, 
lack of availability of native protein still prevented full characterisation of the 
antiserum and assessment of its value when monitoring clinical samples. Analysis by 
western blotting of supernatant samples that exhibited strong anti-TNF-a activity 
using the L929 bioassay (chapter 3) may illustrate activity against native protein 
although these samples did not inhibit the binding of anti-peptide A antiserum to 
peptide A in an ELISA. 
Although antiserum taken from sheep A after the final inoculation showed a 
strong reaction to rhsTNFR-l, pre-immune serum also reacted. Given the findings in 
chapter 5 when pre-immune serum from sheep C reacted against E coli proteins, it is 
likely that the present findings represent a similar phenomenon, because the human 
protein was produced by expression in E coli. Presumably, the sheep had previously 
encountered and mounted an immune response against bacterial proteins. To fully 
assess the activity of anti-peptide A antiserum against the human receptor, both pre-
and post-immune serum could be absorbed against E coli proteins and re-analysed. 
In addition, it would be interesting to assess whether there is any cross-reactivity 
between polyclonal anti-human sTNFR-l antibody and peptides A and B. 
The inhibition ELISA appeared to demonstrate interaction between antiserum 
to peptide A and rhsTNFR-I resulting in reduced binding of the primary antibody to 
the bound antigen. However, these results could not be reproduced consistently, 
despite reducing the amount of bound antigen and increasing the concentration of 
rhsTNFR-l incubated with primary antibody. Treatment of the rhsTNFR-l with a 
mild detergent prior to incubation with antiserum might result in better exposure of 
the peptide site to antibody and thus greater consistency. However, as the peptides 
that were selected for inoculation into sheep were from areas rich in interspecies 
variation with the aim of promoting the production of an immune response, it would 
not be surprising if the resulting antiserum did not recognise the human protein. 
Alternatively the reaction between the antiserum and E coli antigens in rhsTNFR-I 
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may have interfered with the inhibition ELISA and contributed to the inconsistent 
results. 
MAP-containing peptides show a better binding capacity to plastic surfaces 
than monomeric peptides (Tam and Zavala, 1989) although linear peptides were used 
to analyse antiserum in the work presented here because they were readily available. 
The MAPs were easily dissolved in buffer prior to their purification so it is likely that 
their use in analysing antiserum may have been preferable to the use of lin-ear 
peptides. Rigby and others (Rigby et al. 1996) used a MAP as the target antigen to 
detect antibody raised to peptide by an ELISA. The antiserum to peptide B may be 
behaving poorly because of poor binding of peptide B to the microtitre plate. Peptides 
that contain bulky and hydrophobic side chains and those that can form amphiphatic 
helixes or 13 sheets may bind better than others to solid plastic surfaces. 
In the work described in chapter 5, a sheep was selected to generate antibody 
to recombinant feline sTNFR-l to allow an ample volume of antiserum to be 
generated for the development of an assay for the receptor. For the same reason, the 
decision was made to raise anti-peptide antibodies in sheep. Although the sequence 
for ovine TNFR-l has not been reported, the degree of homology between the 
sequences for the cow and the cat (see table 4.1.) is similar to that between the mouse 
and the cat. Consequently, the species are equally likely to recognise the selected 
peptides as foreign. The problem encountered previously with the very small quantity 
of immunogen available in the form of recombinant protein would not be a problem 
with synthesised peptides. 
Little reaction was seen when using peptide B as the capture antigen in the 
ELISA. This may be a result of a poor immune response in sheep B, either because of 
poor immunogenicity of the peptide or because of a problem with the individual 
sheep. However, since immunoreactivity was detected by Western blotting, it is 
perhaps more likely that there was poor binding of this peptide to the microtitre plate. 
Linking the peptide to a carrier such as bovine serum albumin may assist coating of 
the plate with antigen. 
The activity demonstrated against the peptides by Western blotting was 
not to a single low molecular weight band as might be expected, but instead over a 
range less than 29kDa. The poor solubility of the linear peptides may have been 
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affecting their electrophoretic migration. A range of sizes can be caused by truncated 
peptides arising during synthesis but these would have been expected to be at a much 
smaller molecular weight than the bands detected. Antiserum taken from sheep C 
immediately prior to inoculation with peptide did not react with either peptide A or B 
in a Western blot, suggesting that there is no cross-reaction between the anti-GST-
fusion protein antiserum and the peptides. 
The immunocytochemistry study illustrates binding of anti-peptide A 
antiserum to hepatocytes. Since the immunocytochemistry was performed on 
hepatocytes, it is a possibility that the apparent positive staining could result from 
intracellular granulation. However, the antigen retrieval processes of microwave and 
trypsin treatment enhanced antibody binding, and the negative controls did not show 
this binding, supporting the interpretation that the positive staining is real. 
Confirmation could be achieved by staining a different tissue with the same 
antiserum. 
6.7. Further Studies 
The initial aim of further studies would be to determine whether the antiserum to 
peptide A recognises native protein. This could be assessed by examining by western 
blotting supernatants shown by bioassay to exhibit anti-TNF activity. Cross-reactivity 
between the antiserum absorbed with E coli proteins and rhsTNFR-l should be 
assessed. The use of anti-rhsTNFR-l antibody against peptide A in a western blot 
might help to confirm cross-species reactivity. If activity of antiserum from sheep A 
against the native feline protein were demonstrated, then the next step would be to 
return to the inhibition ELISA and to develop it to assess samples. It may be possible 
to use serial dilutions of peptide rather than rhsTNFR-l as standards for pre-
incubation with primary antibody. 
The anti-peptide A antiserum could be used in further immunocytochemical 
studies to examine expression of membrane bound receptor in other tissues, both 
from healthy and diseased cats. 
Anotber method of detecting antiserum activity against the native protein 
would be using flow cytometry. Since receptors for TNFR-l are widespread, white 
blood cells could be used for this analysis. Anti-peptide antisera could be used as the 
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primary antibody, binding to membrane-bound receptor and an anti-sheep FITC 
conjugated antibody used as the secondary antibody. 
6.8. Conclusion 
Antiserum was raised in sheep to two peptides based on the feline TNFR-l sequence 
available. Antiserum to peptide A recognised the linear peptide when it was used as a 
capture antigen in an ELISA. However, the ability of the antiserum to recognise native 
protein could not be assessed in vitro because of lack of availability of native protein. 
This problem has to be addressed before the ELISA can be developed to measure 
soluble receptor in feline samples. 
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Chapter 7: 
Conclusion 
The work presented in this thesis is directed towards the identification of 
markers of inflammation that may be useful when monitoring feline disease. 
Initially, the measurement of alpha-l acid glycoprotein (AGP) was determined to be 
of benefit as an aid to the diagnosis of feline infectious peritonitis. This is of value to 
the clinician while a definitive diagnostic test for this condition remains unavailable. 
The AGP assay is straightforward and likely to be of benefit when monitoring other 
inflammatory conditions in the cat and when assessing response to therapy. It is now 
used routinely as part of an 'FIP' screen in the feline virus unit. 
A recent publication supports our findings that AGP and haptoglobin (Hp) act 
as moderate acute phase proteins in the cat (Kajikawa et al. 1999). The authors 
measured both proteins using radial immunodiffusion assay kits (Saikin Kagaku, 
Japan) and presented a reference range for AGP concentration in healthy cats (0.148-
0.340gll) comparable to that presented in chapter 2 (0.1-0.48g11). The reference 
range that they determined for Hp (0.49-0.783g11) was somewhat narrower than that 
described in chapter 2 (0.04-3. 84g11). After the induction of inflammation, the 
maximum levels of protein were found after 48 hours and the magnitude of rise was 
similar to that detected in the work presented in this thesis. Serum amyloid A (SAA) 
and C-reactive protein (CRP) were also measured in the study. Like AGP and Hp, 
SAA was found to act as a moderate acute phase responder, but levels of CRP did 
not vary significantly between clinically normal cats and hospitalised cats or those 
with induced inflammation. 
The fluctuations in levels of inflammatory cytokines that have been recorded 
over the asymptomatic phase of infection with feline immunodeficiency virus (FIV) 
(Lawrence et al. 1995) suggest that there may be corresponding changes in serum 
concentrations of acute phase proteins. This was found not to be the case, but the 
need for identifying prognostic markers in FIV was apparent. Although the decline in 
CD4 positive lymphocytes has been shown to occur over the asymptomatic phase of 
the disease (Novotney et al. 1990), the technology involving flow cytometry is not 
readily available to the clinician and analysis of samples over 24 hours old is 
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inaccurate. In HIY, an increase in viral load has also been associated with disease 
progression, however the development of an assay that will identify markers of 
disease progression in flY and can be easily applied to samples received from the 
field will be of great benefit when expensive equipment, technical expertise and 
funding are not readily available for lymphocyte subset analysis and real time PCR. 
Soluble forms of the TNF receptors continue to be quoted as useful markers of 
disease progression and response to therapy in my (Aukrust et al. 1999). Thus the 
decision to develop assays for feline soluble TNF receptors and to determine if these 
give useful prognostic information in cats with FlY infection remains sound. The 
initial approach used here was the L929 bioassay to detect anti-TNF activity which 
may be attributable to the presence of feline soluble TNFR-l. Although anti-TNF 
activity was readily demonstrated by this means, the assay results were inconsistent 
and it was subsequently decided that the development of an immunologically-based 
assay may be more reliable. 
Cloning and sequencing of the feline soluble TNF receptors was undertaken 
using peR-based methodology utilising primers based on regions of homology in 
published sequences from different species. Whilst this was successful for feline 
sTNFR-1, only part of the intracellular portion of feline TNFR-2 could be amplified 
using this method. Cloning of feline sTNFR-1 was followed by expression of the 
recombinant protein as a fusion to glutathione-S-transferase. Expression levels were 
extremely poor and analysis of antiserum raised to the expressed protein was 
hampered by the lack of suitable antigen. Expression in an alternative E. coli vector 
did not improve results. 
As the results of analysis of the antiserum to feline sTNFR-l fusion protein 
were disappointing, the decision was made to design 2 peptides based on the known 
feline sequence and use these for the generation of anti-peptide antibody. Antiserum 
to one of the peptides showed very strong anti-peptide reactivity by ELISA, but its 
activity against native protein could not be assessed because of the lack of availability 
of the latter. Initially, human soluble TNF receptors were purified from pools of 300 
litres of urine (Engelmann et al. 1989). It was not feasible to collect such a large 
amount from cats. 
To continue the work of this thesis in the design of assays for soluble feline 
TNF receptors, it is intended to screen a feline thymic cDNA library using the 
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amplified portion of feline TNFR-2 as a probe. Any clones identified by the probe will 
be analysed to obtain the sequence for the remaining portions of the receptor. Once 
this is achieved, as for feline TNFR-l, it is likely that expression as a GST -fusion 
protein will be undertaken and antiserum raised to the expressed protein. 
As discussed in chapter 6, the problems encountered with TNFR-l mean that 
an alternative approach has to be tried for the development of an assay to this 
receptor. The main stumbling block has been the lack of native protein for the 
analysis of generated antiserum. One way to attempt to circumvent this would be to 
attempt expression in a mammalian system, which should produce functional protein. 
Although DNA vaccination is a technique that may give appropriate antiserum, it will 
not solve the problem of the deficiency of suitable antigen with which to analyse 
antiserum and any vector to be used for DNA vaccination should initially be tested 
for expression in mammalian cells in culture. A slightly different approach would be 
to clone a smaller portion of the receptor and attempt expression of this in an E coli 
system to see if expression levels improve. This would be fairly easily performed and 
negative or positive results should be rapidly obtained. 
It may also be useful to analyse the anti-feline TNFR-l antiserum produced 
against both recombinant protein and peptides by flow cytometry. Any reactivity with 
peripheral blood mononuclear cells would provide evidence of recognition of the 
native protein. Any antibody reacting positively could then be used to monitor the 
cell surface expression of the receptor and detect whether a down-regulation in cell 
surface receptor is associated with an up-regulation in soluble receptor. 
APPENDIX 2 
LB Broth 
109 tryptone 
5 g yeast extract 
109 NaCI 
APPENDIX 1 
Dissolve to 1litre in dH20 and autoclave. 
For LB-agar, add l.2-l.5% agarose prior to autoclaving. 
SOC Medium 
20g tryptone 
5 g yeast extract 
0.5g NaCI 
Dissolve to 1 litre in dH20 and autoclave. 
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After autoclaving, add 1ml of sterile MgCh, 1rnl of sterile 250mM KCI and 2.78rnl 
sterile 2M (36%) glucose per 100 mls of medium. 
APPENDIX 2 
Monomer Solution 
60g acrylamide (FW 71.08) 
1.6g bisacrylamide (FW lS4.2) 
Add ddH20 to 200ml 
APPENDIX 2 
4x Running Gel Buffer (1.5M Tris-CI, pH8.8) 
36.3g tris (FW 12l.1) 
Add lS0ml ddH20, adjust pH to 8.8 with HCI and add ddH20 to 200ml 
4x Stacking Gel Buffer (O.5M Tris-CI, pH6.8) 
3.0g tris (FW121.1) 
Add 40ml ddH20, adjust pH to 6.8 with HCI and add ddH20 to SOml 
12.5% Running Gel Recipe 
12.Sml monomer solution 
7.Sm14x running gel buffer 
0.3ml 10% SDS 
9.6ml ddH20 
lS0~1 10% ammonium persulfate 
10~1 TEMED 
Stacking Gel Recipe 
0.88ml monomer solution 
1.66ml stacking gel buffer 
66~110% SDS 
4.06ml ddH20 
33.4~l 10% ammonium persulfate 
3.3~l TEMED 
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APPENDIX 3 
PEPTIDESTRUCTURE of: fcu72344.pep check: 2441 from: 1 to: 189 
TRANSLATE of: fcu72344.gb om check: 3951 from: 14 to: 581 
Hydrophilicity (Kyte-Doollttle) averaged over a window of: 7 
Surface Probability according to Emini 
Chain Flexibility according to Karplus-Schulz 
Secondary Structure according to Chou-Fasman 
Secondary Structure according to Garnier-Osguthorpe-Robson 
Antigenicity Index according to Jameson-Wolf 
Pos AA GlycoS HyPhil SurfPr FlexPr CF-Pred GORP red AI-Ind 
1 M -0.925 0.468 1.000 -0.450 
2 G -0.600 0.528 1. 000 -0.450 
3 L -1. 200 0.307 1.000 -0.450 
4 P -0.800 0.479 1. 000 -0.450 
5 T -0.471 0.479 1. 030 -0.450 
6 V -1.071 0.479 1. 032 -0.450 
7 P -1.071 0.256 1. 030 -0.450 
8 G -0.800 0.307 1. 017 B -0.450 
9 L -0.671 0.639 1. 009 B -0.450 
10 L -0.614 0.341 1.007 H B -0.450 
11 Q -1.443 0.256 1. 003 H B -0.450 
12 P -2.043 0.256 0.996 H B -0.600 
13 L -2.043 0.256 0.976 H B -0.600 
14 V -1.757 0.149 0.952 H B -0.600 
15 L -2.800 0.080 0.931 H H -0.600 
16 L -3.571 0.080 0.917 H H -0.600 
17 A -3.629 0.080 0.914 H H -0.600 
18 L -2.529 0.167 0.917 H H -0.600 
19 L -2.629 0.142 0.918 H H -0.600 
20 V -1.900 0.220 0.920 H H -0.600 
21 E -1. 414 0.413 0.921 H B -0.600 
22 I -1.414 0.413 0.923 H B -0.600 
23 Y -0.229 1. 089 0.926 B -0.150 
24 P -0.229 0.467 0.933 B -0.300 
25 L -0.629 0.961 0.946 B B -0.600 
26 R 0.071 0.607 0.962 B B 0.300 
27 V -0.657 0.324 0.981 B B -0.600 
28 T -1. 486 0.291 0.993 B B -0.600 
29 G -0.714 0.230 0.991 B B -0.600 
30 L -0.900 0.422 0.978 B B -0.600 
31 V -0.843 0.241 0.962 B B -0.600 
32 P -0.300 0.477 0.955 h B -0.300 
33 H 0.143 0.966 0.962 h 0.300 
34 L 1. 329 2.548 0.980 h 0.750 
35 R 2.429 2.854 1. 006 h T 1. 300 
36 D 2.757 4.195 1. 030 h T 1. 300 
37 R 2.943 9.962 1. 048 h T 1. 300 
38 E 3.229 5.138 1. 054 h T 1. 300 
39 K 1. 943 2.157 1. 039 h T 1. 300 
40 R 1. 671 1. 703 1.011 h T 1.300 
41 A 0.671 0.527 0.978 h T 1. 000 
42 I 0.400 0.408 0.960 h 0.300 
43 P 0.343 0.360 0.971 t 0.500 
44 C -0.243 0.353 1. 006 t 0.050 
45 P 0.571 1.007 1. 052 T T 1. 700 
46 Q 1. 400 1. 020 1.080 T T 1. 700 
47 G 0.529 1. 334 1.073 T T 1. 700 
48 K 1. 343 1. 174 1. 041 T 1. 300 
49 Y 1. 343 1. 048 1. 001 T 1. 300 
50 I 1.343 1. 835 0.986 0.750 
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51 H 1. 786 1. 532 0.999 0.750 
52 p 1.729 1. 573 1.034 t T 1. 500 
53 Q 1. 657 3.006 1. 067 T T 1.700 
54 D 1. 657 1. 549 1. 068 T T 1. 700 
55 N 0.843 0.537 1.052 T T 1.550 
56 S 0.257 0.166 1.011 t T 1. 050 
57 I -0.143 0.144 0.973 T 0.100 
58 C -0.086 0.179 0.963 T 0.100 
59 C -0.943 0.071 0.957 T -0.200 
60 T -0.600 0.139 0.971 t T 0.000 
61 K 0.600 0.517 0.986 t T 1. 200 
62 C 1. 014 0.955 0.994 T 1. 000 
63 H 1.471 0.955 1. 015 t T 1. 350 
64 K 1. 557 0.748 1. 030 T T 1. 550 
65 G 0.457 1. 151 1.033 T T 1. 400 
66 T 1. 000 1. 326 1. 019 B T 1. 300 
67 Y 1. 043 1. 066 0.992 B T 1.150 
68 L 0.986 1. 799 0.976 B T 1.150 
69 Y 0.571 0.668 0.972 B T 1. 000 
70 N 0.971 0.739 0.988 B T 1. 000 
71 D 0.843 0.886 1. 016 t T 1. 350 
72 C 1. 614 0.875 1. 031 t T 1. 350 
73 E 1. 486 0.538 1. 049 t T 1. 350 
74 G 0.443 0.266 1. 056 t 0.650 
75 p 0.443 0.828 1.052 T T 1. 250 
76 G 0.900 0.690 1. 050 T T 1. 550 
77 L 0.900 1.164 1. 047 T 1. 300 
78 D 0.486 0.404 1. 047 T 0.850 
79 T 0.900 0.799 1. 047 T T 1. 550 
80 D 1. 343 1. 678 1. 043 T T 1. 700 
81 C 1. 529 0.538 1. 029 t T 1. 350 
82 R 1. 529 0.646 1. 019 T T 1. 550 
83 E 1. 929 0.622 1. 019 T T 1. 550 
84 C 1. 486 1.149 1. 028 T 1.300 
85 E 1.943 0.846 1. 051 T T 1. 550 
86 N G 0.900 0.423 1. 062 T T 1. 550 
87 G 0.500 1.139 1. 056 T 1. 000 
88 T 0.600 0.665 1. 037 0.750 
89 F 0.214 0.554 1.013 0.450 
90 T 0.214 0.969 1. 005 0.450 
91 A 0.657 1.080 1.013 0.900 
92 S 0.743 1. 955 1. 021 0.900 
93 E 0.600 1.117 1. 023 T T 1. 700 
94 N 1.143 2.165 1.011 T T 1. 700 
95 Y 1. 900 2.798 0.996 B T 1.150 
96 L 1.429 0.866 0.985 B T 1. 000 
97 R 0.386 0.444 0.979 B T 0.700 
98 Q 0.000 0.380 0.970 B T 0.700 
99 C -0.543 0.247 0.956 B T -0.200 
100 L 0.114 0.169 0.956 B T 0.700 
101 S 0.029 0.195 0.964 t T 0.900 
102 C -0.829 0.195 0.980 t T 0.000 
103 S 0.171 0.463 1. 005 T T 1. 250 
104 K 1.271 0.691 1. 021 T T 1. 550 
105 C 1.657 2.234 1. 028 t T 1. 500 
106 R 1. 743 1. 650 1. 026 T 1. 300 
107 K 1.814 1. 293 1. 014 T 1. 300 
108 E 1.757 4.176 0.986 T 1.150 
109 M 1. 514 1. 582 0.957 B T 1.150 
110 Y 1.371 1. 370 0.939 B T 1.150 
111 Q 0.171 0.555 0.932 B T 0.700 
112 V -0.214 0.751 0.947 B -0.300 
113 E 0.286 0.741 0.973 B 0.300 
114 I -0.257 0.229 0.996 B -0.300 
115 S -0.657 0.446 1. 010 -0.450 
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116 p -0.657 0.191 1. 006 T -0.050 
117 C -0.971 0.427 0.986 B T -0.200 
118 T 0.314 0.625 0.969 B T 0.700 
119 V 0.700 0.675 0.962 B T 1. 000 
120 Y 0.571 1. 816 0.971 B T 1.150 
121 R 0.329 0.934 0.989 B T 0.700 
122 D -0.129 0.675 0.993 B T 0.100 
123 T 0.529 0.426 0.984 B T 1.000 
124 V -0.014 0.117 0.962 B T 0.100 
125 C -0.014 0.137 0.947 B T 0.100 
126 G 0.043 0.190 0.954 t T 0.900 
127 C 0.443 0.411 0.980 t T 0.900 
128 R 1. 543 1. 327 1. 016 t T 1.500 
129 K 2.086 2.100 1. 042 T T 1. 700 
130 N 2.671 7.675 1. 042 T T 1. 700 
131 Q 3.214 6.140 1. 018 B T 1. 300 
132 Y 2.757 4.810 0.978 B T 1.150 
133 R 2.329 3.145 0.940 B T 1.150 
134 Y 1. 943 2.434 0.923 B T 1.150 
135 Y 1. 943 2.690 0.928 B T 1.150 
136 W 1. 857 1. 982 0.958 B T 1.150 
137 S 1.671 1.721 0.993 0.750 
138 E 1. 086 0.951 1. 010 T 1.150 
139 T 1. 400 1. 567 1.004 T 1. 300 
140 H 0.914 0.627 0.974 B T 1. 000 
141 F 0.257 0.298 0.942 B T 0.700 
142 Q 0.257 0.333 0.920 B T 0.700 
143 C -0.200 0.131 0.915 B T 0.100 
144 L -0.543 0.203 0.925 B T -0.200 
145 N G -0.686 0.097 0.933 B T -0.200 
146 C -1.543 0.097 0.940 B T -0.200 
147 S -1.729 0.097 0.943 B T -0.200 
148 L -0.686 0.097 0.948 B T -0.200 
149 C -1.129 0.178 0.964 B T -0.200 
150 L -0.671 0.192 0.989 B T -0.200 
151 N G -1.386 0.173 1.014 B T -0.050 
152 G -0.343 0.558 1. 027 B T 0.250 
153 T -0.629 0.474 1. 020 B T -0.050 
154 V 0.029 0.395 0.997 B B 0.300 
155 Q -0.829 0.214 0.971 B B -0.600 
156 I -0.329 0.297 0.966 B B -0.300 
157 S 0.071 0.692 0.974 B 0.300 
158 C 0.771 0.577 1. 000 B 0.750 
159 K 0.771 1. 425 1.04l T 1. 300 
160 E 1.914 1.711 1.071 T 1. 300 
161 T 1. 900 4.605 1. 092 T 1. 300 
162 Q 1.657 1.709 1. 096 t T 1. 500 
163 N 0.743 0.529 1. 068 t T 1. 350 
164 T 0.343 0.529 1. 027 B T 0.850 
165 V -0.114 0.164 0.978 B B -0.300 
166 C -0.157 0.139 0.935 B B -0.300 
167 T -0.914 0.097 0.915 B B -0.600 
168 C -0.957 0.129 0.906 B B -0.600 
169 H -0.757 0.209 0.910 h B -0.600 
170 A -0.800 0.125 0.916 h T -0.200 
171 G -1. 443 0.193 0.920 h T -0.200 
172 F -0.443 0.278 0.931 h T -0.200 
173 F -0.843 0.272 0.954 h T -0.200 
174 L -0.086 0.442 0.989 h T 0.100 
175 R 0.357 0.884 1. 027 t T 1. 050 
176 G 0.400 0.547 1. 049 t T 1. 050 
177 N 0.200 0.492 1. 044 t T 1. 050 
178 E 0.857 0.337 1. 014 t T 1. 350 
179 C -0.143 0.182 0.969 B T 0.100 
180 V -0.800 0.084 0.936 B T -0.200 
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181 s -0.800 0.078 0.918 B T -0.200 
182 C -1. 657 0.078 0.913 B T -0.200 
183 V -0.743 0.211 0.932 B T -0.200 
184 N 0.414 0.314 0.957 B T 0.700 
185 C 0.800 0.943 0.994 B T 1.000 
186 K 1. 257 1. 834 1.000 t T 1. 500 
187 K 2.167 1. 458 1. 000 t T 1. 500 
188 N 1. 900 3.477 1. 000 t T 1.500 
189 T 3.000 2.222 1. 000 T 1. 300 
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GLOSSARY 
A adenine 
A:G albumin: globulin 
Ab antibody 
ABL abelson tyrosine kinase 
AGP a-I acid glycoprotein 
AIDS acquired immunodeficiency syndrome 
APP acute phase protein 
C cytosine 
CD cluster of differentiation 
cDNA complementary DNA 
CIAA chloroform:isoamyl alcohol 
CM complete medium 
ConA concanavalin A 
CRP C-reactive protein 
CV coefficient of variation 
dH20 distilled water 
DMSO dimethylsulfoxide 
DNA deoxyribonucleic acid 
dNTPs deoxynucleoside triphosphates 
DPR differential positive rate 
DTT dithiothreitol 
EDTA ethy lenediaminetetra-acetate 
ELISA enzyme-linked immunosorbent assay 
ESR erythrocyte sedimentation rate 
FCoV feline coronavirus 
FIP feline infectious peritonitis 
FIV feline immunodeficiency virus 
G guanme 
GST glutathione-S-transferase 
HI-FCS heat inactivated foetal calf serum 
HIV human immunodeficiency virus 
Hp haptoglobin 
ICAM intercellular adhesion molecule 
IFN interferon 
19 immunoglobulin 
IL interleukin 
IPTG isopropyl·~-D-thiogalactopyranoside 
kDa kiloDaltons 
LPS lipopolysaccharide 
MAP multiple antigenic peptide 
MHC major histocompatability complex 
MMLV Moloney murine leukaemia virus 
NF-KB nuclear factor KB 
NO nitrous oxide 
PBMC peripheral blood mononuclear cells 
PCR nolvmerase chain reaction 
GLOSSARY 
pig-MAP 
RACE 
rhlm 
RNA 
RT-PCR 
SAA 
SDS-PAGE 
SPF 
sTNFR 
T 
TEMED 
Th 
Tm 
TNF 
TNFR 
TP 
TRAF 
pig major acute phase protein 
rapid amplification of cDNA ends 
recombinant human! murine 
ribonucleic acid 
reverse transcription-PCR 
serum amyloid A 
sodium dodecyl sulphate polyacrylamide electrophoresis 
specific pathogen free 
soluble TNFR 
thymine 
N,N,N' ,N' ,-tetramethylethylenediamine 
T helper cell 
melting temperature 
tumour necrosis factor 
TNF receptor 
total protein 
TNFR-2 associated factors 
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